[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, a synonym for Acrokeratosis paraneoplastica could be Aquagenic syringeal acrokeratoderma.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Yes, Weaver syndrome is similar to Sotos syndrome in terms of their overgrowth characteristics and increased risk of neoplasia, including neuroblastoma. Both syndromes are caused by mutations in genes that regulate cell growth and division, leading to abnormal growth and development.\nWeaver syndrome is a rare genetic disorder that is characterized by excessive growth and development during fetal life and childhood, as well as a number of other symptoms such as intellectual disability, delayed speech and language development, and distinctive facial features. Like Sotos syndrome, Weaver syndrome is associated with an increased risk of developing certain types of cancer, including neuroblastoma, a type of cancer that originates in the nerve tissue of the adrenal gland.\nThe information provided in the document highlights the importance of considering neuroblastoma as a potential diagnosis in children with Weaver syndrome who present with symptoms consistent with the syndrome. This is because the combination of overgrowth and neuroblastoma has been observed in previous cases of Weaver syndrome, and early detection and treatment of neuroblastoma can improve outcomes for these children.\nIn summary, while Weaver syndrome and Sotos syndrome are distinct genetic disorders, they share similarities in terms of their overgrowth characteristics and increased risk of neoplasia, including neuroblastoma. Therefore, it is important to be aware of these similarities when evaluating and managing patients with these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome both have overgrowth characteristics and an increased risk of neoplasia, including neuroblastoma.\n2. Weaver syndrome and Sotos syndrome are caused by mutations in genes that regulate cell growth and division.\n3. Weaver syndrome is characterized by excessive growth during fetal life and childhood.\n4. Symptoms of Weaver syndrome include intellectual disability, delayed speech and language development, and distinctive facial features.\n5. Weaver syndrome is associated with an increased risk of developing certain types of cancer, including neuroblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome both have overgrowth characteristics and an increased risk of neoplasia, including neuroblastoma.",
      "Weaver syndrome and Sotos syndrome are caused by mutations in genes that regulate cell growth and division.",
      "Weaver syndrome is characterized by excessive growth during fetal life and childhood.",
      "Symptoms of Weaver syndrome include intellectual disability, delayed speech and language development, and distinctive facial features.",
      "Weaver syndrome is associated with an increased risk of developing certain types of cancer, including neuroblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - Both Weaver syndrome and Sotos syndrome are generally caused by mutations in genes that regulate cell growth and division, specifically the EZH2 gene in Weaver syndrome and the NSD1 gene in Sotos syndrome.\n3. TRUE - Weaver syndrome is indeed characterized by rapid growth beginning in the fetal stage and continuing through childhood.\n4. TRUE - People with Weaver syndrome may show intellectual disability, delayed speech and language development, and distinctive facial features among other symptoms.\n5. FALSE [correction]: While both Weaver syndrome and Sotos syndrome are associated with an increased risk of neoplasia, Weaver syndrome has a specific association with an increased risk of hematologic malignancies and brain tumors, rather than neuroblastoma, which is more commonly associated with Sotos syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the releases of JASPAR database are:\n1. PredictProtein for Debian operating system and derivatives, such as Ubuntu, Bio-Linux, and Cloud BioLinux.\n2. Standard set of open source Debian packages.\n3. Most popular prediction methods from the Rost Lab, including methods for the prediction of secondary structure and solvent accessibility (profphd), nuclear localization signals (predictnls), and intrinsically disordered regions (norsnet).\n4. Two case studies that successfully utilize PredictProtein packages for high performance computing in the cloud: the first analyzes protein disorder for whole organisms, and the second analyzes the effect of all possible single sequence variants in protein coding regions of the human genome.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the viral KP4 protein is to catalyze the hydrolysis of polyprotein pVP2-VP4-VP3 of infectious bursal disease virus. The KP4 protein is a serine protease that self-assembles into tubule-like structures, which are functional enzymes with endopeptidase activity. The protein's activity can be inhibited by 1 mM of Ni⁺ ions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The viral KP4 protein catalyzes the hydrolysis of polyprotein pVP2-VP4-VP3 of infectious bursal disease virus.\n2. KP4 protein is a serine protease.\n3. KP4 self-assembles into tubule-like structures.\n4. KP4 protein has endopeptidase activity.\n5. The activity of KP4 protein can be inhibited by 1 mM of Ni⁺ ions.",
    "llama-2-7b-chat-hf_fact": [
      "The viral KP4 protein catalyzes the hydrolysis of polyprotein pVP2-VP4-VP3 of infectious bursal disease virus.",
      "KP4 protein is a serine protease.",
      "KP4 self-assembles into tubule-like structures.",
      "KP4 protein has endopeptidase activity.",
      "The activity of KP4 protein can be inhibited by 1 mM of Ni⁺ ions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The VP4 protein catalyzes the hydrolysis of polyprotein pVP2-VP4-VP3 of infectious bursal disease virus, not the KP4 protein.\n2. FALSE [correction]: The statement refers to the VP4 protein being a serine protease, not KP4.\n3. UNKNOWN\n4. TRUE – Assume that the reference to KP4 protein having endopeptidase activity was intended to refer to VP4 protein, which is indeed a protease with endopeptidase activity.\n5. UNKNOWN – Without specific information on the KP4 protein or confirmation the statement is referring to the VP4 protein, and without context on the inhibitory conditions, it's not possible to affirm the impact of Ni⁺ ions on its activity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, DITPA (dihydrotestosterone propionate) is a thyroid hormone analog that has been utilized in experimental and clinical studies. Specifically, the document mentions that DHTP (dihydrotestosterone propionate) was used in two experiments to identify sites in the female rat brain where dihydrotestosterone acts to inhibit estradiol-induced feminine sexual behavior. The experiments involved implanting 27 gauge cannulae containing either DHTP or cholesterol into various brain regions, including the lateral septum, preoptic area-anterior hypothalamic area, ventromedial nucleus of the hypothalamus, and caudate putamen. The results of the experiments showed that only lateral septal implants of DHTP resulted in significant reductions in lordotic behavior (a measure of feminine sexual behavior) in response to estradiol treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (dihydrotestosterone propionate) is a thyroid hormone analog used in experimental and clinical studies.\n2. DHTP (dihydrotestosterone propionate) was used in experiments to identify sites in the female rat brain affected by dihydrotestosterone.\n3. In the mentioned studies, 27 gauge cannulae containing DHTP or cholesterol were implanted into various brain regions of rats.\n4. One of the tested brain regions in the experiments included the lateral septum.\n5. According to the results, implants of DHTP in the lateral septum significantly reduced lordotic behavior in female rats in response to estradiol treatment.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (dihydrotestosterone propionate) is a thyroid hormone analog used in experimental and clinical studies.",
      "DHTP (dihydrotestosterone propionate) was used in experiments to identify sites in the female rat brain affected by dihydrotestosterone.",
      "In the mentioned studies, 27 gauge cannulae containing DHTP or cholesterol were implanted into various brain regions of rats.",
      "One of the tested brain regions in the experiments included the lateral septum.",
      "According to the results, implants of DHTP in the lateral septum significantly reduced lordotic behavior in female rats in response to estradiol treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DITPA (3,5-Diiodothyropropionic acid) is a thyroid hormone analog used in experimental and clinical studies, while \"dihydrotestosterone propionate\" does not match DITPA and appears to be an androgen.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While the provided corrections and responses align with knowledge available up until the cutoff in 2023, the specificity of the statements regarding studies may require access to the original research to confirm their accuracy, which is not available in this context. Thus, statements 3, 4, and 5 are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the COUGER tool appears to be a type of dental tool that has been coated with diamond for improved cutting performance and tool life in orthodontic applications. The tool consists of a cemented tungsten carbide (WC-Co) substrate with an average grain size of 1-3 microm, and is either etched with cobalt or alternatively, a titanium nitride (TiN) interlayer is used prior to diamond deposition. The diamond film quality and purity are characterized using scanning electron microscopy (SEM) and micro Raman spectroscopy. The performance of the diamond-coated WC-Co tools, uncoated WC-Co tools, and diamond-embedded (sintered) tools are compared by drilling holes in various materials such as human tooth, borosilicate glass, and acrylic tooth materials. The document suggests that using an interlayer such as TiN prior to diamond deposition provides the best surface preparation for producing dental tools.",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is a dental tool with a diamond coating designed to enhance cutting performance and tool life for orthodontic applications.\n2. The substrate of the COUGER tool is made of cemented tungsten carbide with an average grain size of 1-3 micrometers.\n3. Prior to diamond deposition, the COUGER tool is either etched with cobalt or treated with a titanium nitride (TiN) interlayer.\n4. The quality and purity of the diamond film on the COUGER tool are characterized by scanning electron microscopy (SEM) and micro Raman spectroscopy.\n5. The COUGER tool's performance is compared by drilling holes in various materials, which include human tooth, borosilicate glass, and acrylic tooth materials.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is a dental tool with a diamond coating designed to enhance cutting performance and tool life for orthodontic applications.",
      "The substrate of the COUGER tool is made of cemented tungsten carbide with an average grain size of 1-3 micrometers.",
      "Prior to diamond deposition, the COUGER tool is either etched with cobalt or treated with a titanium nitride (TiN) interlayer.",
      "The quality and purity of the diamond film on the COUGER tool are characterized by scanning electron microscopy (SEM) and micro Raman spectroscopy.",
      "The COUGER tool's performance is compared by drilling holes in various materials, which include human tooth, borosilicate glass, and acrylic tooth materials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (The COUGER tool does not correspond to known dental tools, and the description provided may be fictional or specific to a niche application not widely recognized).\n2. UNKNOWN (Without valid data or source information about the COUGER tool, the substrate composition cannot be confirmed as fact).\n3. UNKNOWN (The specific pre-treatment process for the COUGER tool's diamond deposition is not verifiable without additional context or information).\n4. TRUE (While the COUGER tool's existence is uncertain, the statement about using SEM and micro Raman spectroscopy to characterize diamond film quality and purity is accurate in the context of material science and engineering).\n5. UNKNOWN (The performance comparison of the COUGER tool as described is not verifiable without additional data or confirmation from a reliable source).",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there are no drugs available to treat tick-borne encephalitis (TBE) in individuals with immunity defects. The study suggests that pre-treatment with an inactivated vaccine against TBE does not protect mice with immunity defects against neuroinfection induced by subsequent inoculation with either Langat virus or TBE virus. This implies that the use of a live vaccine against TBE in individuals with immunity defects is dangerous and could potentially lead to affection of the central nervous system.\nTherefore, the answer to the user's question is that there are no drugs available to treat TBE in individuals with immunity defects, and the use of a live vaccine against TBE in such individuals is not recommended due to the risk of adverse effects on the central nervous system.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are no drugs available to treat tick-borne encephalitis (TBE) in individuals with immunity defects.\n2. Pre-treatment with an inactivated vaccine against TBE does not protect mice with immunity defects against neuroinfection from Langat virus or TBE virus.\n3. The use of a live vaccine against TBE in individuals with immunity defects is considered dangerous.\n4. Using a live vaccine against TBE could potentially affect the central nervous system in individuals with immunity defects.",
    "llama-2-7b-chat-hf_fact": [
      "There are no drugs available to treat tick-borne encephalitis (TBE) in individuals with immunity defects.",
      "Pre-treatment with an inactivated vaccine against TBE does not protect mice with immunity defects against neuroinfection from Langat virus or TBE virus.",
      "The use of a live vaccine against TBE in individuals with immunity defects is considered dangerous.",
      "Using a live vaccine against TBE could potentially affect the central nervous system in individuals with immunity defects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: There are no specific antiviral drugs available to treat tick-borne encephalitis (TBE); the treatment is mainly supportive. Individuals with immune deficiencies would not have a specific drug-based treatment targeting TBE.\n2. FALSE [correction]: Pretreatment with an inactivated vaccine could still offer some level of protection against TBE or similar viruses such as Langat virus in mice, even if their immunity is not fully competent. Protection may be limited and not as effective as in individuals with a fully functioning immune system, but to claim no protection without specifying conditions is misleading.\n3. TRUE: Live vaccines typically pose a risk to individuals with immunity defects since their immune systems may be unable to control the vaccine strain virus, which could potentially cause disease.\n4. TRUE: Because live vaccines contain attenuated forms of the virus, there is a theoretical risk that the vaccine could affect the central nervous system in individuals with compromised immune systems. This is why live vaccines are generally contraindicated in these individuals.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations that is available is GenSAS (The Genome Sequence Annotation Server). GenSAS is a secure, web-based genome annotation platform that provides structural and functional annotation, as well as manual curation, and integrates popular command line-based annotation tools under a single, easy-to-use, online interface. It allows users to view annotation data and manually curate gene models, and provides the latest versions of the NCBI RefSeq transcript and protein databases, as well as the SwissProt and TrEMBL protein databases for all users. Additionally, GenSAS enables collaborative annotation through shared projects, and generates the final files of the annotated gene models in common file formats for use with other annotation tools, submission to a repository, and use in publications.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Genome Sequence Annotation Server (GenSAS) is a web-based genome annotation platform.\n2. GenSAS provides structural and functional annotation in addition to manual curation.\n3. The platform integrates popular command line-based annotation tools.\n4. GenSAS offers access to the latest versions of the NCBI RefSeq transcript and protein databases, SwissProt, and TrEMBL protein databases.\n5. GenSAS allows for collaborative annotation through shared projects.",
    "llama-2-7b-chat-hf_fact": [
      "The Genome Sequence Annotation Server (GenSAS) is a web-based genome annotation platform.",
      "GenSAS provides structural and functional annotation in addition to manual curation.",
      "The platform integrates popular command line-based annotation tools.",
      "GenSAS offers access to the latest versions of the NCBI RefSeq transcript and protein databases, SwissProt, and TrEMBL protein databases.",
      "GenSAS allows for collaborative annotation through shared projects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGiven the context and the nature of genomic annotation platforms, these statements align with standard features of such systems. Users should verify against the latest resources and updates on GenSAS for any recent changes to its offerings or capabilities.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the syndromes associated with mutations in the EZH2 gene are:\n1. Cardiovascular malformations: The study found that Ezh2 mutant mice exhibited a wide spectrum of cardiovascular malformations, which led to perinatal death. These malformations included hypoplastic endocardial cushions and impaired endothelial-to-mesenchymal transition (EMT) process in the heart.\n2. Decreased cardiomyocyte proliferation: The study also found that the hearts of Ezh2 mutant mice exhibited decreased cardiomyocyte proliferation and increased apoptosis.\n3. Impaired Hey2 gene expression: The study identified that the Hey2 gene, which is important for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2. The regulation of Hey2 expression by Ezh2 may be independent of Notch signaling activity.\nTherefore, based on the information provided in the document, mutations in the EZH2 gene are associated with cardiovascular malformations, decreased cardiomyocyte proliferation, and impaired expression of the Hey2 gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with cardiovascular malformations in Ezh2 mutant mice.\n2. These cardiovascular malformations can lead to perinatal death in Ezh2 mutant mice.\n3. Ezh2 mutant mice can exhibit decreased cardiomyocyte proliferation.\n4. Increased apoptosis is observed in the hearts of Ezh2 mutant mice with EZH2 gene mutations.\n5. The Hey2 gene, crucial for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2 and can be affected by mutations in the EZH2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with cardiovascular malformations in Ezh2 mutant mice.",
      "These cardiovascular malformations can lead to perinatal death in Ezh2 mutant mice.",
      "Ezh2 mutant mice can exhibit decreased cardiomyocyte proliferation.",
      "Increased apoptosis is observed in the hearts of Ezh2 mutant mice with EZH2 gene mutations.",
      "The Hey2 gene, crucial for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2 and can be affected by mutations in the EZH2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Mutations in the EZH2 gene have been associated with a variety of developmental disorders and defects including cardiovascular malformations in organism models like mice.\n2. TRUE: Cardiovascular malformations can be severe enough to cause perinatal death in mouse models, including those with mutations in the EZH2 gene.\n3. TRUE: Alterations in the EZH2 gene can affect heart development, and one of the observed effects in mouse models can include decreased cardiomyocyte proliferation.\n4. TRUE: Increased apoptosis, or programmed cell death, is often observed in developmental disorders affecting the heart, and this could occur in Ezh2 mutant mice with EZH2 gene mutations.\n5. TRUE: The Hey2 gene is known to be important in cardiac development, and because EZH2 is involved in gene regulatory networks, it is plausible that Hey2 could be affected by mutations in the EZH2 gene in the context of cardiomyocyte proliferation and morphogenesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Spectrin: The document mentions that spectrin is one of the proteins that undergoes a dimer-to-tetramer transition, and provides information on the proportion of alpha-helix in both the dimer and tetramer association states.\n2. Ankyrin: The document also mentions that ankyrin is another protein that undergoes a dimer-to-tetramer transition, and provides information on the temperature-dependent changes in the conformation of both states.\nIt is important to note that this list may not be exhaustive, as there may be other human proteins that undergo a dimer-to-tetramer transition that are not mentioned in the provided document. Additionally, the information provided may not be applicable to all isoforms of these proteins, and further research may be necessary to confirm the presence of a dimer-to-tetramer transition in each isoform.",
    "llama-2-7b-chat-hf_fact_raw": "1. Spectrin is a human protein that undergoes a dimer-to-tetramer transition.\n2. Spectrin's dimer and tetramer association states have different proportions of alpha-helix.\n3. Ankyrin is another human protein that undergoes a dimer-to-tetramer transition.\n4. Ankyrin's dimer-to-tetramer transition is temperature-dependent.\n5. The list of human proteins provided that undergo a dimer-to-tetramer transition may not be exhaustive.",
    "llama-2-7b-chat-hf_fact": [
      "Spectrin is a human protein that undergoes a dimer-to-tetramer transition.",
      "Spectrin's dimer and tetramer association states have different proportions of alpha-helix.",
      "Ankyrin is another human protein that undergoes a dimer-to-tetramer transition.",
      "Ankyrin's dimer-to-tetramer transition is temperature-dependent.",
      "The list of human proteins provided that undergo a dimer-to-tetramer transition may not be exhaustive."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: Ankyrin does not undergo a dimer-to-tetramer transition; it is a protein that associates with spectrin.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is likely to be SERCA (sarcoplasmic reticulum Ca-ATPase).\nThe document mentions that PLN is a small regulatory membrane protein involved in the regulation of SERCA, and that oligomerization and posttranslational phosphorylation of PLN can affect the molecular mechanism of SERCA's regulation. Additionally, the document discusses the potential use of PLN analogs in gene therapy, which suggests that PLN is a key player in the regulation of SERCA activity.\nTherefore, based on the information provided in Document-0, it can be inferred that SERCA is the protein that has been found to interact with PLN and is also an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein SERCA (sarcoplasmic reticulum Ca-ATPase) interacts with phospholamban (PLN).\n2. Phospholamban (PLN) is a small regulatory membrane protein.\n3. The regulation of SERCA involves oligomerization and posttranslational phosphorylation of PLN.\n4. Phospholamban (PLN) affects the molecular mechanism of SERCA's regulation.\n5. PLN analogs are being considered for use in gene therapy.",
    "llama-2-7b-chat-hf_fact": [
      "The protein SERCA (sarcoplasmic reticulum Ca-ATPase) interacts with phospholamban (PLN).",
      "Phospholamban (PLN) is a small regulatory membrane protein.",
      "The regulation of SERCA involves oligomerization and posttranslational phosphorylation of PLN.",
      "Phospholamban (PLN) affects the molecular mechanism of SERCA's regulation.",
      "PLN analogs are being considered for use in gene therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is some evidence to suggest that vitamin D supplementation may reduce the incidence of falls in older people. The D-Vitaal study mentioned in the document found that vitamin D supplementation was effective in reducing the incidence of major depressive disorder and anxiety symptoms in older adults, which are both risk factors for falls. While the study did not specifically investigate the effect of vitamin D supplementation on falls, the findings suggest that it may have a positive impact on overall mental and physical health in this population.\nIt is important to note that the study had a relatively small sample size and was conducted in a specific population of older adults with low vitamin D levels. Further research is needed to confirm these findings and establish the generalizability of the results to other populations. However, the study provides some evidence to suggest that vitamin D supplementation may be a useful preventive intervention strategy for reducing the risk of falls in older adults.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitamin D supplementation may reduce the incidence of falls in older people according to some evidence.\n2. The D-Vitaal study indicated that vitamin D supplementation was effective in reducing the incidence of major depressive disorder and anxiety symptoms in older adults.\n3. Major depressive disorder and anxiety symptoms are risk factors for falls.\n4. The D-Vitaal study had a small sample size.\n5. The D-Vitaal study was conducted in a specific population of older adults with low vitamin D levels.",
    "llama-2-7b-chat-hf_fact": [
      "Vitamin D supplementation may reduce the incidence of falls in older people according to some evidence.",
      "The D-Vitaal study indicated that vitamin D supplementation was effective in reducing the incidence of major depressive disorder and anxiety symptoms in older adults.",
      "Major depressive disorder and anxiety symptoms are risk factors for falls.",
      "The D-Vitaal study had a small sample size.",
      "The D-Vitaal study was conducted in a specific population of older adults with low vitamin D levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While the D-Vitaal study aimed to investigate the effects of vitamin D supplementation, there's no widely recognized evidence to confirm its effectiveness in reducing the incidence of major depressive disorder and anxiety symptoms. Rather, the study focused on the effects of vitamin D on functional limitations, not directly on depression and anxiety outcomes.\n3. TRUE\n4. UNKNOWN: The actual sample size of the D-Vitaal study has not been provided, so it is not possible to determine the truthfulness of this statement without further information.\n5. TRUE: The D-Vitaal study generally focuses on older adults with specific conditions or deficiencies like low vitamin D levels.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there does appear to be an association between Jarid2 and miR-155 in Th17 cells. The document states that high levels of microRNA-155 (miR-155) are associated with poor outcome in acute myeloid leukemia (AML), and that miR-155 is regulated by NF-κB, which is in part controlled by the NEDD8-dependent ubiquitin ligases. The document also mentions that MLN4924, an inhibitor of NEDD8-activating enzyme, decreases binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells. This results in the upregulation of the miR-155 targets SHIP1 and PU.1, leading to monocytic differentiation and apoptosis. Overall, the document suggests that targeting miR-155 with MLN4924 may be a potential therapeutic approach for AML.\nIn particular, the document highlights the following associations between Jarid2 and miR-155:\n1. Regulation of miR-155 by NF-κB: The document states that NF-κB is a transcription factor that regulates the expression of miR-155 in AML cells.\n2. Inhibition of NEDD8-activating enzyme: The document mentions that MLN4924, an inhibitor of NEDD8-activating enzyme, decreases binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells.\n3. Upregulation of miR-155 targets: The document shows that downregulation of miR-155 leads to the upregulation of its targets SHIP1 and PU.1, which are involved in monocytic differentiation and apoptosis.\nBased on these associations, it can be inferred that Jarid2 may play a role in regulating the expression of miR-155 in Th17 cells, possibly by modulating the activity",
    "llama-2-7b-chat-hf_fact_raw": "1. High levels of microRNA-155 (miR-155) are associated with poor outcomes in acute myeloid leukemia (AML).\n2. NF-κB regulates the expression of miR-155 in AML cells.\n3. MLN4924 is an inhibitor of NEDD8-activating enzyme.\n4. MLN4924 decreases the binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells.\n5. Downregulation of miR-155 leads to upregulation of its targets SHIP1 and PU.1, which are involved in monocytic differentiation and apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "High levels of microRNA-155 (miR-155) are associated with poor outcomes in acute myeloid leukemia (AML).",
      "NF-κB regulates the expression of miR-155 in AML cells.",
      "MLN4924 is an inhibitor of NEDD8-activating enzyme.",
      "MLN4924 decreases the binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells.",
      "Downregulation of miR-155 leads to upregulation of its targets SHIP1 and PU.1, which are involved in monocytic differentiation and apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: High levels of microRNA-155 (miR-155) are associated with poor prognostic outcomes in various cancers, including acute myeloid leukemia (AML), as reported in scientific literature.\n2. TRUE: NF-κB is known to regulate the expression of various genes, including miR-155, particularly in immune and inflammatory responses, and this regulatory relationship may extend to AML cells.\n3. TRUE: MLN4924, also known as pevonedistat, is a small molecule inhibitor that targets NEDD8-activating enzyme, which is involved in the neddylation pathway that modifies proteins.\n4. UNKNOWN: Without specific research or data, it is unclear whether MLN4924 directly decreases the binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells, although it is plausible given the roles of NF-κB and neddylation in cellular processes.\n5. UNKNOWN: The specific impact of miR-155 downregulation on the upregulation of its target genes SHIP1 and PU.1 and their roles in monocytic differentiation and apoptosis in AML cells requires specific supporting evidence which is not provided here.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 Hox genes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the phosphorylation consensus motifs for Casein Kinase 1 (CK1):\n1. Ser/Thr-Pro-Ser/Thr (STPS)\n2. Ser/Thr-Tyr-Ser/Thr (STYS)\n3. Ser/Thr-Pro-Gly-Ser/Thr (SPGS)\n4. Ser/Thr-Pro-Gly-Tyr-Ser/Thr (SPGY)\n5. Ser/Thr-Pro-Gly-Pro-Ser/Thr (SPGPS)\nThese consensus motifs are commonly found in the phosphorylation sites of CK1 and are important for its regulation by phosphorylation.\nIt's worth noting that the specific phosphorylation sites and consensus motifs of CK1 can vary depending on the source and the specific isoform of the enzyme. Additionally, the phosphorylation status of CK1 can be regulated by a variety of upstream kinases and phosphatases, which can also affect its activity and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. One of the phosphorylation consensus motifs for Casein Kinase 1 (CK1) is Ser/Thr-Pro-Ser/Thr (STPS).\n2. Another phosphorylation consensus motif for CK1 is Ser/Thr-Tyr-Ser/Thr (STYS).\n3. The motif Ser/Thr-Pro-Gly-Ser/Thr (SPGS) is also a phosphorylation consensus for CK1.\n4. The motif Ser/Thr-Pro-Gly-Tyr-Ser/Thr (SPGY) is a phosphorylation consensus for CK1.\n5. Ser/Thr-Pro-Gly-Pro-Ser/Thr (SPGPS) is listed as a phosphorylation consensus motif for CK1.",
    "llama-2-7b-chat-hf_fact": [
      "One of the phosphorylation consensus motifs for Casein Kinase 1 (CK1) is Ser/Thr-Pro-Ser/Thr (STPS).",
      "Another phosphorylation consensus motif for CK1 is Ser/Thr-Tyr-Ser/Thr (STYS).",
      "The motif Ser/Thr-Pro-Gly-Ser/Thr (SPGS) is also a phosphorylation consensus for CK1.",
      "The motif Ser/Thr-Pro-Gly-Tyr-Ser/Thr (SPGY) is a phosphorylation consensus for CK1.",
      "Ser/Thr-Pro-Gly-Pro-Ser/Thr (SPGPS) is listed as a phosphorylation consensus motif for CK1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CK1 generally targets serine or threonine residues that are followed by a proline, but the exact motif Ser/Thr-Tyr-Ser/Thr (STYS) is not a recognized consensus motif for CK1.\n3. FALSE [correction]: While CK1 does target serine or threonine residues followed by proline, the specific motif Ser/Thr-Pro-Gly-Ser/Thr (SPGS) is not a standard consensus motif for CK1.\n4. UNKNOWN: Without specific literature or database references, it is unclear if Ser/Thr-Pro-Gly-Tyr-Ser/Thr (SPGY) is a valid phosphorylation consensus motif for CK1.\n5. UNKNOWN: Without specific literature or database references, it is unclear if Ser/Thr-Pro-Gly-Pro-Ser/Thr (SPGPS) is a valid phosphorylation consensus motif for CK1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Hemoglobin J Sardegna: This is a human Hb variant in which a posttranslational deamidation process takes place, transforming an Asn to an Asp residue at position 50 (alpha50(CD8)His-->Asn -->Asp).\n2. Alpha-globin: The alpha2-globin gene is selectively amplified in this variant, and the protein sequence is determined.\n3. Beta-globin: The beta-globin gene is also expressed in this variant, although the document does not provide specific information on the beta-globin protein sequence.\nIt is important to note that the document focuses on the characterization of the Hemoglobin J Sardegna variant, and does not provide information on other proteins encoded by the ASPH gene. However, the document does mention other proteins in which Asn or Gln residues have been implicated by DNA analysis alone, such as:\n1. Myoglobin: A protein found in muscle tissue that is involved in the transport of oxygen.\n2. Ceruloplasmin: A copper-containing protein found in blood plasma that is involved in the transport of copper ions.\n3. Haemoglobin F: A variant of the hemoglobin protein found in some individuals with sickle cell anemia.\nThese findings suggest that the ASPH gene encodes multiple proteins that play important roles in various physiological processes, and that the complete characterization of variant proteins by use of both DNA and protein analyses is important for understanding their molecular mechanisms and clinical significance.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hemoglobin J Sardegna is a variant where a deamidation process converts an Asn to an Asp residue at position 50 (alpha50(CD8)His-->Asn -->Asp).\n2. Alpha-globin is part of the proteins encoded by the ASPH gene, with the alpha2-globin gene being selectively amplified in the Hemoglobin J Sardegna variant.\n3. Beta-globin is also expressed in the Hemoglobin J Sardegna variant encoded by the ASPH gene.\n4. Myoglobin, associated with oxygen transport in muscle tissue, is mentioned as a protein that has Asn or Gln residues implicated by DNA analysis.\n5. Ceruloplasmin, which contains copper and is involved in the transport of copper ions in blood plasma, is identified in relation to the ASPH gene.",
    "llama-2-7b-chat-hf_fact": [
      "Hemoglobin J Sardegna is a variant where a deamidation process converts an Asn to an Asp residue at position 50 (alpha50(CD8)His-->Asn -->Asp).",
      "Alpha-globin is part of the proteins encoded by the ASPH gene, with the alpha2-globin gene being selectively amplified in the Hemoglobin J Sardegna variant.",
      "Beta-globin is also expressed in the Hemoglobin J Sardegna variant encoded by the ASPH gene.",
      "Myoglobin, associated with oxygen transport in muscle tissue, is mentioned as a protein that has Asn or Gln residues implicated by DNA analysis.",
      "Ceruloplasmin, which contains copper and is involved in the transport of copper ions in blood plasma, is identified in relation to the ASPH gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The alpha-globin proteins are encoded by the HBA1 and HBA2 genes, not the ASPH gene.\n3. TRUE – Beta-globin is expressed in all forms of hemoglobin, including variants like Hemoglobin J Sardegna, but it is encoded by the HBB gene, not the ASPH gene.\n4. UNKNOWN\n5. FALSE [correction]: Ceruloplasmin is indeed a copper-binding protein involved in iron metabolism, but it is not encoded by the ASPH gene; rather, it is encoded by the CP gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, empagliflozin was FDA approved in 2014. According to the document, the EMPA-REG OUTCOME trial, which was conducted to investigate the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes, was completed in 2014. Additionally, the document mentions that the results of the trial were published in 2015. Therefore, based on the information provided, empagliflozin was FDA approved in 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.\n2. The EMPA-REG OUTCOME trial investigating the effect of empagliflozin on aminotransferases in individuals with type 2 diabetes was completed in 2014.\n3. The results of the EMPA-REG OUTCOME trial were published in 2015.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014.",
      "The EMPA-REG OUTCOME trial investigating the effect of empagliflozin on aminotransferases in individuals with type 2 diabetes was completed in 2014.",
      "The results of the EMPA-REG OUTCOME trial were published in 2015."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The EMPA-REG OUTCOME trial investigated the effect of empagliflozin on cardiovascular outcomes in individuals with type 2 diabetes, not specifically on aminotransferases.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the loss of the protein Lon1 in the plant Arabidopsis has been shown to result in a loss of virulence in the bacterial pathogen Ralstonia solanacearum. Specifically, a study found that a mutation in the sigma(70) protein of R. solanacearum, which is mediated by the Lon1 protein, resulted in a loss of in planta growth and virulence. This suggests that the Lon1 protein plays a critical role in the growth and virulence of R. solanacearum in Arabidopsis, and that its loss can lead to a decrease in the bacteria's ability to cause disease in the plant.",
    "llama-2-7b-chat-hf_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis results in loss of virulence of the bacterial pathogen Ralstonia solanacearum.\n2. A mutation in the sigma(70) protein of Ralstonia solanacearum, which is mediated by the Lon1 protein, leads to a reduction in in planta growth and virulence.\n3. The Lon1 protein is important for the growth and virulence of Ralstonia solanacearum in Arabidopsis plants.",
    "llama-2-7b-chat-hf_fact": [
      "Loss of the protein Lon1 in Arabidopsis results in loss of virulence of the bacterial pathogen Ralstonia solanacearum.",
      "A mutation in the sigma(70) protein of Ralstonia solanacearum, which is mediated by the Lon1 protein, leads to a reduction in in planta growth and virulence.",
      "The Lon1 protein is important for the growth and virulence of Ralstonia solanacearum in Arabidopsis plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Loss of the protein Lon1 in Arabidopsis would not result in loss of virulence of the bacterial pathogen Ralstonia solanacearum, since Lon1 is presumably a protein in Arabidopsis, not the pathogen. The loss in Arabidopsis would more likely affect the plant's response or resistance to the pathogen.\n2. UNKNOWN: Without further context, it is unclear whether a mutation in the sigma(70) protein of Ralstonia solanacearum is mediated by the plant's Lon1 protein or if there is a direct relationship between the Lon1 protein in Arabidopsis and mutations in the bacteria's sigma(70) protein.\n3. FALSE [correction]: The Lon1 protein is important for Arabidopsis, not for the growth and virulence of Ralstonia solanacearum. Typically, proteins named in the context of a plant (like Lon1 in Arabidopsis) are part of the plant's biology, not that of the pathogen infecting the plant.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is no linker histone in the yeast genome. The document states that there are only two copies of the histone genes H2A and H2B within the haploid yeast genome, and these copies are separated by a minimum distance of 35-60 kb from each other. Additionally, the document states that sequences coding for histones H3 and H4 have not been detected in the immediate vicinity of the genes for H2A and H2B. These findings suggest that there is no linker histone present in the yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no linker histone present in the yeast genome.\n2. The haploid yeast genome contains only two copies of the histone genes H2A and H2B.\n3. The two copies of the histone genes H2A and H2B are separated by a minimum distance of 35-60 kilobases.\n4. Sequences coding for histones H3 and H4 have not been detected near the genes for H2A and H2B in the yeast genome.",
    "llama-2-7b-chat-hf_fact": [
      "There is no linker histone present in the yeast genome.",
      "The haploid yeast genome contains only two copies of the histone genes H2A and H2B.",
      "The two copies of the histone genes H2A and H2B are separated by a minimum distance of 35-60 kilobases.",
      "Sequences coding for histones H3 and H4 have not been detected near the genes for H2A and H2B in the yeast genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The yeast Saccharomyces cerevisiae lacks linker histone H1, which is generally present in other eukaryotic cells.\n2. FALSE [correction]: The haploid yeast genome contains two sets of histone genes, each containing one copy of H2A, H2B, H3, and H4, not only two copies of the histone genes H2A and H2B.\n3. FALSE [correction]: The two copies of the histone genes are not separated by 35-60 kilobases. Instead, in budding yeast, there are two histone gene clusters, each approximately 1 kilobase long, with the two clusters separated by a greater distance.\n4. FALSE [correction]: Sequences coding for histones H3 and H4 are, in fact, found near the genes for H2A and H2B within the histone gene clusters in the yeast genome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is no evidence to suggest that tomato juice specifically lowers cholesterol levels. The study you mentioned found that tomato juice consumption resulted in a significant reduction in total cholesterol and LDL-C only in the control group at the end of the study, but no significant differences were observed in the remainder of the assessed parameters along the study. This suggests that tomato juice may have favorable effects on lipid metabolism, but further research is needed to confirm this finding. Additionally, the study did not investigate the effects of tomato juice on cholesterol levels specifically, so it is unclear whether the observed reduction in total cholesterol and LDL-C was due to the tomato juice itself or other factors. Therefore, while there is some evidence to suggest that tomato juice may have beneficial effects on lipid metabolism, there is currently no conclusive evidence to support the claim that tomato juice lowers cholesterol levels.",
    "llama-2-7b-chat-hf_fact_raw": "1. The study mentioned found a significant reduction in total cholesterol and LDL-C in the control group at the end of the study with the consumption of tomato juice.\n2. No significant differences were observed in the remainder of the assessed parameters along the study.\n3. The study did not investigate the effects of tomato juice on cholesterol levels specifically.\n4. Further research is needed to confirm the effects of tomato juice on lipid metabolism.\n5. There is currently no conclusive evidence to support the claim that tomato juice lowers cholesterol levels.",
    "llama-2-7b-chat-hf_fact": [
      "The study mentioned found a significant reduction in total cholesterol and LDL-C in the control group at the end of the study with the consumption of tomato juice.",
      "No significant differences were observed in the remainder of the assessed parameters along the study.",
      "The study did not investigate the effects of tomato juice on cholesterol levels specifically.",
      "Further research is needed to confirm the effects of tomato juice on lipid metabolism.",
      "There is currently no conclusive evidence to support the claim that tomato juice lowers cholesterol levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (The statement implies a specific study's findings, but without the details of the study, we cannot verify the claim.)\n2. UNKNOWN (Similar to statement 1, we lack the specific context or details of the study to verify this claim.)\n3. FALSE [correction]: The study did investigate the effects of tomato juice on cholesterol levels, as implied by statement 1 mentioning a reduction in total cholesterol and LDL-C.\n4. TRUE (This is a common conclusion for scientific studies, emphasizing the need for additional research to build upon initial findings and generalize the results.)\n5. UNKNOWN (This statement requires a broad review of existing research on the topic, and without having that comprehensive overview, we cannot confirm or deny the claim with certainty.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Hsp70 and Hsp110 affect mRNA stability in the following ways:\n1. Hsp70: The document states that Hsp70 mRNA is little present in the sham control brain, indicating that it is not significantly involved in mRNA stability in the absence of stress. However, after transient global ischemia, Hsp70 mRNA is selectively induced in some cell populations, such as dentate granule cells and hippocampal cells, especially in the dentate gyrus, at 1 and 3 hours after ischemia. This suggests that Hsp70 may play a role in protecting mRNA from degradation during stressful conditions, particularly in these cell populations.\n2. Hsp110: The document does not provide information about the induction of Hsp110 mRNA after transient global ischemia. Therefore, it cannot be concluded whether Hsp110 affects mRNA stability in the same way as Hsp70.\nIn summary, the document suggests that Hsp70 may play a role in protecting mRNA from degradation during stressful conditions, such as transient global ischemia, particularly in certain cell populations. However, further research is needed to fully understand the role of Hsp70 and Hsp110 in mRNA stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 mRNA is little present in the sham control brain.\n2. After transient global ischemia, Hsp70 mRNA is selectively induced in some cell populations like dentate granule cells and hippocampal cells, especially in the dentate gyrus, at 1 and 3 hours after ischemia.\n3. Hsp70 may play a role in protecting mRNA from degradation during stressful conditions.\n4. There is selective induction of Hsp70 mRNA in response to transient global ischemia.\n5. The document does not provide information about the induction of Hsp110 mRNA after transient global ischemia.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 mRNA is little present in the sham control brain.",
      "After transient global ischemia, Hsp70 mRNA is selectively induced in some cell populations like dentate granule cells and hippocampal cells, especially in the dentate gyrus, at 1 and 3 hours after ischemia.",
      "Hsp70 may play a role in protecting mRNA from degradation during stressful conditions.",
      "There is selective induction of Hsp70 mRNA in response to transient global ischemia.",
      "The document does not provide information about the induction of Hsp110 mRNA after transient global ischemia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE: Hsp70 is a heat shock protein that is known for its role in protecting cells from stress. It helps in the stabilization of proteins and protection of the cellular structure, which could include roles in preventing mRNA degradation during stress.\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or passage to verify the details about Hsp70 mRNA levels in the sham control brain, the induction in cell populations after ischemia, and the potential information about Hsp110 mRNA, responses to statements 1, 2, 4, and 5 would require additional information to confirm their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following deiodinases are present in skeletal muscle:\n1. Type 1 deiodinase (D1): The document mentions the presence of abnormal mitochondria with thin connecting stalks, large electron-dense bodies, and abnormal cristae in the affected muscle. These changes are consistent with the action of D1, which is involved in the deiodination of thyroid hormones and plays a role in regulating mitochondrial function.\n2. Type 2 deiodinase (D2): The document also mentions the presence of vacuoles of variable size clustered in subsarcolemmal positions and in rows between myofibrils in the affected muscle. These vacuoles are consistent with the action of D2, which is involved in the deiodination of thyroid hormones and plays a role in regulating protein synthesis and degradation.\nIt is important to note that these findings are based on the analysis of skeletal muscle from cattle with progressive degenerative myeloencephalopathy, and may not be directly applicable to humans. However, the presence of these deiodinases in skeletal muscle is a well-established fact, and their involvement in muscle function and disease is a widely accepted concept in the field of endocrinology and muscle physiology.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 1 deiodinase (D1) is present in skeletal muscle and is involved in the deiodination of thyroid hormones.\n2. Type 1 deiodinase (D1) plays a role in regulating mitochondrial function.\n3. Type 2 deiodinase (D2) is present in skeletal muscle and is involved in the deiodination of thyroid hormones.\n4. Type 2 deiodinase (D2) plays a role in regulating protein synthesis and degradation.\n5. The presence of Type 1 and Type 2 deiodinases in skeletal muscle is a well-established fact.",
    "llama-2-7b-chat-hf_fact": [
      "Type 1 deiodinase (D1) is present in skeletal muscle and is involved in the deiodination of thyroid hormones.",
      "Type 1 deiodinase (D1) plays a role in regulating mitochondrial function.",
      "Type 2 deiodinase (D2) is present in skeletal muscle and is involved in the deiodination of thyroid hormones.",
      "Type 2 deiodinase (D2) plays a role in regulating protein synthesis and degradation.",
      "The presence of Type 1 and Type 2 deiodinases in skeletal muscle is a well-established fact."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Type 1 deiodinase (D1) is primarily present in the liver, kidneys, and thyroid, not significantly in skeletal muscle. It is Type 2 deiodinase (D2) that is present in skeletal muscle and is involved in the deiodination of thyroid hormones.\n2. TRUE: Type 1 deiodinase (D1) has been implicated in regulating mitochondrial function, although this is more commonly associated with Type 2 deiodinase (D2).\n3. TRUE: Type 2 deiodinase (D2) is present in skeletal muscle and is involved in the conversion of thyroxine (T4) to the more active triiodothyronine (T3), thus it plays a role in the deiodination of thyroid hormones.\n4. TRUE: Type 2 deiodinase (D2) has been shown to play a role in regulating protein synthesis and degradation in skeletal muscle, particularly as it relates to thyroid hormone signaling and action.\n5. FALSE [correction]: While Type 2 deiodinase (D2) is well-established as being present in skeletal muscle, Type 1 deiodinase (D1) is not significantly present in skeletal muscle, so the combined statement, as it is, is not accurate.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the inflammatory caspase proteins:\n1. Caspase-1: As mentioned in the document, caspase-1 is a key endoprotease responsible for the post-translational processing of pro-inflammatory cytokines IL-1, 18 & 33. Excessive secretion of IL-1 leads to numerous inflammatory and autoimmune diseases, making caspase-1 inhibition an important therapeutic strategy for developing newer anti-inflammatory agents.\n2. Caspase-3: The document mentions that the ligand-based 3D pharmacophore model was generated using a data set of 27 compounds, and a validated pharmacophore hypothesis (Hypo 1) was used to screen ZINC and Minimaybridge chemical databases. This suggests that caspase-3 is also an inflammatory caspase protein.\n3. Caspase-7: The document mentions that the cross-docking study was also carried out using crystal structure of caspase-1, 3, 7 and 8 to identify the key residual interaction for specific caspase-1 inhibition. This suggests that caspase-7 is also an inflammatory caspase protein.\n4. Caspase-8: The document mentions that the cross-docking study was also carried out using crystal structure of caspase-1, 3, 7 and 8 to identify the key residual interaction for specific caspase-1 inhibition. This suggests that caspase-8 is also an inflammatory caspase protein.\nTherefore, based on the information provided in the document, the following are some of the inflammatory caspase proteins:\n1. Caspase-1\n2. Caspase-3\n3. Caspase-7\n4. Caspase-8",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is responsible for the post-translational processing of pro-inflammatory cytokines IL-1, 18 & 33.\n2. Caspase-1 inhibition is considered a potential therapeutic strategy for developing anti-inflammatory agents.\n3. Caspase-3 is suggested to be an inflammatory caspase protein based on the document provided.\n4. Caspase-7 is indicated as an inflammatory caspase protein by the document referenced.\n5. Caspase-8 is included as an inflammatory caspase protein according to the document mentioned.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is responsible for the post-translational processing of pro-inflammatory cytokines IL-1, 18 & 33.",
      "Caspase-1 inhibition is considered a potential therapeutic strategy for developing anti-inflammatory agents.",
      "Caspase-3 is suggested to be an inflammatory caspase protein based on the document provided.",
      "Caspase-7 is indicated as an inflammatory caspase protein by the document referenced.",
      "Caspase-8 is included as an inflammatory caspase protein according to the document mentioned."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Caspase-1 is responsible for the post-translational processing of pro-inflammatory cytokines IL-1 and IL-18, but not IL-33.\n2. TRUE\n3. FALSE [correction]: Caspase-3 is not typically classified as an inflammatory caspase; it is more commonly associated with the execution phase of apoptosis.\n4. FALSE [correction]: Similar to Caspase-3, Caspase-7 is also more commonly associated with the execution phase of apoptosis, not inflammation.\n5. FALSE [correction]: Caspase-8 is mainly implicated in the initiation of apoptosis and not typically categorized as an inflammatory caspase.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is a link between the Aurora B kinase and the polycomb protein Ring1B. The document mentions that AIBp, a protein that interacts with Aurora-A, also interacts with hNinein, which overlaps with a previously reported binding site of GSK3beta. GSK3beta is a known regulator of Ring1B, a polycomb protein involved in the maintenance of gene silencing and chromatin modification.\nTherefore, it is possible that AIBp may also interact with Ring1B, and that this interaction may play a role in the regulation of Ring1B's activity. However, further research is needed to confirm this hypothesis and to fully understand the mechanisms by which AIBp and Aurora-A interact with Ring1B.\nIn summary, while the document does not directly address the link between Aurora B kinase and Ring1B, the interaction between AIBp and hNinein suggests a possible connection between these proteins and the regulation of Ring1B.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase is linked to the polycomb protein Ring1B.\n2. AIBp, a protein that interacts with Aurora-A, also interacts with hNinein.\n3. GSK3beta, which is a known regulator of Ring1B, overlaps with a previously reported binding site of hNinein.\n4. Ring1B is a polycomb protein involved in the maintenance of gene silencing and chromatin modification.\n5. Further research is necessary to confirm the interaction between AIBp and Ring1B and to understand the mechanisms of this interaction.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase is linked to the polycomb protein Ring1B.",
      "AIBp, a protein that interacts with Aurora-A, also interacts with hNinein.",
      "GSK3beta, which is a known regulator of Ring1B, overlaps with a previously reported binding site of hNinein.",
      "Ring1B is a polycomb protein involved in the maintenance of gene silencing and chromatin modification.",
      "Further research is necessary to confirm the interaction between AIBp and Ring1B and to understand the mechanisms of this interaction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nWithout specific context or detailed information from a reliable source regarding the interactions between these proteins and their functions, the truthfulness of statements 1, 2, 3, and 5 cannot be determined. However, statement 4 is true as Ring1B is indeed a polycomb protein involved in gene silencing and chromatin modifications.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice site motifs:\n1. GU-rich sequences: The study found that GU-rich sequences are overrepresented at the donor splice site, particularly in the 5' untranslated regions (5' UTRs) of transcripts.\n2. AG dinucleotides: The study found that AG dinucleotides are also overrepresented at the donor splice site, particularly in the 3' untranslated regions (3' UTRs) of transcripts.\nAcceptor splice site motifs:\n1. GT-rich sequences: The study found that GT-rich sequences are overrepresented at the acceptor splice site, particularly in the introns of transcripts.\n2. AG dinucleotides: The study found that AG dinucleotides are also overrepresented at the acceptor splice site, particularly in the 5' UTRs of transcripts.\nIt is important to note that these motifs are not exclusive to vertebrates and may be conserved across different species. Additionally, the study did not investigate the specific motifs at the intron-exon boundaries, but it is likely that they are also enriched with GU-rich and AG dinucleotides.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences are overrepresented at the donor splice site in the 5' untranslated regions (5' UTRs) of transcripts in vertebrates.\n2. AG dinucleotides are overrepresented at the donor splice site in the 3' untranslated regions (3' UTRs) of transcripts in vertebrates.\n3. GT-rich sequences are overrepresented at the acceptor splice site in the introns of transcripts in vertebrates.\n4. AG dinucleotides are overrepresented at the acceptor splice site in the 5' UTRs of transcripts in vertebrates.\n5. The identified non-canonical sequence motifs at the donor and acceptor splice sites are not exclusive to vertebrates and may be conserved across different species.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences are overrepresented at the donor splice site in the 5' untranslated regions (5' UTRs) of transcripts in vertebrates.",
      "AG dinucleotides are overrepresented at the donor splice site in the 3' untranslated regions (3' UTRs) of transcripts in vertebrates.",
      "GT-rich sequences are overrepresented at the acceptor splice site in the introns of transcripts in vertebrates.",
      "AG dinucleotides are overrepresented at the acceptor splice site in the 5' UTRs of transcripts in vertebrates.",
      "The identified non-canonical sequence motifs at the donor and acceptor splice sites are not exclusive to vertebrates and may be conserved across different species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - GU-rich sequences are typically found at the donor splice site, which is at the 5' end of introns, not specifically the 5' UTRs, but the statement can still be considered true with regards to 5' end of introns.\n2. FALSE [correction]: AG dinucleotides are overrepresented at the acceptor splice site in the introns of transcripts in vertebrates, not at the donor splice site in the 3' UTRs.\n3. TRUE - GT-rich sequences are often associated with the consensus sequence at the donor splice site (which contains GT) in introns, not specifically the acceptor splice site, but GT is an essential part of the donor splice site motif which may lead to confusion, so some might say the exact phrasing in the statement is ambiguous.\n4. FALSE [correction]: AG dinucleotides are overrepresented at the acceptor splice site at the 3' end of introns in transcripts in vertebrates, not in the 5' UTRs.\n5. TRUE - While the canonical splice site sequences are conserved across many species, non-canonical motifs have also been identified across different species, though their prevalence and conservation might vary.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the event that results in the acetylation of S6K1 is the G1/S transition. The document states that the SCF(Cdc4) ubiquitin ligase controls Clb6 proteolysis, which requires cyclin-dependent kinases activity, during the G1/S transition. Additionally, the document mentions that both APC(Cdh1) and SCF(Cdc4)-dependent proteolysis of Clb6 at the G1/S border are crucial for multiple cell cycle regulated events, including proper expression of Clb2, the G1/S and G2/M cell cycle transitions, and for proper completion of cell division at mitotic exit. Therefore, it can be inferred that the acetylation of S6K1 occurs during the G1/S transition.",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 occurs during the G1/S transition.\n2. SCF(Cdc4) ubiquitin ligase controls Clb6 proteolysis.\n3. The control of Clb6 proteolysis requires cyclin-dependent kinases activity.\n4. SCF(Cdc4)-dependent proteolysis of Clb6 at the G1/S border is essential for multiple cell cycle regulated events.\n5. The proper expression of Clb2, the G1/S and G2/M cell cycle transitions, and proper completion of cell division at mitotic exit depend on APC(Cdh1) and SCF(Cdc4)-dependent proteolysis of Clb6.",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 occurs during the G1/S transition.",
      "SCF(Cdc4) ubiquitin ligase controls Clb6 proteolysis.",
      "The control of Clb6 proteolysis requires cyclin-dependent kinases activity.",
      "SCF(Cdc4)-dependent proteolysis of Clb6 at the G1/S border is essential for multiple cell cycle regulated events.",
      "The proper expression of Clb2, the G1/S and G2/M cell cycle transitions, and proper completion of cell division at mitotic exit depend on APC(Cdh1) and SCF(Cdc4)-dependent proteolysis of Clb6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the acetylation of S6K1 (ribosomal protein S6 kinase) during the G1/S transition is specific and would require a biological context or a particular study as reference to verify its accuracy.\n\n2. TRUE: SCF(Cdc4) is a ubiquitin ligase complex known to control the degradation of various proteins, including cyclins such as Clb6, through proteolysis.\n\n3. TRUE: The control of Clb6 proteolysis generally involves cyclin-dependent kinases (CDKs), as CDK activity is essential for cell cycle progression and for targeting cyclin degradation by ubiquitin ligases such as SCF(Cdc4).\n\n4. TRUE: SCF(Cdc4)-dependent proteolysis of Clb6 at the G1/S transition is known to be important for the regulation of the cell cycle, although \"essential\" is a strong term and may depend on the specific organism or cell type context.\n\n5. UNKNOWN: The effects of APC(Cdh1) and SCF(Cdc4) on Clb2 expression and the various cell cycle transitions and completion of cell division is a complex topic, and the statement involves multiple processes that occur at various stages of the cell cycle. This would require specific biological knowledge or literature to verify its accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the cause of episodic ataxia type 6 in the Slovak three-generation family is a novel heterozygous missense variant of the calcium voltage-gated channel subunit alpha1 A gene (CACNA1A) on chromosome 19p13. The variant, c.5264A>G (p.Glu1755Gly), is located in the pore loop of domain IV of the calcium channel alpha-1A subunit and results in changing a highly conserved glutamic acid within the pore loop. This variant is believed to disrupt the normal functioning of the calcium channel, leading to the recurrent episodes of ataxia observed in the family members.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 in the Slovak three-generation family is caused by a novel heterozygous missense variant of the CACNA1A gene.\n2. The CACNA1A gene is located on chromosome 19p13.\n3. The variant responsible for episodic ataxia type 6 is c.5264A>G (p.Glu1755Gly).\n4. The variant is located in the pore loop of domain IV of the calcium channel alpha-1A subunit.\n5. The mutation changes a highly conserved glutamic acid within the pore loop which disrupts the normal functioning of the calcium channel.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 in the Slovak three-generation family is caused by a novel heterozygous missense variant of the CACNA1A gene.",
      "The CACNA1A gene is located on chromosome 19p13.",
      "The variant responsible for episodic ataxia type 6 is c.5264A>G (p.Glu1755Gly).",
      "The variant is located in the pore loop of domain IV of the calcium channel alpha-1A subunit.",
      "The mutation changes a highly conserved glutamic acid within the pore loop which disrupts the normal functioning of the calcium channel."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific literature or study referring to this particular case involving a Slovak three-generation family, the statement cannot be corroborated.\n2. TRUE: The CACNA1A gene is indeed located on chromosome 19p13.\n3. UNKNOWN: The statement provides a specific mutation notation, but without a reference to a specific study or source reporting this finding, the truth of this statement cannot be confirmed.\n4. UNKNOWN: While the statement provides detailed information about the location of the variant within the protein structure, verification requires a reference to corresponding scientific literature.\n5. UNKNOWN: The statement about the impact of the mutation on the protein function suggests biological knowledge about the effects of the mutation, but the truth of the statement can only be confirmed with a proper scientific source or study.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, chromomethylases are not present in animal genomes. The document states that the mitochondrial genomes of animal cells are typically small and circular-mapping, with 37 or fewer tightly packed genes. In contrast, the mitochondrial genome of the choanoflagellate Monosiga brevicollis is four times as large as that of animals and contains two times as many protein genes. Additionally, the ichthyosporean mitochondrial genome consists of several hundred linear chromosomes that share elaborate terminal-specific sequence patterns. These findings suggest that chromomethylases, which are enzymes involved in the methylation of chromosomes, are not present in animal genomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are not present in animal genomes.\n2. The mitochondrial genomes of animal cells are typically small and circular-mapping.\n3. Animal mitochondrial genomes usually have 37 or fewer tightly packed genes.\n4. The mitochondrial genome of the choanoflagellate Monosiga brevicollis is four times as large as that of animals.\n5. The ichthyosporean mitochondrial genome consists of several hundred linear chromosomes with elaborate terminal-specific sequence patterns.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are not present in animal genomes.",
      "The mitochondrial genomes of animal cells are typically small and circular-mapping.",
      "Animal mitochondrial genomes usually have 37 or fewer tightly packed genes.",
      "The mitochondrial genome of the choanoflagellate Monosiga brevicollis is four times as large as that of animals.",
      "The ichthyosporean mitochondrial genome consists of several hundred linear chromosomes with elaborate terminal-specific sequence patterns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Chromomethylases are a type of DNA methyltransferase found predominantly in plants, and to date, there is no evidence to suggest their presence in animal genomes.\n2. TRUE: The mitochondrial genomes of animal cells are indeed typically small and circular.\n3. TRUE: Animal mitochondrial genomes generally contain 37 genes that are tightly packed, with very little non-coding DNA.\n4. UNKNOWN: Without specific knowledge of the mitochondrial genome size of Monosiga brevicollis in comparison to typical animal mitochondrial genomes, we cannot confirm or refute this statement.\n5. UNKNOWN: The ichthyosporean mitochondrial genome details are quite specific, and without additional context or reference, it's not possible to accurately assess the truth of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following packages in R/Bioconductor are available for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: This package provides a collection of tools for the analysis of TFBS motifs, including the conversion of PFMs into k-mer vectors for alignment-free comparison.\n2. MotifFinder: This package uses a combination of alignment-free and alignment-based methods to identify and quantify the similarity of TFBS motifs.\n3. TFCluster: This package uses a clustering algorithm to group TFBS motifs based on their similarity, allowing for the identification of similar motifs and the classification of transcription factors into different families.\n4. MotifSearch: This package uses a combination of alignment-free and alignment-based methods to search for similar TFBS motifs in a database of known motifs.\n5. TranscriptionFactor binding site (TFBS) analysis: This package provides a comprehensive set of tools for the analysis of TFBS motifs, including the calculation of binding free energy, the prediction of transcription factor binding sites, and the identification of regulatory elements.\n6. RMotif: This package provides a collection of tools for the analysis of TFBS motifs, including the calculation of motif frequency, the identification of motif clusters, and the prediction of transcription factor binding sites.\n7. MotifMiner: This package provides a comprehensive set of tools for the analysis of TFBS motifs, including the calculation of motif frequency, the identification of motif clusters, and the prediction of transcription factor binding sites.\n8. TFBS-Tools: This package provides a collection of tools for the analysis of TFBS motifs, including the calculation of motif frequency, the identification of motif clusters, and the prediction of transcription factor binding sites.\nThese packages can be used for various tasks such as motif discovery, motif clustering, and transcription factor binding site prediction.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSTools is a package in R/Bioconductor for transcription factor binding site (TFBS) analysis.\n2. MotifFinder is a package in R/Bioconductor that identifies and quantifies the similarity of TFBS motifs.\n3. TFCluster is an R/Bioconductor package that clusters TFBS motifs based on their similarity.\n4. MotifSearch is an R/Bioconductor package designed to search for similar TFBS motifs in a database.\n5. RMotif is an R/Bioconductor package for the analysis of TFBS motifs, including calculation of motif frequency and prediction of transcription factor binding sites.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSTools is a package in R/Bioconductor for transcription factor binding site (TFBS) analysis.",
      "MotifFinder is a package in R/Bioconductor that identifies and quantifies the similarity of TFBS motifs.",
      "TFCluster is an R/Bioconductor package that clusters TFBS motifs based on their similarity.",
      "MotifSearch is an R/Bioconductor package designed to search for similar TFBS motifs in a database.",
      "RMotif is an R/Bioconductor package for the analysis of TFBS motifs, including calculation of motif frequency and prediction of transcription factor binding sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (While \"MotifFinder\" is suggestive of a package that could identify and quantify motif similarity, without specific knowledge or a reliable source, it's not possible to confirm the existence or functionality of a package by this name in R/Bioconductor.)\n3. UNKNOWN (Without specific knowledge or a reliable source, it's not possible to confirm the existence or functionality of \"TFCluster\" as an R/Bioconductor package for clustering TFBS motifs.)\n4. UNKNOWN (Similarly to the above, without specific knowledge or a reliable source, one cannot confirm the existence or the specific functionality of \"MotifSearch\" in R/Bioconductor.)\n5. UNKNOWN (The package \"RMotif\" is not a well-known package within R/Bioconductor based on the provided knowledge cutoff, but without additional information or context, its existence and functionality cannot be confirmed or denied.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some clinical trials for the prevention of sarcopenia:\n1. The European Working Group on Sarcopenia in Older People (EWGSOP) criteria-based exercise program: This study examined the effectiveness of an exercise program based on the EWGSOP criteria in preventing sarcopenia in older adults. The program included resistance training, aerobic exercise, and balance training, and was found to be effective in reducing the incidence of sarcopenia in this population.\n2. Vitamin D and calcium supplementation: This study investigated the effect of vitamin D and calcium supplementation on the prevention of sarcopenia in older adults. The results showed that supplementation with these nutrients was associated with a reduced incidence of sarcopenia.\n3. Protein supplementation: This study examined the effect of protein supplementation on the prevention of sarcopenia in older adults. The results showed that protein supplementation was associated with a reduced incidence of sarcopenia and improved muscle mass.\n4. Resistance training with progressive overload: This study investigated the effect of resistance training with progressive overload on the prevention of sarcopenia in older adults. The results showed that resistance training with progressive overload was effective in reducing the incidence of sarcopenia and improving muscle strength.\n5. High-intensity interval training (HIIT): This study examined the effect of HIIT on the prevention of sarcopenia in older adults. The results showed that HIIT was effective in reducing the incidence of sarcopenia and improving cardiovascular fitness.\n6. Mind-body exercise: This study investigated the effect of mind-body exercise, such as yoga and tai chi, on the prevention of sarcopenia in older adults. The results showed that mind-body exercise was associated with a reduced incidence of sarcopenia and improved muscle strength.\n7. Social support interventions: This study examined the effect of social support interventions, such as group exercise and social activities, on the prevention of sarcopenia in older adults. The results showed that social support interventions were",
    "llama-2-7b-chat-hf_fact_raw": "1. The European Working Group on Sarcopenia in Older People (EWGSOP) has criteria-based exercise programs aimed at preventing sarcopenia in older adults.\n2. A study found that vitamin D and calcium supplementation was associated with a reduced incidence of sarcopenia in older adults.\n3. Protein supplementation was shown to be associated with reduced incidence of sarcopenia and improved muscle mass in older adults according to a study.\n4. Resistance training with progressive overload was effective in reducing the incidence of sarcopenia and improving muscle strength in older adults, as shown by a study.\n5. High-intensity interval training (HIIT) was found to be effective in reducing the incidence of sarcopenia and improving cardiovascular fitness in older adults, based on the results of a study.",
    "llama-2-7b-chat-hf_fact": [
      "The European Working Group on Sarcopenia in Older People (EWGSOP) has criteria-based exercise programs aimed at preventing sarcopenia in older adults.",
      "A study found that vitamin D and calcium supplementation was associated with a reduced incidence of sarcopenia in older adults.",
      "Protein supplementation was shown to be associated with reduced incidence of sarcopenia and improved muscle mass in older adults according to a study.",
      "Resistance training with progressive overload was effective in reducing the incidence of sarcopenia and improving muscle strength in older adults, as shown by a study.",
      "High-intensity interval training (HIIT) was found to be effective in reducing the incidence of sarcopenia and improving cardiovascular fitness in older adults, based on the results of a study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGenerally, these statements are consistent with widely accepted findings in the field of geriatrics and exercise science. Resistance training, protein supplementation, and vitamin D with calcium supplementation are known interventions to help prevent or manage sarcopenia. High-intensity interval training is also recognized for both cardiovascular benefits and its potential impact on muscle strength and mass. Please note that the truthfulness of these statements depends on the specific studies and consensus they're based on; without access to the exact data or studies, the responses are given in good faith based on common scientific understanding as of my knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the database of molecular recognition features in membrane proteins is the \"large membrane protein benchmark dataset\".",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the case study, it appears that rivaroxaban is metabolized in the kidneys to some extent. The patient in the study had an estimated glomerular filtration rate (eGFR) of 46.7 mL/min, which suggests that their kidneys were not functioning optimally. As a result, the patient experienced elevated PT and aPTT levels, which are indicative of rivaroxaban-induced gastrointestinal bleeding.\nWhile the guidelines do not provide specific guidance on how to use rivaroxaban in patients with renal insufficiency, it is important to consider the potential impact of renal impairment on the drug's metabolism and pharmacokinetics. In general, patients with renal insufficiency may require lower doses of rivaroxaban or more frequent monitoring of coagulation levels to avoid bleeding complications.\nIn this case, the patient's sudden syncope and pulselessness on the third day after discontinuing rivaroxaban suggest that the drug may have caused a significant bleeding event, despite the patient's initial improvement in hemoglobin levels. This highlights the importance of close monitoring of coagulation levels and prompt intervention in patients who are at risk of bleeding complications.\nIn summary, while the guidelines do not provide specific guidance on how to use rivaroxaban in patients with renal insufficiency, it is important to consider the potential impact of renal impairment on the drug's metabolism and pharmacokinetics, and to monitor coagulation levels closely in these patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys to some extent.\n2. An estimated glomerular filtration rate (eGFR) of 46.7 mL/min suggests suboptimal kidney function.\n3. Elevated PT and aPTT levels can be indicative of rivaroxaban-induced gastrointestinal bleeding.\n4. Patients with renal insufficiency may require lower doses of rivaroxaban or more frequent monitoring of coagulation levels to avoid bleeding complications.\n5. Sudden syncope and pulselessness after discontinuing rivaroxaban can suggest a significant bleeding event related to the drug.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys to some extent.",
      "An estimated glomerular filtration rate (eGFR) of 46.7 mL/min suggests suboptimal kidney function.",
      "Elevated PT and aPTT levels can be indicative of rivaroxaban-induced gastrointestinal bleeding.",
      "Patients with renal insufficiency may require lower doses of rivaroxaban or more frequent monitoring of coagulation levels to avoid bleeding complications.",
      "Sudden syncope and pulselessness after discontinuing rivaroxaban can suggest a significant bleeding event related to the drug."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Elevated PT and aPTT levels may indicate a coagulation disorder, but they are not specific indicators of rivaroxaban-induced gastrointestinal bleeding. Gastrointestinal bleeding might present with symptoms like bloody stool or vomit, abdominal pain, and low blood pressure.\n4. TRUE\n5. FALSE [correction]: Sudden syncope (fainting) and pulselessness are more likely to suggest a cardiac event such as a heart attack or arrhythmia. Significant bleeding might cause hypotension and shock, but pulselessness is a sign of cardiac arrest, which can have other causes beyond bleeding events.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genes that are regulated by TRalpha2 in the heart are MLC3F transcripts. The document shows that MLC3F transcripts are left/right regionalized in the mouse heart during embryonic development, with expression predominantly in the future left ventricle and right atrium, and later down-regulated in the left ventricle. The document also suggests that post-transcriptional regulation prevents the fast myosin isoform from contributing to myocardial contraction. Therefore, TRalpha2 is shown to regulate the expression of MLC3F transcripts in the heart.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates the genes MLC3F transcripts in the heart.\n2. MLC3F transcripts are regionalized in the mouse heart during embryonic development.\n3. MLC3F transcript expression is predominantly in the future left ventricle and right atrium of the mouse heart during embryonic development.\n4. MLC3F transcripts are later down-regulated in the left ventricle during development.\n5. Post-transcriptional regulation prevents the fast myosin isoform from contributing to myocardial contraction, as suggested by the document.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates the genes MLC3F transcripts in the heart.",
      "MLC3F transcripts are regionalized in the mouse heart during embryonic development.",
      "MLC3F transcript expression is predominantly in the future left ventricle and right atrium of the mouse heart during embryonic development.",
      "MLC3F transcripts are later down-regulated in the left ventricle during development.",
      "Post-transcriptional regulation prevents the fast myosin isoform from contributing to myocardial contraction, as suggested by the document."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without additional context or specific knowledge about the gene regulation of MLC3F (Myosin Light Chain 3F) and its role in heart development, I cannot verify the statements regarding TRalpha2 regulation, regionalization, expression patterns, or post-transcriptional regulation effects on myocardial contraction. These statements would require specific scientific knowledge or access to the relevant documents or studies in which these claims were made.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are some available biomedical question answering systems:\n1. Restricted domain question answering system: The document describes a restricted domain question answering system that is specifically designed for the medical domain. This system uses natural language processing (NLP) techniques to infer the logic forms of questions and treat them accordingly.\n2. Unified Medical Language System (UMLS): The document mentions the use of UMLS to handle medical terminology in the question answering system. UMLS is a comprehensive database of medical terms and concepts that can be used to improve the accuracy of the system.\n3. WordNet: The document also mentions the use of WordNet to manage open-domain terminology in the question answering system. WordNet is a large lexical database that provides a network of words and their relationships, which can be useful in understanding the context of medical questions.\n4. Natural language processing (NLP) techniques: The main computing methods of the question answering system are based on NLP techniques, which allow the system to analyze and understand the meaning of medical questions and provide accurate answers.\n5. Local or remote document collections: The system allows for the possibility of locally or remotely managed document collections, which can be useful in providing up-to-date and relevant information to users.\nSome examples of biomedical question answering systems that use similar techniques include:\n1. PubMed Central: A free full-text database of biomedical literature, including articles, books, and other publications.\n2. Google Scholar: A search engine for scholarly literature across many disciplines and sources, including articles, theses, books, and conference papers.\n3. BioASQ: A benchmark dataset for biomedical question answering, which includes a collection of questions and answers on various biomedical topics.\n4. MedlinePlus: A government website that provides a comprehensive collection of health information, including a symptom checker, drug information, and a medical encyclopedia.\n5. UpToDate: A clinical decision support resource that provides evidence-based information on various medical topics, including diagnosis, treatment, and management of diseases.\nThese are just a few examples of the many biomedical question answering systems available. Each system has its own strengths and limitations, and the choice of which system to use will depend on the specific needs and requirements of the user.",
    "llama-2-7b-chat-hf_fact_raw": "1. A restricted domain question answering system designed for the medical domain uses NLP techniques to infer logic forms of questions.\n2. The Unified Medical Language System (UMLS) is a comprehensive database of medical terms and concepts.\n3. WordNet is a large lexical database that provides a network of words and their relationships.\n4. PubMed Central is a free full-text database for biomedical literature.\n5. UpToDate is a clinical decision support resource that provides evidence-based information on medical topics.",
    "llama-2-7b-chat-hf_fact": [
      "A restricted domain question answering system designed for the medical domain uses NLP techniques to infer logic forms of questions.",
      "The Unified Medical Language System (UMLS) is a comprehensive database of medical terms and concepts.",
      "WordNet is a large lexical database that provides a network of words and their relationships.",
      "PubMed Central is a free full-text database for biomedical literature.",
      "UpToDate is a clinical decision support resource that provides evidence-based information on medical topics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the trancription factor that activates the betalain pathway is GATA-6. The document mentions that GATA-6 plays a role in the maintenance of the differentiated phenotype in vascular smooth muscle cells (VSMCs) and that it interacts with the nuclear factor of activated T cell (NFAT) family members, which are involved in the betalain pathway. Additionally, the document shows that NFATc1, a member of the NFAT family, potentiates GATA-6-activated transcription of the smooth muscle-myosin heavy chain (Sm-MHC) gene, which is a downstream target of GATA-6. These findings suggest that GATA-6 is the trancription factor that activates the betalain pathway in VSMCs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor that activates the betalain pathway is GATA-6.\n2. GATA-6 is involved in the maintenance of the differentiated phenotype in vascular smooth muscle cells.\n3. GATA-6 interacts with the nuclear factor of activated T cell (NFAT) family members.\n4. NFAT family members are involved in the betalain pathway.\n5. NFATc1 potentiates GATA-6-activated transcription of the smooth muscle-myosin heavy chain (Sm-MHC) gene.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor that activates the betalain pathway is GATA-6.",
      "GATA-6 is involved in the maintenance of the differentiated phenotype in vascular smooth muscle cells.",
      "GATA-6 interacts with the nuclear factor of activated T cell (NFAT) family members.",
      "NFAT family members are involved in the betalain pathway.",
      "NFATc1 potentiates GATA-6-activated transcription of the smooth muscle-myosin heavy chain (Sm-MHC) gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The transcription factor that activates the betalain pathway has not been specified as GATA-6; in plants, this would typically involve different factors such as MYB or bHLH family transcription factors.\n2. TRUE\n3. TRUE\n4. UNKNOWN: The involvement of NFAT family members specifically in the betalain pathway is not commonly established within scientific literature, as NFAT family members are generally known for their role in immune response.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. Titanium dioxide (TiO2): TiO2 has been shown to enrich phosphopeptides with high specificity, but optimization is needed to reduce non-specific bindings. The document suggests that using an NH4Glu solution for column wash after loading peptide mixtures can significantly increase the efficiency of TiO2 phosphopeptide enrichment.\n2. Data-dependent neutral loss nano-RPLC-MS2-MS3 analysis: This approach combines multiple mass spectrometry techniques to identify and quantify phosphopeptides. The document reports that a total of 858 phosphopeptides corresponding to 1034 distinct phosphosites were identified using this method in combination with the improved TiO2 enrichment procedure.\nIt is important to note that the study suggests that evaluation of confidence levels for phosphopeptide identification via the reversed sequence database searching strategy might underestimate the false positive rate. Therefore, it is crucial to use multiple techniques and validation methods to confirm the identity of phosphopeptides.",
    "llama-2-7b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2) is used to enrich phosphopeptides with high specificity.\n2. Using an NH4Glu solution for column wash after loading peptide mixtures can significantly increase the efficiency of TiO2 phosphopeptide enrichment.\n3. Data-dependent neutral loss nano-RPLC-MS2-MS3 analysis identifies and quantifies phosphopeptides.\n4. The document identified 858 phosphopeptides corresponding to 1034 distinct phosphosites using the method mentioned above in combination with improved TiO2 enrichment.\n5. The study suggests evaluating confidence levels for phosphopeptide identification via reversed sequence database searching strategy might underestimate false positive rates.",
    "llama-2-7b-chat-hf_fact": [
      "Titanium dioxide (TiO2) is used to enrich phosphopeptides with high specificity.",
      "Using an NH4Glu solution for column wash after loading peptide mixtures can significantly increase the efficiency of TiO2 phosphopeptide enrichment.",
      "Data-dependent neutral loss nano-RPLC-MS2-MS3 analysis identifies and quantifies phosphopeptides.",
      "The document identified 858 phosphopeptides corresponding to 1034 distinct phosphosites using the method mentioned above in combination with improved TiO2 enrichment.",
      "The study suggests evaluating confidence levels for phosphopeptide identification via reversed sequence database searching strategy might underestimate false positive rates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Titanium dioxide (TiO2) is commonly used in proteomics to selectively enrich phosphorylated peptides (phosphopeptides) due to its affinity for the phosphate groups.\n2. TRUE - Ammonium glutamate (NH4Glu) solution is often used for the column wash in TiO2 phosphopeptide enrichment protocols. Its use can suppress non-specific binding and thus increase the specificity and efficiency of phosphopeptide enrichment.\n3. TRUE - Data-dependent neutral loss nano-reversed phase liquid chromatography followed by tandem mass spectrometry with an additional MS3 for analysis of neutral loss events (nano-RPLC-MS2-MS3) is an analytical technique used to identify and quantify phosphopeptides based on their specific fragmentation patterns.\n4. UNKNOWN - Without access to the document or specific study that identified 858 phosphopeptides corresponding to 1034 distinct phosphosites, the validity of this statement cannot be determined.\n5. UNKNOWN - The statement about evaluating confidence levels with a reversed sequence database search strategy potentially underestimating false positive rates is opinion or conclusion oriented. Without context, the methodology, or evidence from the specific study, the truthfulness of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disorder that is rated by the Palmini classification is group II, which includes the Madelung deformity, the Kirner deformity, and congenital trigger fingers and trigger thumbs.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is possible that viruses may be involved in the etiology of human subacute thyroiditis. The document mentions that the diagnosis of subacute thyroiditis is based on typical symptoms and findings, including thyroid pain, high fever, tenderness on palpating the thyroid gland, transient symptoms of thyrotoxicosis, and hypersedimentation. These symptoms are consistent with a viral infection of the thyroid gland, which can cause inflammation and damage to the gland.\nAdditionally, the document mentions that diseases of the thyroid gland may exist concurrently with subacute thyroiditis, such as Hashimoto disease and Graves disease. Hashimoto disease is an autoimmune disorder that can cause inflammation of the thyroid gland, while Graves disease is an autoimmune disorder that can cause hyperthyroidism. Both of these conditions can be caused by viral infections, and it is possible that they may be involved in the etiology of subacute thyroiditis.\nHowever, it is important to note that the document does not provide any direct evidence of a viral etiology for subacute thyroiditis. Further research and studies are needed to determine the exact cause of this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses may be involved in the etiology of human subacute thyroiditis.\n2. Diagnosis of subacute thyroiditis is based on symptoms such as thyroid pain, high fever, tenderness on palpating the thyroid gland, transient symptoms of thyrotoxicosis, and hypersedimentation.\n3. Symptoms of subacute thyroiditis are consistent with a viral infection of the thyroid gland.\n4. Hashimoto disease and Graves disease, which can be associated with subacute thyroiditis, can be caused by viral infections.\n5. There is no direct evidence provided that confirms a viral etiology for subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses may be involved in the etiology of human subacute thyroiditis.",
      "Diagnosis of subacute thyroiditis is based on symptoms such as thyroid pain, high fever, tenderness on palpating the thyroid gland, transient symptoms of thyrotoxicosis, and hypersedimentation.",
      "Symptoms of subacute thyroiditis are consistent with a viral infection of the thyroid gland.",
      "Hashimoto disease and Graves disease, which can be associated with subacute thyroiditis, can be caused by viral infections.",
      "There is no direct evidence provided that confirms a viral etiology for subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While both Hashimoto's disease and Graves' disease are autoimmune thyroid disorders and may have complex causes, they are not typically associated with subacute thyroiditis and are not known to be caused by viral infections.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that STAT3 is involved in the suppression of autophagy through its inhibitory effects on the EIF2AK2 pathway. The document states that persistent activation of STAT3 signalling has been linked to oncogenesis and the development of chemotherapy resistance in glioblastoma and other cancers, and that inhibition of the STAT3 pathway represents an attractive therapeutic approach for cancer. Additionally, the document mentions that LLL-3, a small molecule compound that inhibits STAT3, inhibited viability of U87, U373, and U251 glioblastoma cells and induced apoptosis of these cells, as well as prolonged the survival of mice bearing U87 glioblastoma tumours. These findings suggest that inhibition of STAT3 may have a positive impact on the suppression of autophagy in glioblastoma cells. Therefore, it is likely that STAT3 is involved in the regulation of autophagy through its inhibitory effects on the EIF2AK2 pathway in glioblastoma cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in the suppression of autophagy through its inhibitory effects on the EIF2AK2 pathway.\n2. Persistent activation of STAT3 signaling is linked to oncogenesis and the development of chemotherapy resistance in glioblastoma and other cancers.\n3. Inhibition of the STAT3 pathway is considered an attractive therapeutic approach for cancer.\n4. LLL-3, a compound that inhibits STAT3, decreased the viability of U87, U373, and U251 glioblastoma cells and induced apoptosis in these cells.\n5. Inhibition of STAT3 prolonged the survival of mice bearing U87 glioblastoma tumors.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in the suppression of autophagy through its inhibitory effects on the EIF2AK2 pathway.",
      "Persistent activation of STAT3 signaling is linked to oncogenesis and the development of chemotherapy resistance in glioblastoma and other cancers.",
      "Inhibition of the STAT3 pathway is considered an attractive therapeutic approach for cancer.",
      "LLL-3, a compound that inhibits STAT3, decreased the viability of U87, U373, and U251 glioblastoma cells and induced apoptosis in these cells.",
      "Inhibition of STAT3 prolonged the survival of mice bearing U87 glioblastoma tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The role of STAT3 in autophagy regulation is complex. However, without specific references to literature or data showing the connection between STAT3 and the inhibition of autophagy through the EIF2AK2 pathway, the truth value of this statement cannot be determined.\n\n2. TRUE: Persistent activation of STAT3 has been widely reported in literature to be associated with oncogenesis and the development of chemotherapy resistance in various cancers, including glioblastoma.\n\n3. TRUE: Given the role of the STAT3 pathway in cancer progression and chemoresistance, inhibition of STAT3 is indeed considered a potential therapeutic strategy for treating cancer.\n\n4. UNKNOWN: The effects of LLL-3 on the viability and apoptosis of glioblastoma cells such as U87, U373, and U251 are specific findings that require experimental evidence. Without access to the study or experimental results, the truth of this statement cannot be verified.\n\n5. UNKNOWN: The survival impact of STAT3 inhibition in mice with U87 glioblastoma tumors is also a specific research finding. Without the appropriate scientific studies or data, the truth of this claim cannot be assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "The Theatre software tool is a cloud-based platform designed to facilitate integrative genomic analysis by non-programmers. It offers a growing set of \"recipes,\" which are short workflows that guide investigators through high-utility analysis tasks, making complex biomedical analyses more accessible to the broader biomedical research community. By streamlining the interaction with multiple software tools and data resources, GenomeSpace enables investigators to focus on their research questions rather than the technical details of data analysis.\nSome of the key features of Theatre software tool include:\n1. Integration of multiple bioinformatics tools and data resources: GenomeSpace currently supports the interaction of 20 bioinformatics tools and data resources, making it a comprehensive platform for genomic analysis.\n2. User-friendly interface: The platform offers a user-friendly interface that allows non-programmers to perform complex analyses without requiring extensive programming knowledge.\n3. Recipes: GenomeSpace provides a growing set of recipes that guide investigators through high-utility analysis tasks, making it easier to perform common tasks such as variant analysis, gene expression analysis, and more.\n4. Cloud-based infrastructure: The platform is cloud-based, which means that users can access it from anywhere and do not need to worry about managing infrastructure.\n5. Collaboration: GenomeSpace is designed to facilitate collaboration among researchers, allowing them to share data and results more easily.\nIn summary, the Theatre software tool is a powerful platform that enables non-programmers to perform complex genomic analyses using a user-friendly interface and a growing set of recipes. Its cloud-based infrastructure and collaboration features make it an ideal platform for researchers to streamline their workflows and focus on their research questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre software tool is a cloud-based platform used for integrative genomic analysis.\n2. It is designed to be accessible to non-programmers for conducting complex biomedical analyses.\n3. GenomeSpace, which is part of the Theatre software tool, supports the interaction of 20 bioinformatics tools and data resources.\n4. The platform provides a user-friendly interface that allows users to perform analyses without extensive programming knowledge.\n5. Theatre software tool offers a cloud-based infrastructure enabling access from anywhere without the need for users to manage infrastructure.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre software tool is a cloud-based platform used for integrative genomic analysis.",
      "It is designed to be accessible to non-programmers for conducting complex biomedical analyses.",
      "GenomeSpace, which is part of the Theatre software tool, supports the interaction of 20 bioinformatics tools and data resources.",
      "The platform provides a user-friendly interface that allows users to perform analyses without extensive programming knowledge.",
      "Theatre software tool offers a cloud-based infrastructure enabling access from anywhere without the need for users to manage infrastructure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided don't correspond to a well-known or universally recognized \"Theatre software tool\" for genomic analysis, and without additional context or specific details, it is not possible to verify the claims about the features and capabilities of such a tool. Therefore, the veracity of the statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is quadratic, running in time proportional to the product of the lengths of the sequences being aligned.",
    "llama-2-7b-chat-hf_fact_raw": "1. The execution time (complexity) of the Smith-Waterman algorithm is quadratic.\n2. The running time of the Smith-Waterman algorithm is proportional to the product of the lengths of the two sequences being aligned.",
    "llama-2-7b-chat-hf_fact": [
      "The execution time (complexity) of the Smith-Waterman algorithm is quadratic.",
      "The running time of the Smith-Waterman algorithm is proportional to the product of the lengths of the two sequences being aligned."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, FLVCR1 is a member of the SLC26 gene family, specifically the SLC26A6 member.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the interacting partners of GATA-1 that have been discovered using the biotinylation tagging approach:\n1. Friend of GATA (FOG): As mentioned in the document, GATA-1 and FOG are zinc-finger transcription factors that physically interact to play essential roles in erythroid and megakaryocytic development.\n2. Other transcription factors: The document does not provide specific information on the other transcription factors that interact with GATA-1. However, it is likely that GATA-1 interacts with other transcription factors that are involved in erythroid and megakaryocytic development, as well as other cellular processes.\n3. Coactivators and corepressors: GATA-1 may also interact with coactivators and corepressors that help regulate its transcriptional activity.\n4. Chromatin-modifying enzymes: GATA-1 may interact with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases, that help regulate its ability to recruit other transcription factors and activate gene expression.\n5. Non-coding RNAs: GATA-1 may also interact with non-coding RNAs, such as microRNAs and long non-coding RNAs, that help regulate its transcriptional activity and gene expression.\nOverall, the biotinylation tagging approach has provided valuable insights into the interacting partners of GATA-1 and their roles in regulating erythroid and megakaryocytic development. Further studies are needed to fully understand the molecular mechanisms underlying these interactions and their implications for human health and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with the zinc-finger transcription factor Friend of GATA (FOG).\n2. GATA-1 is implicated in playing essential roles in erythroid and megakaryocytic development.\n3. GATA-1 may interact with coactivators and corepressors that regulate its transcriptional activity.\n4. GATA-1 may engage with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases.\n5. GATA-1 may interact with non-coding RNAs, including microRNAs and long non-coding RNAs.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with the zinc-finger transcription factor Friend of GATA (FOG).",
      "GATA-1 is implicated in playing essential roles in erythroid and megakaryocytic development.",
      "GATA-1 may interact with coactivators and corepressors that regulate its transcriptional activity.",
      "GATA-1 may engage with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases.",
      "GATA-1 may interact with non-coding RNAs, including microRNAs and long non-coding RNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on currently available scientific knowledge, these statements about GATA-1 are consistent with what is understood about this transcription factor. GATA-1 is indeed known to interact with the FOG family of proteins, play crucial roles in hematopoietic lineages (such as erythroid and megakaryocytic development), and interact with various regulatory proteins that can affect its activity, including chromatin-modifying enzymes and potentially non-coding RNAs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that TAF10 (Thyroid Auxiliary Factor 10) interacting with the GATA1 transcription factor can lead to the activation of the TTF-1 gene transcription. Specifically, the document states that GATA-6, a member of the zinc finger family of transcription factors, co-expresses with TTF-1 in the respiratory epithelium in vivo and in vitro, and that GATA-6 strongly enhances the activity of the human TTF-1 gene promoter in vitro. Additionally, the document reports that GATA-6, but not GATA-5, markedly activated TTF-1 gene transcription in HeLa cells, and that EMSA and supershift analysis with GATA-6 antiserum demonstrated that GATA-6 in MLE-15 cell nuclear extracts bound to an element located 96-101 base pairs from the major start of the TTF-1 gene transcription. These findings suggest that GATA-6 can interact with the TTF-1 gene promoter and enhance its transcriptional activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 (Thyroid Auxiliary Factor 10) interaction with the GATA1 transcription factor can lead to the activation of TTF-1 gene transcription.\n2. GATA-6 co-expresses with TTF-1 in the respiratory epithelium both in vivo and in vitro.\n3. GATA-6 enhances the activity of the human TTF-1 gene promoter in vitro.\n4. GATA-6, not GATA-5, can significantly activate TTF-1 gene transcription in HeLa cells.\n5. GATA-6 binds to an element 96-101 base pairs from the major start of the TTF-1 gene transcription, as demonstrated by EMSA and supershift analysis with GATA-6 antiserum.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 (Thyroid Auxiliary Factor 10) interaction with the GATA1 transcription factor can lead to the activation of TTF-1 gene transcription.",
      "GATA-6 co-expresses with TTF-1 in the respiratory epithelium both in vivo and in vitro.",
      "GATA-6 enhances the activity of the human TTF-1 gene promoter in vitro.",
      "GATA-6, not GATA-5, can significantly activate TTF-1 gene transcription in HeLa cells.",
      "GATA-6 binds to an element 96-101 base pairs from the major start of the TTF-1 gene transcription, as demonstrated by EMSA and supershift analysis with GATA-6 antiserum."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The interaction between TAF10 and GATA1 and its role in the activation of TTF-1 (also known as NKX2-1) gene transcription needs specific scientific literature support to validate such a claim. Furthermore, TAF10 is not a commonly recognized acronym in the context of thyroid transcription factors, which may suggest a misprint or specialized nomenclature not widely recognized.\n   \n2. TRUE: GATA-6 and TTF-1 (NKX2-1) co-expression in respiratory epithelium is supported by scientific literature, as both are known to play roles in lung development and are expressed in lung tissue.\n\n3. TRUE: The statement is consistent with scientific research suggesting that GATA-6 can enhance the activity of the TTF-1 gene promoter in certain in vitro conditions. However, detailed experimental evidence would be required for absolute validation.\n\n4. UNKNOWN: The ability of GATA-6 to significantly activate TTF-1 gene transcription in HeLa cells specifically would depend on experimental data. This cell line is commonly used in research, but activation could be contextual based on the experimental conditions and cellular environment.\n\n5. TRUE: Binding of GATA-6 to a specific element within the TTF-1 gene promoter and its identification through an electrophoretic mobility shift assay (EMSA) and supershift analysis with specific GATA-6 antiserum is a detailed and specific claim likely based on experimental research findings.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are decision support systems for chronic pain management. The study you provided highlights the need for such systems to enhance assessment and improve pain management in clinical practice. Here are some decision support systems that can be used for chronic pain management:\n1. PainCheck: This is the electronic patient-reported pain monitoring system developed in the study you provided. PainCheck is designed to be integrated into existing electronic health records and can be used to monitor pain levels and assess the effectiveness of pain management strategies.\n2. PainAssessment: This is a decision support system that uses a combination of patient-reported outcomes and clinical data to assess pain intensity and quality. It also provides recommendations for pain management based on the patient's individual needs.\n3. Chronic Pain Management System (CPMS): This system is designed to provide a comprehensive approach to chronic pain management. It includes a range of decision support tools, such as pain assessment scales, treatment planning templates, and communication tools for healthcare providers.\n4. Pain Management Decision Support System (PMDSS): This system is designed to provide healthcare providers with evidence-based recommendations for chronic pain management. It includes a range of decision support tools, such as pain assessment scales, treatment planning templates, and communication tools for healthcare providers.\n5. Electronic Pain Management System (EPMS): This system is designed to provide a comprehensive approach to chronic pain management. It includes a range of decision support tools, such as pain assessment scales, treatment planning templates, and communication tools for healthcare providers.\nThese decision support systems can help healthcare providers to assess pain levels, identify the underlying causes of pain, and develop personalized treatment plans. They can also help to improve communication between healthcare providers and patients, and provide ongoing support for pain management.\nIn conclusion, decision support systems have the potential to improve chronic pain management by providing healthcare providers with the tools and resources they need to make informed decisions about pain management. By integrating these systems into clinical practice, healthcare providers can provide more effective and personalized care for patients with chronic pain.",
    "llama-2-7b-chat-hf_fact_raw": "1. PainCheck is an electronic patient-reported pain monitoring system that integrates into existing electronic health records.\n2. PainAssessment is a decision support system that uses patient-reported outcomes and clinical data to assess pain intensity and quality and offers pain management recommendations.\n3. Chronic Pain Management System (CPMS) is designed to offer a comprehensive approach to chronic pain management, including decision support tools like assessment scales and treatment planning templates.\n4. Pain Management Decision Support System (PMDSS) provides healthcare providers with evidence-based recommendations for chronic pain management.\n5. Electronic Pain Management System (EPMS) includes decision support tools such as pain assessment scales and communication tools for healthcare providers.",
    "llama-2-7b-chat-hf_fact": [
      "PainCheck is an electronic patient-reported pain monitoring system that integrates into existing electronic health records.",
      "PainAssessment is a decision support system that uses patient-reported outcomes and clinical data to assess pain intensity and quality and offers pain management recommendations.",
      "Chronic Pain Management System (CPMS) is designed to offer a comprehensive approach to chronic pain management, including decision support tools like assessment scales and treatment planning templates.",
      "Pain Management Decision Support System (PMDSS) provides healthcare providers with evidence-based recommendations for chronic pain management.",
      "Electronic Pain Management System (EPMS) includes decision support tools such as pain assessment scales and communication tools for healthcare providers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or reference materials, it’s impossible to verify the accuracy of these statements about hypothetical or proprietary systems. If these systems are factual and described accurately in these statements, then there is not enough information provided to determine the truthfulness of each one.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the subcellular localization of the protein angiogenin is in the cytoplasm of Escherichia coli BL21-CodonPlus(DE3)-RIL cells. The document states that the protein was expressed in the cytoplasm of these cells using a pET expression vector, and that it accumulated in the form of insoluble aggregates. It also mentions that the proteins were renatured and purified using cation-exchange chromatography and reversed-phase HPLC, and that the yields of pure mAngrp and mAng-3 were 7.6 and 12 mg/liter culture, respectively, with a yield of 30 mg/liter culture for mAng-4. Therefore, it can be concluded that angiogenin is localized in the cytoplasm of E. coli cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein angiogenin localizes in the cytoplasm of Escherichia coli BL21-CodonPlus(DE3)-RIL cells.\n2. Angiogenin was expressed in these cells using a pET expression vector.\n3. The expressed angiogenin accumulated in the form of insoluble aggregates.\n4. The angiogenin proteins were renatured and purified using cation-exchange chromatography and reversed-phase HPLC.\n5. Yields of pure mAngrp and mAng-3 angiogenin were 7.6 and 12 mg/liter culture, respectively, with a yield of 30 mg/liter culture for mAng-4.",
    "llama-2-7b-chat-hf_fact": [
      "The protein angiogenin localizes in the cytoplasm of Escherichia coli BL21-CodonPlus(DE3)-RIL cells.",
      "Angiogenin was expressed in these cells using a pET expression vector.",
      "The expressed angiogenin accumulated in the form of insoluble aggregates.",
      "The angiogenin proteins were renatured and purified using cation-exchange chromatography and reversed-phase HPLC.",
      "Yields of pure mAngrp and mAng-3 angiogenin were 7.6 and 12 mg/liter culture, respectively, with a yield of 30 mg/liter culture for mAng-4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe given statements appear to be specific claims about a scientific process but lack context that would confirm their accuracy. Without the original passage or access to associated scientific literature, the veracity of statements about the localization, accumulation, and yields of protein cannot be determined with certainty. Statement 2 is assumed true based on the common use of pET expression vectors for protein expression in E. coli, but the other statements require specialized knowledge or reference material to verify.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ranolazine appears to affect kinase signaling activation in the heart by increasing the duration of the action potential and reducing the refractory period, which can lead to an increase in ventricular repolarization. The document states that chronic treatment with amiodarone or dronedarone as well as sotalol significantly increased action potential duration at 90% repolarization (APD(90)), and that additional treatment with ranolazine further increased APD(90) in amiodarone- and dronedarone-pretreated hearts. Additionally, ranolazine increased postrepolarization refractoriness, which suggests that it may affect the ability of the heart to recover from each heartbeat and prepare for the next one.\nIt is worth noting that the document also mentions that acute application of sotalol increased dispersion of repolarization, which suggests that sotalol may have a different effect on the heart's electrical activity compared to amiodarone and dronedarone. However, the document does not provide information on how ranolazine affects dispersion of repolarization.\nIn summary, based on the information provided in the document, ranolazine appears to increase the duration of the action potential and reduce the refractory period in the heart, which can lead to an increase in ventricular repolarization. However, the document does not provide information on the effect of ranolazine on dispersion of repolarization.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine increases the duration of the action potential in the heart.\n2. Ranolazine reduces the refractory period in the heart.\n3. Chronic treatment with amiodarone or dronedarone increases action potential duration at 90% repolarization (APD(90)).\n4. Additional treatment with ranolazine further increases APD(90) in amiodarone- and dronedarone-pretreated hearts.\n5. Acute application of sotalol increases dispersion of repolarization.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine increases the duration of the action potential in the heart.",
      "Ranolazine reduces the refractory period in the heart.",
      "Chronic treatment with amiodarone or dronedarone increases action potential duration at 90% repolarization (APD(90)).",
      "Additional treatment with ranolazine further increases APD(90) in amiodarone- and dronedarone-pretreated hearts.",
      "Acute application of sotalol increases dispersion of repolarization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine reduces, rather than increases, the duration of the action potential in the heart. It is primarily known for its action as an anti-anginal medication and works by inhibiting the late phase of the sodium current thereby reducing intracellular calcium overload and ultimately decreasing myocardial oxygen demand.\n2. TRUE: While the main action of ranolazine is to inhibit the late phase of the sodium current, this can also lead to a reduced refractory period in the heart tissue under certain conditions.\n3. TRUE: Chronic treatment with amiodarone or dronedarone is known to increase the action potential duration at 90% repolarization (APD(90)), which can help to prevent arrhythmias. Both drugs are class III antiarrhythmic agents that work by prolonging the cardiac action potential.\n4. UNKNOWN: The effect of additional treatment with ranolazine on APD(90) in amiodarone- or dronedarone-pretreated hearts may depend on the specific experimental or clinical context and without additional specific information, it's unclear what the outcome would be.\n5. TRUE: Acute application of sotalol, a Class III antiarrhythmic drug that blocks potassium channels, is known to prolong repolarization and can also increase the dispersion of repolarization, which is a measure of the variability of repolarization times across the myocardium. This can lead to a proarrhythmic risk in some patients.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the regulation of Vsr endonuclease appears to be independent of the growth phase of bacteria. The study found that strains lacking the neutral, histone-like, DNA-binding protein H-NS (hns-rpoS-double mutants) are more viable at high osmolarity at 37°C than hns+rpoS- cells during stationary phase. This suggests that the regulation of Vsr endonuclease is not dependent on the growth phase of the bacteria.\nAdditionally, the study found that the leucine-responsive regulatory protein acts without H-NS to protect a strain containing an rpoS mutation from death in stationary phase at high osmolarity. This further supports the idea that the regulation of Vsr endonuclease is independent of the growth phase of bacteria.\nIt is worth noting that the study did not observe differential viability at high osmolarity at 30°C or at normal osmolarity at 37°C, which suggests that the effect of H-NS on Vsr endonuclease regulation is specific to high osmolarity conditions.\nIn summary, based on the information provided in Document-0, the regulation of Vsr endonuclease appears to be independent of the growth phase of bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is reported to be independent of the growth phase of bacteria.\n2. Strains lacking the DNA-binding protein H-NS (hns-rpoS-double mutants) are more viable at high osmolarity at 37°C than hns+rpoS- cells during stationary phase.\n3. The leucine-responsive regulatory protein can protect a strain containing an rpoS mutation from death in stationary phase at high osmolarity without the involvement of H-NS.\n4. The study indicates no differential viability at high osmolarity at 30°C or normal osmolarity at 37°C in the context of Vsr endonuclease regulation and H-NS.\n5. The effect of H-NS on Vsr endonuclease regulation is specific to high osmolarity conditions.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is reported to be independent of the growth phase of bacteria.",
      "Strains lacking the DNA-binding protein H-NS (hns-rpoS-double mutants) are more viable at high osmolarity at 37°C than hns+rpoS- cells during stationary phase.",
      "The leucine-responsive regulatory protein can protect a strain containing an rpoS mutation from death in stationary phase at high osmolarity without the involvement of H-NS.",
      "The study indicates no differential viability at high osmolarity at 30°C or normal osmolarity at 37°C in the context of Vsr endonuclease regulation and H-NS.",
      "The effect of H-NS on Vsr endonuclease regulation is specific to high osmolarity conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context regarding the specific mechanisms of Vsr endonuclease regulation in bacteria, the truth of this statement cannot be determined from the given information.\n2. UNKNOWN: This statement depends on specific experimental results that have not been provided. Hence, the truth of this statement cannot be ascertained without knowing the results of comparisons between survival rates of hns-rpoS-double mutants and hns+rpoS- cells at high osmolarity.\n3. UNKNOWN: The statement mentions the effect of the leucine-responsive regulatory protein in the context of an rpoS mutation and high osmolarity, but without specific information or experimental data, it is impossible to verify its truthfulness.\n4. UNKNOWN: This statement refers to the results of a study on differential viability in certain conditions. Without access to that study or additional information, the truth of this statement remains undetermined.\n5. UNKNOWN: As with the previous statements, this one also refers to specific experimental findings about the role of H-NS in regulating Vsr endonuclease. Without the specific details of these findings, it is not possible to verify the correctness of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there are several computational tools available for the prediction of beta-barrel transmembrane proteins. These tools can be broadly classified into two categories:\n1. Tools for identifying potential transmembrane proteins in a pool of new sequences:\n* TMHMM: This tool uses a combination of sequence analysis and structural information to predict the transmembrane helices in a protein. It can also predict the transmembrane beta-barrel structure.\n* SignalP: This tool predicts the presence of signal peptides in a protein sequence, which can help identify potential transmembrane proteins.\n* PredictProtein: This tool predicts the structure and function of a protein based on its sequence. It can also predict the transmembrane regions of a protein.\n2. Tools for identifying the transmembrane regions of known integral membrane proteins:\n* TM-align: This tool aligns multiple transmembrane protein structures to identify the conserved regions that are important for transmembrane helix formation.\n* TM-pred: This tool predicts the transmembrane regions of a protein based on its sequence. It uses a combination of sequence analysis and structural information to make its predictions.\n* I-TASSER: This tool predicts the structure and function of a protein based on its sequence. It can also predict the transmembrane regions of a protein.\nIt is important to note that the accuracy of these tools depends on how closely the query protein fits the model used by the tool. Therefore, it is recommended to submit the protein of interest to all methods and choose the results with the highest confidence scores.",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a computational tool used to predict transmembrane helices in proteins and can also predict transmembrane beta-barrel structures.\n2. SignalP predicts the presence of signal peptides in protein sequences, which can help identify potential transmembrane proteins.\n3. PredictProtein predicts the structure and function of a protein based on its sequence, and can predict transmembrane regions.\n4. TM-align aligns multiple transmembrane protein structures to identify conserved regions important for transmembrane helix formation.\n5. I-TASSER predicts the structure and function of a protein based on its sequence and can also predict transmembrane regions of a protein.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a computational tool used to predict transmembrane helices in proteins and can also predict transmembrane beta-barrel structures.",
      "SignalP predicts the presence of signal peptides in protein sequences, which can help identify potential transmembrane proteins.",
      "PredictProtein predicts the structure and function of a protein based on its sequence, and can predict transmembrane regions.",
      "TM-align aligns multiple transmembrane protein structures to identify conserved regions important for transmembrane helix formation.",
      "I-TASSER predicts the structure and function of a protein based on its sequence and can also predict transmembrane regions of a protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TMHMM is a computational tool used to predict transmembrane helices in proteins, but it does not predict transmembrane beta-barrel structures.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: TM-align is a tool for the alignment of protein structures, but it's not specifically described as aligning multiple transmembrane protein structures nor focused on identifying conserved regions important for transmembrane helix formation. It's usually for general protein structure alignment.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Galassi classification is used for obsessive-compulsive disorder (OCD). The document mentions that the vast majority of French psychiatrists use international classifications, mainly for research purposes, and that almost 3/4 of them have used the Galassi classification at least once in the context of scientific studies or natural science surveys. Additionally, the document notes that terminology tends to evolve, particularly among younger psychiatrists, and that the notion of obsessional disorder is gradually coming to replace that of obsessional neurosis. Given these points, it can be inferred that Galassi classification is used for OCD, which is one of the disorders that the classification system is designed to diagnose and classify.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is used for diagnosing and classifying obsessive-compulsive disorder (OCD).\n2. The vast majority of French psychiatrists use international classifications for research purposes.\n3. Almost 3/4 of French psychiatrists have used the Galassi classification at least once.\n4. The document indicates a trend among younger psychiatrists to evolve terminology related to obsessional disorders.\n5. The term \"obsessional disorder\" is gradually replacing \"obsessional neurosis\" in psychiatric nomenclature.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is used for diagnosing and classifying obsessive-compulsive disorder (OCD).",
      "The vast majority of French psychiatrists use international classifications for research purposes.",
      "Almost 3/4 of French psychiatrists have used the Galassi classification at least once.",
      "The document indicates a trend among younger psychiatrists to evolve terminology related to obsessional disorders.",
      "The term \"obsessional disorder\" is gradually replacing \"obsessional neurosis\" in psychiatric nomenclature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is not used for diagnosing and classifying obsessive-compulsive disorder (OCD). It is actually known for classifying meniscal tears of the knee.\n2. TRUE: It is reasonable to assume that the vast majority of French psychiatrists, like their international colleagues, would use widely recognized international classifications (like the DSM or ICD) for research purposes.\n3. FALSE [correction]: Without specific supporting information, it is unlikely that almost 3/4 of French psychiatrists have used the Galassi classification, which is related to meniscal tears and not psychiatry.\n4. UNKNOWN: Without further context regarding the specific document and its content, it is impossible to confirm the trend mentioned.\n5. UNKNOWN: The change in psychiatric nomenclature would need specific evidence from psychiatric literature or general consensus in the field to confirm this statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the common features of Shapiro syndrome are:\n1. Infantile spasms: Shapiro syndrome is characterized by the presence of infantile spasms, which are a type of seizure that occurs in infants under the age of 1 year.\n2. Defects of the corpus callosum: Shapiro syndrome is associated with defects of the corpus callosum, which is the bundle of nerve fibers that connects the two hemispheres of the brain.\n3. Chorioretinopathy: Shapiro syndrome can cause chorioretinopathy, which is a disorder of the retina and choroid.\n4. Mental subnormality: Individuals with Shapiro syndrome often have mental subnormality, which can manifest as developmental delays or intellectual disability.\n5. Characteristic EEG changes: Shapiro syndrome is characterized by characteristic EEG changes, including slow spikes and sharp waves.\n6. Vertebral anomalies: Shapiro syndrome can cause vertebral anomalies, such as scoliosis or kyphosis.\n7. Microphthalmos and colobomata: Shapiro syndrome can cause microphthalmos, which is a condition where the eyes are smaller than normal, and colobomata, which is a condition where there is a gap or missing portion of the brain.\nIt is important to note that Shapiro syndrome affects only the female sex, as stated in Document-0.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by infantile spasms, which are seizures that occur in infants under the age of 1 year.\n2. Shapiro syndrome is associated with defects of the corpus callosum, the bundle of nerve fibers connecting the two brain hemispheres.\n3. Chorioretinopathy, a disorder of the retina and choroid, can be a feature of Shapiro syndrome.\n4. Individuals with Shapiro syndrome often have developmental delays or intellectual disability, referred to as mental subnormality.\n5. Shapiro syndrome is characterized by specific EEG changes, including slow spikes and sharp waves.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by infantile spasms, which are seizures that occur in infants under the age of 1 year.",
      "Shapiro syndrome is associated with defects of the corpus callosum, the bundle of nerve fibers connecting the two brain hemispheres.",
      "Chorioretinopathy, a disorder of the retina and choroid, can be a feature of Shapiro syndrome.",
      "Individuals with Shapiro syndrome often have developmental delays or intellectual disability, referred to as mental subnormality.",
      "Shapiro syndrome is characterized by specific EEG changes, including slow spikes and sharp waves."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent hypothermia, hyperhidrosis, and agenesis of the corpus callosum, not specifically infantile spasms.\n2. TRUE\n3. UNKNOWN\n4. TRUE \n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disease that is linked to mutations within BRAG1 is craniopharyngioma. The study found that 8 out of 10 craniopharyngiomas analyzed had mutations in the CTNNB1 gene, including two cases with double mutations in both CTNNB1 and FGFR3. In contrast, ameloblastic tumors were found to be more frequently mutated in the FGFR2 gene (4 out of 9 cases), with one case also carrying mutations in TP53 and PTEN. No mutations were detected in the 22 genes analyzed in the remaining samples. Therefore, the study suggests that craniopharyngiomas are more likely to have mutations in the CTNNB1 gene, while ameloblastic tumors are more likely to have mutations in the FGFR2 gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within BRAG1 are linked to the disease craniopharyngioma.\n2. The study indicated that 8 out of 10 craniopharyngiomas analyzed had mutations in the CTNNB1 gene.\n3. Two cases of craniopharyngiomas had double mutations in both CTNNB1 and FGFR3.\n4. Ameloblastic tumors were more frequently mutated in the FGFR2 gene in 4 out of 9 cases analyzed.\n5. One case of an ameloblastic tumor also had mutations in TP53 and PTEN.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within BRAG1 are linked to the disease craniopharyngioma.",
      "The study indicated that 8 out of 10 craniopharyngiomas analyzed had mutations in the CTNNB1 gene.",
      "Two cases of craniopharyngiomas had double mutations in both CTNNB1 and FGFR3.",
      "Ameloblastic tumors were more frequently mutated in the FGFR2 gene in 4 out of 9 cases analyzed.",
      "One case of an ameloblastic tumor also had mutations in TP53 and PTEN."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations within BRCA1 are not linked to craniopharyngioma, as there is no known gene named BRAG1 that is associated with this disease. BRCA1 mutations are primarily known for increasing the risk of breast and ovarian cancer.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and the determination of facts rely largely on the specific data from scientific studies, which have not been provided. Without access to the study or studies that the statements are derived from, it is not possible to verify the genetic mutations associated with craniopharyngiomas and ameloblastic tumors, hence the UNKNOWN responses.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the main inhibitor of protein phosphatase 1 (PP1) is \"nuclear inhibitor of PP1\" (NIPP1).",
    "llama-2-7b-chat-hf_fact_raw": "1. The main inhibitor of protein phosphatase 1 (PP1) is the \"nuclear inhibitor of PP1\" (NIPP1).",
    "llama-2-7b-chat-hf_fact": [
      "The main inhibitor of protein phosphatase 1 (PP1) is the \"nuclear inhibitor of PP1\" (NIPP1)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The main inhibitor of protein phosphatase 1 (PP1) is \"Inhibitor 1\" (I-1), not \"nuclear inhibitor of PP1\" (NIPP1). NIPP1 is one of several regulators of PP1.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. DNA polymerase I: The information provided suggests that DNA polymerase I plays a direct role in promoting MMS and transformation-induced mutagenesis in competent cells.\n2. Increased sensitivity to MMS: During the development of competence in Bacillus subtilis, there is an increased sensitivity to methyl methanesulfonate (MMS) treatments. This increased sensitivity may contribute to the increased frequency of reverse mutations among MMS-revertible markers.\n3. 2-Aminopurine (AP)-induced mutagenesis: The information provided shows that the frequency of 2-aminopurine (AP)-induced mutagenesis is the same in competent and non-competent cultures, suggesting that the mechanism of AP-induced mutagenesis is not affected by the stationary phase.\nTherefore, the mechanisms that underlie adaptive mutagenesis in Bacillus subtilis are primarily related to the activity of DNA polymerase I and the increased sensitivity of competent cells to mutagenic agents such as MMS.",
    "llama-2-7b-chat-hf_fact_raw": "1. DNA polymerase I is involved in promoting MMS and transformation-induced mutagenesis in competent Bacillus subtilis cells.\n2. Bacillus subtilis shows increased sensitivity to methyl methanesulfonate (MMS) treatments during the development of competence.\n3. The increased sensitivity to MMS in Bacillus subtilis may lead to a higher frequency of reverse mutations in MMS-revertible markers.\n4. The frequency of 2-aminopurine (AP)-induced mutagenesis is consistent in both competent and non-competent Bacillus subtilis cultures.\n5. The activities of DNA polymerase I and the sensitivity to mutagenic agents like MMS contribute to adaptive mutagenesis in Bacillus subtilis.",
    "llama-2-7b-chat-hf_fact": [
      "DNA polymerase I is involved in promoting MMS and transformation-induced mutagenesis in competent Bacillus subtilis cells.",
      "Bacillus subtilis shows increased sensitivity to methyl methanesulfonate (MMS) treatments during the development of competence.",
      "The increased sensitivity to MMS in Bacillus subtilis may lead to a higher frequency of reverse mutations in MMS-revertible markers.",
      "The frequency of 2-aminopurine (AP)-induced mutagenesis is consistent in both competent and non-competent Bacillus subtilis cultures.",
      "The activities of DNA polymerase I and the sensitivity to mutagenic agents like MMS contribute to adaptive mutagenesis in Bacillus subtilis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The increased sensitivity to MMS in Bacillus subtilis may actually lead to a higher frequency of mutations in MMS-sensitive markers, not necessarily reversions.\n4. FALSE [correction]: The frequency of 2-aminopurine (AP)-induced mutagenesis may increase in competent Bacillus subtilis cultures due to an altered mutation spectrum during competence - the statement does not specify whether it increases or remains the same, thus without additional context, it's difficult to assess the consistency.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it appears that the causes of erucism (or enucleation, evisceration, and exenteration) can vary depending on the country and cultural background of the population. In Malawi and Israel, differences in medical facilities, standard of living, and cultural background were found to contribute to differences in the etiology of these procedures.\nIt is important to note that erucism is a complex condition that can have multiple causes, including medical, social, and cultural factors. In some cases, erucism may be caused by a lack of access to medical facilities or poor medical care, while in other cases it may be caused by cultural or social factors.\nWithout additional information, it is difficult to provide a definitive answer to the user's question about the causes of erucism. However, it is clear that the causes of this condition can vary widely depending on the context and population in question.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, hydrochlorothiazide is a diuretic medication that is used to treat hypertension (high blood pressure) and edema (excess fluid accumulation in the body). The document suggests that certain genetic variations in the NEDD4L gene may influence the ability of the NEDD4L protein to reduce epithelial sodium channel expression, which may in turn affect the response to hydrochlorothiazide therapy. Specifically, the document reports associations between certain NEDD4L polymorphisms and decreased blood pressure response to hydrochlorothiazide in whites, as well as an increased risk for adverse cardiovascular outcomes in whites not treated with hydrochlorothiazide.\nTherefore, the indications for hydrochlorothiazide based on the information provided in the document are:\n1. Treatment of hypertension: Hydrochlorothiazide is a diuretic medication that can help lower blood pressure in individuals with hypertension.\n2. Treatment of edema: Hydrochlorothiazide can help reduce excess fluid accumulation in the body, which can be beneficial in the treatment of edema.\n3. Prediction of blood pressure response: The NEDD4L polymorphisms identified in the document may be used to predict an individual's response to hydrochlorothiazide therapy, including their likelihood of experiencing a decrease in blood pressure.\n4. Risk assessment for adverse cardiovascular outcomes: The document suggests that certain NEDD4L polymorphisms may be associated with an increased risk for adverse cardiovascular outcomes in individuals not treated with hydrochlorothiazide. Therefore, these polymorphisms may be used to assess an individual's risk for these outcomes when treated with hydrochlorothiazide.\nIt is important to note that these indications are based on the information provided in the document and may not be applicable to all individuals. Further research and clinical trials are needed to confirm these findings and establish the clinical utility of using NEDD4L polymorphisms to predict response to hydrochlorothiazide therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to treat edema (excess fluid accumulation in the body).\n3. Certain genetic variations in the NEDD4L gene may influence the response to hydrochlorothiazide therapy.\n4. Associations between certain NEDD4L polymorphisms and decreased blood pressure response to hydrochlorothiazide have been reported in whites.\n5. Certain NEDD4L polymorphisms may be associated with an increased risk for adverse cardiovascular outcomes in whites not treated with hydrochlorothiazide.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to treat edema (excess fluid accumulation in the body).",
      "Certain genetic variations in the NEDD4L gene may influence the response to hydrochlorothiazide therapy.",
      "Associations between certain NEDD4L polymorphisms and decreased blood pressure response to hydrochlorothiazide have been reported in whites.",
      "Certain NEDD4L polymorphisms may be associated with an increased risk for adverse cardiovascular outcomes in whites not treated with hydrochlorothiazide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. The information provided in the document you provided mentions the use of a material called Zenoderm, which is derived from porcine corium, in the treatment of complete rectal prolapse. While the document does not specifically mention incontinence, it is possible that the material may have been used in the treatment of this condition as well.\nSilicon is a biocompatible material that has been used in various medical applications, including the treatment of incontinence. It is known for its inert, non-irritant, and pliable properties, which make it an ideal material for use in the body. In the case of rectal prolapse, the use of a silicon-based material like Zenoderm may help to provide support and stability to the rectal tissue, reducing the symptoms of incontinence.\nIt is worth noting that the use of silicon in the treatment of incontinence is not limited to the treatment of rectal prolapse. Silicon-based materials have also been used in the treatment of other types of incontinence, such as stress urinary incontinence (SUI). In these cases, the silicon material is typically used to create a supportive structure that helps to prevent the involuntary leakage of urine.\nIn summary, while the document you provided does not specifically mention the use of silicon in the treatment of incontinence, it is possible that the material may have been used in this context based on its biocompatible properties and potential benefits for rectal prolapse treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. Zenoderm, derived from porcine corium, has been used in the treatment of complete rectal prolapse.\n3. Silicon is known for its biocompatible, inert, non-irritant, and pliable properties.\n4. Silicon-based materials are used in medical applications other than rectal prolapse, such as stress urinary incontinence (SUI).\n5. In cases of stress urinary incontinence, silicon is used to create a structure to prevent involuntary urine leakage.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "Zenoderm, derived from porcine corium, has been used in the treatment of complete rectal prolapse.",
      "Silicon is known for its biocompatible, inert, non-irritant, and pliable properties.",
      "Silicon-based materials are used in medical applications other than rectal prolapse, such as stress urinary incontinence (SUI).",
      "In cases of stress urinary incontinence, silicon is used to create a structure to prevent involuntary urine leakage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, is used in the treatment of incontinence.\n2. UNKNOWN\n3. TRUE (Although \"silicon\" should be \"silicone\" in most biomedical contexts)\n4. TRUE (Again, it should be \"silicone\" when referring to medical applications)\n5. TRUE (The statement is correct if referring to silicone; silicon is a chemical element, while silicone is a polymer used for medical purposes including incontinence devices.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no direct association between the moon cycle and the rupture risk of intracranial aneurysms. The study focuses on identifying risk factors for the rupture of unruptured intracranial aneurysms (UIAs) through a multidimensional modeling approach. The risk factors being analyzed include genetic factors, biomarkers, hemodynamic factors, and HRMRI findings.\nThe study does not mention the moon cycle as a potential risk factor for UIA rupture, and there is no scientific evidence to support a correlation between the two. The moon cycle is a cyclical pattern of the Earth's orbit around the sun, and it does not have any known effects on the human body or brain.\nTherefore, based on the information provided in the document, there is no association between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no direct association between the moon cycle and the rupture risk of intracranial aneurysms according to the document referenced.\n2. The study referenced is focused on identifying risk factors for the rupture of unruptured intracranial aneurysms (UIAs) using a multidimensional modeling approach.\n3. The risk factors being analyzed in the study include genetic factors, biomarkers, hemodynamic factors, and HRMRI findings.\n4. The moon cycle is not mentioned as a potential risk factor for UIA rupture in the study.\n5. The moon cycle is a cyclical pattern of the Earth's moon and does not have any known effects on the human body or brain according to the document referenced.",
    "llama-2-7b-chat-hf_fact": [
      "There is no direct association between the moon cycle and the rupture risk of intracranial aneurysms according to the document referenced.",
      "The study referenced is focused on identifying risk factors for the rupture of unruptured intracranial aneurysms (UIAs) using a multidimensional modeling approach.",
      "The risk factors being analyzed in the study include genetic factors, biomarkers, hemodynamic factors, and HRMRI findings.",
      "The moon cycle is not mentioned as a potential risk factor for UIA rupture in the study.",
      "The moon cycle is a cyclical pattern of the Earth's moon and does not have any known effects on the human body or brain according to the document referenced."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: While the document referenced may state there is no direct association between the moon cycle and the rupture risk of intracranial aneurysms, it cannot be definitively stated that the moon cycle has no known effects on the human body or brain, as there is some scientific literature that explores potential correlations between the moon cycle and various aspects of human health and behavior, even if such correlations are not widely accepted or conclusively proven.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein does regulate the splicing process. According to the information provided in Document-0, HuR is an RNA-binding protein that regulates the stability and translation of target mRNAs. While the document does not specifically mention splicing, it is implied that HuR may also play a role in this process.\nHuR is known to bind to specific sequences in the 3' untranslated region (UTR) of target mRNAs and regulate their stability and translation. The 3' UTR of many mRNAs contains splice sites, which are recognized by the spliceosome and determine the final mRNA product after splicing. HuR's ability to bind to the 3' UTR and regulate mRNA stability and translation could potentially affect the splicing process by influencing the expression of specific splice variants.\nTherefore, while the document does not directly address splicing, it suggests that HuR may play a role in regulating the splicing process by influencing the stability and translation of mRNAs that undergo splicing.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein is an RNA-binding protein that regulates the stability and translation of target mRNAs.\n2. The 3' untranslated region (UTR) of target mRNAs, which HuR is known to bind, contains splice sites.\n3. The spliceosome recognizes splice sites in the 3' UTR.\n4. HuR's binding to the 3' UTR could potentially affect the splicing process by influencing the expression of specific splice variants.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein is an RNA-binding protein that regulates the stability and translation of target mRNAs.",
      "The 3' untranslated region (UTR) of target mRNAs, which HuR is known to bind, contains splice sites.",
      "The spliceosome recognizes splice sites in the 3' UTR.",
      "HuR's binding to the 3' UTR could potentially affect the splicing process by influencing the expression of specific splice variants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 3' untranslated region (UTR) of target mRNAs, which HuR is known to bind, typically does not contain splice sites. Splice sites are usually found in the exonic and intronic regions, not the 3' UTR.\n3. FALSE [correction]: The spliceosome recognizes splice sites within the exons and introns of pre-mRNA, not typically in the 3' UTR.\n4. FALSE [correction]: Since the 3' UTR usually does not contain splice sites, HuR's binding to the 3' UTR is unlikely to affect the splicing process directly. It could however affect mRNA stability and translation, which can have an indirect influence on the expression of specific splice variants.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the known functions of the prothymosin alpha c-terminal peptide (ProT) are:\n1. Stimulation of cell proliferation and differentiation through epigenetic or genomic mechanisms: ProT functions intracellularly to promote cell growth and differentiation by modulating gene expression through unknown mechanisms.\n2. Regulation of cell defensive mechanisms: ProT interacts with the Nrf2-Keap1 system, which is involved in the response to oxidative stress and the regulation of antioxidant defenses.\n3. Inhibition of apoptosome formation: ProT binds to Apaf-1 and prevents the formation of apoptosomes, which are structures involved in the execution of programmed cell death.\n4. Inhibition of necrosis: ProT is released from the nucleus upon ischemia stress and inhibits necrosis, a form of cell death that occurs due to injury or stress.\n5. Immunological actions: ProT has been reported to activate the Toll-like receptor 4, which is involved in the recognition of pathogen-associated molecular patterns and the activation of immune responses.\n6. Retention of cleaved ProT in the cytosol: Under apoptotic conditions, the C-terminus of ProT is cleaved off, leading to the retention of the cleaved protein in the cytosol, where it inhibits apoptosome formation.\nOverall, ProT appears to play a multifaceted role in maintaining cellular robustness and resistance to stress, both through intracellular and extracellular mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (ProT) functions intracellularly to promote cell growth and differentiation through mechanisms that modulate gene expression.\n2. ProT interacts with the Nrf2-Keap1 system, which is involved in the response to oxidative stress and regulates antioxidant defenses.\n3. ProT binds to Apaf-1 and prevents the formation of apoptosomes, structures involved in programmed cell death.\n4. ProT is released from the nucleus upon ischemia stress and inhibits necrosis.\n5. ProT activates the Toll-like receptor 4, which is involved in immune response activation.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (ProT) functions intracellularly to promote cell growth and differentiation through mechanisms that modulate gene expression.",
      "ProT interacts with the Nrf2-Keap1 system, which is involved in the response to oxidative stress and regulates antioxidant defenses.",
      "ProT binds to Apaf-1 and prevents the formation of apoptosomes, structures involved in programmed cell death.",
      "ProT is released from the nucleus upon ischemia stress and inhibits necrosis.",
      "ProT activates the Toll-like receptor 4, which is involved in immune response activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There is no evidence that Prothymosin alpha c-terminal peptide (ProT) activates the Toll-like receptor 4. Activation of Toll-like receptor 4 is generally associated with recognition of bacterial lipopolysaccharides and other pathogen-associated molecular patterns, not ProT.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the peptide that plays a pivotal role in human cystatin C fibrillization is cystatin C. The study found that cystatin C levels were higher in patients with ischemic stroke complicating atrial fibrillation (AF) compared to control subjects, and that the level of cystatin C was positively associated with IL-6 and hsCRP. These findings suggest that cystatin C may play a role in the fibrillization of AF, and that it may be a useful marker for identifying patients at high risk of stroke.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide that plays a pivotal role in human cystatin C fibrillization is cystatin C.\n2. Higher levels of cystatin C were found in patients with ischemic stroke complicating atrial fibrillation (AF) than in control subjects.\n3. The level of cystatin C was positively associated with interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP).\n4. Cystatin C may be a marker for identifying patients at high risk of stroke.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide that plays a pivotal role in human cystatin C fibrillization is cystatin C.",
      "Higher levels of cystatin C were found in patients with ischemic stroke complicating atrial fibrillation (AF) than in control subjects.",
      "The level of cystatin C was positively associated with interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP).",
      "Cystatin C may be a marker for identifying patients at high risk of stroke."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThese statements pertain to scientific findings that have likely been investigated in research relating to the biomarkers of stroke risk and inflammation. Cystatin C is indeed a biomarker associated with cardiovascular diseases, and increased levels have been associated with conditions like atrial fibrillation and stroke. The levels of cystatin C might be correlated with other markers of inflammation such as IL-6 and hsCRP, and due to these correlations, cystatin C may serve as a marker for identifying patients at high risk of stroke. However, without specific studies to reference, these statements are taken at face value from the context provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the answer to the user's question is:\nYes, the concentration of protein HIF-1α is expected to increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\nThe document mentions that after the third MPA injection, mean growth hormone (GH) levels increased significantly and continued to increase slightly after the fourth and fifth injections. HIF-1α is a transcription factor that plays a critical role in regulating cellular responses to hypoxia, including glucose metabolism. Therefore, it is likely that the increase in GH levels after MPA administration will lead to an increase in HIF-1α concentration.\nAdditionally, the document mentions that MPA administration causes moderate disturbance of glucose homoeostasis, which can also contribute to an increase in HIF-1α concentration. HIF-1α is activated in response to hypoxia and glucose deprivation, and its activity is involved in the regulation of glucose metabolism.\nIn summary, based on the information provided in Document-0, it is reasonable to expect that the concentration of protein HIF-1α will increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
    "llama-2-7b-chat-hf_fact_raw": "1. Administration of the cytoprotective prodrug \"amifostine\" (ethyol) is expected to increase the concentration of protein HIF-1α.\n2. Mean growth hormone (GH) levels increased significantly after the third MPA injection.\n3. Growth hormone levels continued to increase slightly after the fourth and fifth MPA injections.\n4. Administration of MPA causes moderate disturbance of glucose homeostasis.\n5. HIF-1α is a transcription factor that is activated in response to hypoxia and glucose deprivation.",
    "llama-2-7b-chat-hf_fact": [
      "Administration of the cytoprotective prodrug \"amifostine\" (ethyol) is expected to increase the concentration of protein HIF-1α.",
      "Mean growth hormone (GH) levels increased significantly after the third MPA injection.",
      "Growth hormone levels continued to increase slightly after the fourth and fifth MPA injections.",
      "Administration of MPA causes moderate disturbance of glucose homeostasis.",
      "HIF-1α is a transcription factor that is activated in response to hypoxia and glucose deprivation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is not enough information provided to confirm the relationship between the administration of amifostine (ethyol) and the concentration of HIF-1α. Amifostine is known to protect cells from the harmful effects of chemotherapy and radiation therapy, but its impact on HIF-1α levels would need to be established by specific research.\n\n2. UNKNOWN: Without context specifying what MPA stands for, it is not possible to determine the truth of this statement. Additionally, growth hormone responses can vary based on a number of factors, including the population studied, the dosing, and the frequency of MPA injections.\n\n3. UNKNOWN: Similar to the previous statement, the effect of MPA injections on growth hormone levels would require specific context and data from studies to confirm or refute the statement.\n\n4. UNKNOWN: The statement about the administration of MPA causing moderate disturbance of glucose homeostasis would need to be supported by clinical or scientific evidence relevant to MPA's effects on glucose metabolism.\n\n5. TRUE: HIF-1α (hypoxia-inducible factor 1-alpha) is indeed a transcription factor that is activated in response to hypoxia, and it can also be involved in the cellular response to glucose deprivation. It helps to adapt the cell to low oxygen conditions by activating various genes.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, SET7 is known to deposit the following histone marks:\n1. H3K4me3: SET7 is involved in the monoubiquitination of H3K4, leading to the activation of various genes involved in cellular processes such as transcriptional elongation, chromatin remodeling, and DNA repair.\n2. H3K27me3: SET7 has been shown to be involved in the trimethylation of H3K27, which is known to be a repressive mark in gene expression.\n3. H3K9me3: SET7 has been implicated in the tri-methylation of H3K9, which is associated with gene silencing and chromatin compaction.\n4. H2A.Z: SET7 has been shown to be involved in the monoubiquitination of H2A.Z, which is involved in the regulation of chromatin structure and gene expression.\nTherefore, based on the information provided in the document, SET7 is known to deposit the histone marks H3K4me3, H3K27me3, H3K9me3, and H2A.Z.",
    "llama-2-7b-chat-hf_fact_raw": "1. SET7 is involved in the monoubiquitination of histone H3 at lysine 4 (H3K4me3).\n2. SET7 has been shown to be involved in the trimethylation of histone H3 at lysine 27 (H3K27me3), which is a repressive mark in gene expression.\n3. SET7 has been implicated in the tri-methylation of histone H3 at lysine 9 (H3K9me3), associated with gene silencing and chromatin compaction.\n4. SET7 is involved in the monoubiquitination of H2A.Z, which is involved in the regulation of chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "SET7 is involved in the monoubiquitination of histone H3 at lysine 4 (H3K4me3).",
      "SET7 has been shown to be involved in the trimethylation of histone H3 at lysine 27 (H3K27me3), which is a repressive mark in gene expression.",
      "SET7 has been implicated in the tri-methylation of histone H3 at lysine 9 (H3K9me3), associated with gene silencing and chromatin compaction.",
      "SET7 is involved in the monoubiquitination of H2A.Z, which is involved in the regulation of chromatin structure and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SET7 (also known as SETD7) is known for catalyzing the mono-methylation of histone H3 at lysine 4 (H3K4me1), not the monoubiquitination of H3 or its tri-methylation at K4 (H3K4me3).\n2. FALSE [correction]: SET7 specifically catalyzes the mono-methylation at lysine 4 of histone H3 and has not been shown to be involved in the trimethylation of histone H3 at lysine 27 (H3K27me3), which is typically catalyzed by other methyltransferases like EZH2 as part of the PRC2 complex.\n3. FALSE [correction]: SET7 is responsible for mono-methylation of lysine 9 (H3K9me1) but is not implicated in the tri-methylation of histone H3 at lysine 9 (H3K9me3), which is associated with gene silencing and is carried out by other enzymes like SUV39H1.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the localization of the protein encoded by the gene DNAJC11 is on chromosome 2, specifically on the region of 2q13-q14.",
    "llama-2-7b-chat-hf_fact_raw": "1. The gene DNAJC11 is located on chromosome 2.\n2. The specific region of the DNAJC11 gene on chromosome 2 is 2q13-q14.",
    "llama-2-7b-chat-hf_fact": [
      "The gene DNAJC11 is located on chromosome 2.",
      "The specific region of the DNAJC11 gene on chromosome 2 is 2q13-q14."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The DNAJC11 gene is located on chromosome 4q22.1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, ultraconserved elements are depleted among copy number variants (CNVs).\nThe document states that the study focused on regions that never seem to vary in the general population, hypothesizing that these are copy number stable because variations within them are deleterious. The results show that copy number stable regions are characterized by correlation with a number of genomic features, allowing the researchers to define a list of genomic regions that are dosage sensitive in humans. These dosage-sensitive regions show significant overlap with de novo CNVs identified in patients with intellectual disability or autism, and there is also a significant association between copy number stable regions and rare inherited variants in autism patients, but not in controls.\nTherefore, the study suggests that regions that are copy number stable in the general population are less likely to have CNVs, which supports the idea that ultraconserved elements are depleted among CNVs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are less likely to have copy number variants (CNVs) in the general population.\n2. The study hypothesizes that variations within ultraconserved elements are deleterious.\n3. The regions characterized by a correlation with genomic features were used to define a list of dosage-sensitive regions in humans.\n4. Dosage-sensitive regions significantly overlap with de novo CNVs found in patients with intellectual disability or autism.\n5. There is a significant association between copy number stable regions and rare inherited variants in autism patients, but not in controls.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are less likely to have copy number variants (CNVs) in the general population.",
      "The study hypothesizes that variations within ultraconserved elements are deleterious.",
      "The regions characterized by a correlation with genomic features were used to define a list of dosage-sensitive regions in humans.",
      "Dosage-sensitive regions significantly overlap with de novo CNVs found in patients with intellectual disability or autism.",
      "There is a significant association between copy number stable regions and rare inherited variants in autism patients, but not in controls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements are highly conserved regions of the genome, and they are less likely to have copy number variants (CNVs) because variations in these regions have the potential to be more deleterious, leading to strong purifying selection against such changes.\n\n2. TRUE: The study's hypothesis that variations within ultraconserved elements are deleterious is based on the high degree of conservation observed for these elements, which suggests that they have been maintained by natural selection because they are important for organism survival and function.\n\n3. TRUE: If the statement is referring to a specific study that is examining the correlation between genomic features and regions of the genome, and then defining dosage-sensitive regions based on this analysis, this is a plausible approach. Dosage-sensitive regions are typically regions where gene dosage (i.e., the number of copies of a gene or genomic region) is crucial and changes can lead to phenotypic consequences.\n\n4. TRUE: Dosage-sensitive regions are often implicated in developmental disorders, and de novo (new) CNVs that occur in these regions can be associated with conditions like intellectual disability and autism spectrum disorders. Studies have found significant overlap between such dosage-sensitive regions and the de novo CNVs present in individuals affected by these conditions.\n\n5. UNKNOWN: While there may be studies that suggest an association between copy number stable regions and rare inherited variants in autism patients, this statement requires specific knowledge about the results of those studies in order to verify its truthfulness. Without further context or reference to specific research findings, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the substrate of the Haspin kinase during mitosis is histone H3 at Thr3 (H3T3ph). Haspin phosphorylates H3T3ph, providing a chromatin binding site for the chromosomal passenger complex (CPC) at centromeres to regulate chromosome segregation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is histone H3 at Thr3 (H3T3ph).\n2. Haspin kinase phosphorylates H3T3ph.\n3. The phosphorylation of H3T3ph by Haspin kinase provides a chromatin binding site for the chromosomal passenger complex (CPC).\n4. The chromosomal passenger complex (CPC) binds at centromeres to regulate chromosome segregation.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is histone H3 at Thr3 (H3T3ph).",
      "Haspin kinase phosphorylates H3T3ph.",
      "The phosphorylation of H3T3ph by Haspin kinase provides a chromatin binding site for the chromosomal passenger complex (CPC).",
      "The chromosomal passenger complex (CPC) binds at centromeres to regulate chromosome segregation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nExplanation:\n1. Histone H3 at threonine 3 (H3T3ph) is indeed a substrate of Haspin kinase during mitosis; H3T3ph means histone H3 when threonine 3 is phosphorylated.\n2. Haspin kinase phosphorylates the threonine 3 residue on histone H3, and the presence of H3T3ph indicates this phosphorylation has occurred.\n3. The phosphorylation of histone H3 at threonine 3 by Haspin kinase does create a binding site for the chromosomal passenger complex, which is crucial for its mitotic functions.\n4. The chromosomal passenger complex plays a critical role in regulating chromosome segregation during mitosis, and it is known to bind at centromeres, among other locations on the chromatids.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mechanism of viroid replication involves an RNA-based rolling-circle mechanism with three steps:\n1. Synthesis of longer-than-unit strands: Host DNA-dependent RNA polymerases are recruited and redirected to transcribe RNA templates, leading to the synthesis of longer-than-unit strands of viroid RNA.\n2. Cleavage to unit-length: In family Avsunviroidae, this step is mediated by hammerhead ribozymes, which cleave the longer strands to produce unit-length viroid RNA.\n3. Circularization: The resulting fragmented RNA is then circularized through an RNA ligase or autocatalytically, resulting in the formation of a circular, self-complementary RNA molecule.\nThis mechanism of replication is RNA-dependent and does not involve the encoding of any protein. Instead, viroids rely on their hosts' cellular machinery to replicate their RNA genome. The consistent but still fragmentary picture of viroid replication has emerged from a combination of in vitro and in vivo studies, including the use of transgenic plants expressing viroid RNAs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroid replication involves an RNA-based rolling-circle mechanism.\n2. Host DNA-dependent RNA polymerases transcribe RNA templates, synthesizing longer-than-unit strands of viroid RNA.\n3. In the Avsunviroidae family, hammerhead ribozymes mediate the cleavage of longer RNA strands to produce unit-length viroid RNA.\n4. The fragmented RNA is circularized through an RNA ligase or autocatalytically to form a circular RNA molecule.\n5. Viroid replication does not encode any protein but relies on the host's cellular machinery.",
    "llama-2-7b-chat-hf_fact": [
      "Viroid replication involves an RNA-based rolling-circle mechanism.",
      "Host DNA-dependent RNA polymerases transcribe RNA templates, synthesizing longer-than-unit strands of viroid RNA.",
      "In the Avsunviroidae family, hammerhead ribozymes mediate the cleavage of longer RNA strands to produce unit-length viroid RNA.",
      "The fragmented RNA is circularized through an RNA ligase or autocatalytically to form a circular RNA molecule.",
      "Viroid replication does not encode any protein but relies on the host's cellular machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids use host RNA polymerases to synthesize new RNA, but they do not involve DNA-dependent RNA polymerases since viroids consist of RNA, not DNA. \n3. TRUE\n4. UNKNOWN (While RNA ligases or autocatalytic cleavage can be involved, the exact mechanism can depend on the type of viroid and the specific cellular conditions, and the statement doesn't specify which type of viroid is being referred to.)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy (DMD). The document describes a case where a fetal muscle biopsy was performed to diagnose DMD, but the sample was contaminated by maternal tissue due to the design of the biopsy needle. This highlights the importance of careful needle insertion and proper sampling techniques to avoid maternal contamination. While fibronectin is a protein that is involved in muscle development and maintenance, it is not specifically mentioned in the document as a biomarker for DMD. Therefore, based on the information provided, fibronectin is not a reliable serum biomarker for DMD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is a protein involved in muscle development and maintenance.\n2. Fibronectin is not a reliable serum biomarker for Duchenne muscular dystrophy (DMD) according to the provided document.\n3. A case described in the document involved a fetal muscle biopsy to diagnose DMD.\n4. The biopsy sample was contaminated by maternal tissue due to the design of the biopsy needle.\n5. Proper sampling techniques are important to avoid maternal contamination during a muscle biopsy.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is a protein involved in muscle development and maintenance.",
      "Fibronectin is not a reliable serum biomarker for Duchenne muscular dystrophy (DMD) according to the provided document.",
      "A case described in the document involved a fetal muscle biopsy to diagnose DMD.",
      "The biopsy sample was contaminated by maternal tissue due to the design of the biopsy needle.",
      "Proper sampling techniques are important to avoid maternal contamination during a muscle biopsy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fibronectin is a glycoprotein involved in cell adhesion, growth, migration, and differentiation, but it is not specifically characterized by its role in muscle development and maintenance.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the passage, the following major epigenome projects are contained in the DeepBlue epigenomic data server:\n1. StatEpigen: A manually curated and annotated database that contains information on interdependencies between genetic and epigenetic signals in colorectal cancer (CRC) research.\n2. EpiGeNet: A graph database for storage and querying of conditional relationships between molecular (genetic and epigenetic) events observed at different stages of colorectal oncogenesis.\nThese two projects are mentioned in the passage as sources of data that were extracted and imported into the EpiGeNet graph database for further analysis and querying.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the StatEpigen project.\n2. StatEpigen is focused on genetic and epigenetic signals in colorectal cancer (CRC) research.\n3. The DeepBlue epigenomic data server contains data from the EpiGeNet project.\n4. EpiGeNet is a graph database storing conditional relationships between molecular events observed at different stages of colorectal oncogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the StatEpigen project.",
      "StatEpigen is focused on genetic and epigenetic signals in colorectal cancer (CRC) research.",
      "The DeepBlue epigenomic data server contains data from the EpiGeNet project.",
      "EpiGeNet is a graph database storing conditional relationships between molecular events observed at different stages of colorectal oncogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The DeepBlue epigenomic data server contains data from various epigenomic projects, but there is no documentation or public record confirming a project named \"StatEpigen.\" DeepBlue is more commonly associated with the BLUEPRINT project and other datasets.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nSince the information provided lacks the context needed for definitive answers on statements 2, 3, and 4, and since \"StatEpigen\" and \"EpiGeNet\" do not match commonly known projects associated with the DeepBlue server, their statuses are unknown and cannot be accurately determined without further context or information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the question and the document, the tool that employs self-organizing maps for analyzing synonymous codon usage is likely \"Multivariate analyses\".\nThe document mentions that multivariate analyses are often used to identify trends of variation in synonymous codon usage among genes, and that these analyses need to be performed on properly normalized codon usage data to avoid biases masking this synonymous variation. The document also mentions that alternative normalized data, called \"relative adaptiveness\" in the literature, can be used to avoid these biases and identify more trends of variation among genes.\nSelf-organizing maps (SOMs) are a type of neural network that can be used for multivariate analysis and data visualization. They consist of a two-dimensional grid of neurons, with each neuron representing a point in the high-dimensional data space. The neurons are connected to each other in a way that creates a mapping from the high-dimensional data space to the lower-dimensional grid.\nGiven the mention of multivariate analyses and the need to visualize the data in a lower-dimensional space, it is likely that the tool being used is a SOM. However, without further information, it is impossible to say which specific tool or software is being used.",
    "llama-2-7b-chat-hf_fact_raw": "1. Self-organizing maps (SOMs) are used for analyzing synonymous codon usage.\n2. Multivariate analyses can identify trends of variation in synonymous codon usage among genes.\n3. Properly normalized codon usage data is necessary for multivariate analyses to avoid biases.\n4. The alternative normalized data, known as \"relative adaptiveness,\" can be used in multivariate analyses to identify trends among genes.\n5. Self-organizing maps consist of a two-dimensional grid of neurons that represent points in high-dimensional data space.",
    "llama-2-7b-chat-hf_fact": [
      "Self-organizing maps (SOMs) are used for analyzing synonymous codon usage.",
      "Multivariate analyses can identify trends of variation in synonymous codon usage among genes.",
      "Properly normalized codon usage data is necessary for multivariate analyses to avoid biases.",
      "The alternative normalized data, known as \"relative adaptiveness,\" can be used in multivariate analyses to identify trends among genes.",
      "Self-organizing maps consist of a two-dimensional grid of neurons that represent points in high-dimensional data space."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Self-organizing maps (SOMs) are a type of artificial neural network and can be used for various kinds of data analysis, including the analysis of synonymous codon usage, which is a pattern observed in the genetic makeup of organisms.\n2. TRUE: Multivariate analyses, such as principal component analysis or correspondence analysis, can indeed identify trends of variation in synonymous codon usage among different genes, helping to understand the genetic variation and evolutionary patterns.\n3. TRUE: Proper normalization of codon usage data is essential for multivariate analyses to ensure that results are not skewed by factors such as gene length or compositional biases.\n4. UNKNOWN: The term \"relative adaptiveness\" is not standard in the context of codon usage data normalization; typically, terms like \"Relative Synonymous Codon Usage\" (RSCU) are used. Without additional context, it is not possible to confirm the specific use of \"relative adaptiveness\" in this manner.\n5. TRUE: Self-organizing maps indeed consist of a two-dimensional grid of neurons (also called nodes or units) that organize themselves to represent high-dimensional input data through training, thus reducing dimensions and capturing essential features of the data space.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MINDY-1 appears to be a study investigating the Theory of Mind performance of female cocaine-dependent users (CDUs) and its associations with various aspects of cocaine use. The study used the Reading the Mind in the Eyes Test (RMET) and the Hinting task to assess Theory of Mind, and found impairments in negative mental states and second-order false-belief understanding in the CDU group compared to the healthy control group. Additionally, the study found that Theory of Mind impairment was associated with drug use characteristics such as craving and number of hospitalizations. Overall, the study suggests that high-demand Theory of Mind is impaired in CDU women, and that these deficits may be related to drug addiction severity and worse clinical and social outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a study investigating the Theory of Mind performance in female cocaine-dependent users (CDUs).\n2. The study utilized the Reading the Mind in the Eyes Test (RMET) and the Hinting task to assess Theory of Mind.\n3. The study found impairments in negative mental states and second-order false-belief understanding in the CDU group compared to a healthy control group.\n4. The study discovered an association between Theory of Mind impairment and drug use characteristics such as craving and number of hospitalizations.\n5. The conclusion of the study suggests that deficits in high-demand Theory of Mind may be related to the severity of drug addiction and associated with worse clinical and social outcomes.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a study investigating the Theory of Mind performance in female cocaine-dependent users (CDUs).",
      "The study utilized the Reading the Mind in the Eyes Test (RMET) and the Hinting task to assess Theory of Mind.",
      "The study found impairments in negative mental states and second-order false-belief understanding in the CDU group compared to a healthy control group.",
      "The study discovered an association between Theory of Mind impairment and drug use characteristics such as craving and number of hospitalizations.",
      "The conclusion of the study suggests that deficits in high-demand Theory of Mind may be related to the severity of drug addiction and associated with worse clinical and social outcomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout additional information, it is not possible to verify the specific findings and conclusions of the hypothetical MINDY-1 study. Therefore, the responses are based on the assumption that the statements accurately reflect the outcomes of the study as presented. If the study and its outcomes are entirely fictional or if the details provided are not accurate, the responses would differ.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is \"Sequence Information and Genomic Analysis\" (SIGA). This software package is an integrated tool that provides graphical and textual analysis of various genomic sequence features, including conserved genomic loci, and is available for free to the biomedical research community. The package can be accessed or downloaded from the URL provided in the information.",
    "llama-2-7b-chat-hf_fact_raw": "1. \"Sequence Information and Genomic Analysis\" (SIGA) is a software package available for the analysis of conserved genomic loci.\n2. SIGA provides graphical and textual analysis of various genomic sequence features.\n3. SIGA is available for free to the biomedical research community. \n4. SIGA can be accessed or downloaded from a specific URL.\n\n(Note: The verification of the last statement would require the actual URL, which is not provided in the response.)",
    "llama-2-7b-chat-hf_fact": [
      "\"Sequence Information and Genomic Analysis\" (SIGA) is a software package available for the analysis of conserved genomic loci.",
      "SIGA provides graphical and textual analysis of various genomic sequence features.",
      "SIGA is available for free to the biomedical research community.",
      "SIGA can be accessed or downloaded from a specific URL.",
      "ote: The verification of the last statement would require the actual URL, which is not provided in the response.)"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the provided statements, there is no verifiable context or source to confirm the specific details about \"Sequence Information and Genomic Analysis\" (SIGA), including its features, availability, or means of access. Therefore, without additional information, the truth value of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the three diseases associated with the PIEZO2 gene are:\n1. Autosomal-recessive nephrotic syndrome: Mutations in the NPHS2 gene, which encodes the protein podocin, can cause this rare genetic disorder.\n2. Proteinuria: The NPHS2 gene has been associated with proteinuria in several populations, which is a condition where there is an abnormal amount of protein in the urine.\n3. End-stage renal disease (ESRD): The NPHS2 gene has been linked to ESRD in African American (AA) populations, which is a condition where the kidneys fail to function properly and can lead to kidney failure.\nIt is important to note that these associations were identified through genetic analysis and may not necessarily be the only causes of these diseases. Further research is needed to confirm these findings and to better understand the relationship between the PIEZO2 gene and these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it can be concluded that ERAP1-ERAP2 dimerization promotes the proliferation of prostatic smooth muscle cells (PSMCs) by inducing the expression of insulin-like growth factor 1 (IGF1) via estrogen receptor alpha (ERalpha). The study found that estrogen treatment (17beta-estradiol, E2) increased the proliferation of PSMCs and the expression of the IGF1 gene in the normal control group, but not in the ERalpha-siRNA group. Additionally, exogenous IGF1 failed to induce the proliferation of ERalpha-reduced PSMCs, suggesting that the interaction between ERAP1-ERAP2 and IGF1 is necessary for the proliferation of PSMCs. Therefore, it can be concluded that ERAP1-ERAP2 dimerization promotes the proliferation of PSMCs by inducing the expression of IGF1 via ERalpha.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization induces the expression of insulin-like growth factor 1 (IGF1) via estrogen receptor alpha (ERalpha).\n2. Estrogen treatment with 17beta-estradiol (E2) increased the proliferation of prostatic smooth muscle cells (PSMCs) and the expression of the IGF1 gene in a normal control group.\n3. Estrogen treatment did not increase the proliferation of PSMCs or the expression of the IGF1 gene in the ERalpha-siRNA group.\n4. Exogenous IGF1 did not induce the proliferation of PSMCs with reduced ERalpha.\n5. The interaction between ERAP1-ERAP2 and IGF1 is necessary for the proliferation of PSMCs.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization induces the expression of insulin-like growth factor 1 (IGF1) via estrogen receptor alpha (ERalpha).",
      "Estrogen treatment with 17beta-estradiol (E2) increased the proliferation of prostatic smooth muscle cells (PSMCs) and the expression of the IGF1 gene in a normal control group.",
      "Estrogen treatment did not increase the proliferation of PSMCs or the expression of the IGF1 gene in the ERalpha-siRNA group.",
      "Exogenous IGF1 did not induce the proliferation of PSMCs with reduced ERalpha.",
      "The interaction between ERAP1-ERAP2 and IGF1 is necessary for the proliferation of PSMCs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements revolve around biological processes involving ERAP1-ERAP2 dimerization, estrogen receptor alpha (ERalpha), and insulin-like growth factor 1 (IGF1), particularly in the context of prostatic smooth muscle cells (PSMCs). Without specific references to scientific research data or studies that support these claims, it's not possible to definitively assess the truthfulness of these statements. As they pertain to specialized knowledge within the field of molecular biology, the accuracy of these claims would need to be verified against current scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, R-spondin 1 and noggin appear to play different roles in non-damaged gallbladders.\nNoggin is an extracellular antagonist of bone morphogenetic proteins (BMPs) and binds to BMPs, blocking their binding to BMP-specific receptors and negatively regulating BMP-induced osteoblastic differentiation. In this study, the up-regulation of noggin mRNA expression in response to recombinant human BMP-2 (rhBMP-2) in C2C12 cells was observed, suggesting that noggin may play a role in regulating BMP signaling in these cells. Silencing of noggin expression using small interfering RNA (siRNA) accelerated BMP-induced osteoblastic differentiation, suggesting that eliminating negative regulation of BMP effects by noggin may enhance new bone formation.\nIn contrast, R-spondin 1 is a secreted protein that has been shown to promote the differentiation of mesenchymal stem cells into osteoblasts and to enhance bone formation in vivo. However, there is no information in the provided document about the role of R-spondin 1 in non-damaged gallbladders.\nIn summary, the document suggests that noggin may play a negative regulatory role in BMP signaling in non-damaged gallbladders, while R-spondin 1 may have a positive role in promoting osteoblast differentiation and bone formation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Noggin is an extracellular antagonist of bone morphogenetic proteins (BMPs).\n2. Noggin binds to BMPs, preventing their binding to BMP-specific receptors.\n3. Up-regulation of noggin mRNA expression is observed in response to recombinant human BMP-2 in C2C12 cells.\n4. Silencing of noggin expression using small interfering RNA (siRNA) accelerates BMP-induced osteoblastic differentiation.\n5. R-spondin 1 promotes the differentiation of mesenchymal stem cells into osteoblasts and enhances bone formation in vivo.",
    "llama-2-7b-chat-hf_fact": [
      "Noggin is an extracellular antagonist of bone morphogenetic proteins (BMPs).",
      "Noggin binds to BMPs, preventing their binding to BMP-specific receptors.",
      "Up-regulation of noggin mRNA expression is observed in response to recombinant human BMP-2 in C2C12 cells.",
      "Silencing of noggin expression using small interfering RNA (siRNA) accelerates BMP-induced osteoblastic differentiation.",
      "R-spondin 1 promotes the differentiation of mesenchymal stem cells into osteoblasts and enhances bone formation in vivo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nExplanation:\n1. Noggin is indeed an extracellular antagonist of bone morphogenetic proteins, which makes this statement true.\n2. Functionally, noggin binds to BMPs to inhibit their interaction with their respective receptors, so this is also true.\n3. The third statement is difficult to evaluate without specific experimental data or a reference to a study that demonstrates this response. Therefore, the truthfulness of this statement is classified as UNKNOWN.\n4. Silencing noggin expression to accelerate BMP-induced osteoblastic differentiation is a logical conclusion based on noggin's role as an antagonist of BMPs. If noggin is removed or inhibited, BMPs can more effectively induce their normal functions, including osteoblastic differentiation.\n5. It is known from various studies that R-spondin 1 can promote the differentiation of mesenchymal stem cells into osteoblasts and enhance bone formation, hence this statement is true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it appears that NADPH oxidase 5 does require subunits for function. Specifically, the document states that membrane-bound NADPH oxidase subunits are present in the lipid raft compartment of neutrophils, and that cytosolic NADPH oxidase components are mainly absent from but are recruited to rafts upon Fcgamma receptor activation. This suggests that the subunits of NADPH oxidase 5 are localized to lipid rafts in the neutrophil membrane, and that these subunits play a role in the activation of the enzyme. Additionally, the document states that protein kinase C isotypes are also recruited to the rafts, which further suggests that the subunits of NADPH oxidase 5 are part of a larger complex that is involved in the enzyme's function. Therefore, based on the information provided in Document-0, it can be concluded that NADPH oxidase 5 does require subunits for function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 requires subunits for function.\n2. Membrane-bound NADPH oxidase subunits are present in the lipid raft compartment of neutrophils.\n3. Cytosolic NADPH oxidase components are mainly absent from lipid rafts but are recruited to them upon Fcgamma receptor activation.\n4. Protein kinase C isotypes are recruited to lipid rafts along with NADPH oxidase subunits.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 requires subunits for function.",
      "Membrane-bound NADPH oxidase subunits are present in the lipid raft compartment of neutrophils.",
      "Cytosolic NADPH oxidase components are mainly absent from lipid rafts but are recruited to them upon Fcgamma receptor activation.",
      "Protein kinase C isotypes are recruited to lipid rafts along with NADPH oxidase subunits."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nWhile these statements may generally be accurate in regards to the functions and characteristics of NADPH oxidase and its interaction with lipid rafts, without a specific reference to verify against, they are assumed to be true based on common scientific understanding of the topic. If there is additional context or specific research findings that contradict these statements, those details would be necessary to accurately confirm or correct each statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there appears to be a connection between furin and hepcidin in the context of iron metabolism.\nFurin is a protease enzyme that is involved in the processing and activation of various proteins, including hepcidin. Hepcidin, on the other hand, is a peptide hormone that plays a key role in regulating iron metabolism by modulating iron absorption and release from reticuloendothelial cells.\nThe document suggests that hepcidin expression is downregulated in response to anemia and hypoxia, which can lead to increased iron release from reticuloendothelial cells and increased iron absorption. This suggests that hepcidin may play a role in maintaining iron homeostasis under various pathophysiological conditions.\nFurin may be involved in the regulation of hepcidin expression, as the document mentions that furin is involved in the processing and activation of hepcidin. For example, furin may be responsible for activating hepcidin in response to anemia or hypoxia, leading to the downregulation of hepcidin expression and the release of iron from reticuloendothelial cells.\nOverall, the connection between furin and hepcidin in the context of iron metabolism appears to be related to the regulation of hepcidin expression and the maintenance of iron homeostasis under various pathophysiological conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the processing and activation of various proteins, including hepcidin.\n2. Hepcidin is a peptide hormone that regulates iron metabolism by modulating iron absorption and release from reticuloendothelial cells.\n3. Hepcidin expression is downregulated in response to anemia and hypoxia, leading to increased iron release from reticuloendothelial cells and increased iron absorption.\n4. Furin is involved in the regulation of hepcidin expression, potentially activating hepcidin in response to conditions like anemia or hypoxia.\n5. The role of hepcidin is to maintain iron homeostasis under various pathophysiological conditions.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the processing and activation of various proteins, including hepcidin.",
      "Hepcidin is a peptide hormone that regulates iron metabolism by modulating iron absorption and release from reticuloendothelial cells.",
      "Hepcidin expression is downregulated in response to anemia and hypoxia, leading to increased iron release from reticuloendothelial cells and increased iron absorption.",
      "Furin is involved in the regulation of hepcidin expression, potentially activating hepcidin in response to conditions like anemia or hypoxia.",
      "The role of hepcidin is to maintain iron homeostasis under various pathophysiological conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Furin processes precursor proteins into their mature form but does not directly regulate hepcidin expression. It is involved in the processing and activation of various proteins, but the regulation of hepcidin in response to anemia or hypoxia is not directly mediated by furin.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the largest metabolic gene cluster in yeast is the Candida albicans group.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of LIMT lncRNA (lncRNA-CLMAT3) in colorectal liver metastasis (CLM) is as follows:\n1. Differential expression: The study found that lncRNA-CLMAT3 is differentially expressed in CLM tissue compared to non-metastatic colorectal cancer (CRC) tissue.\n2. Clinical value: High expression of lncRNA-CLMAT3 was found to be associated with poor prognosis in patients with CRC, including shorter overall survival duration and increased risk of liver and lymph node metastasis.\n3. Regulation of cellular processes: The study suggests that lncRNA-CLMAT3 may play a role in the regulation of various cellular processes, including cell proliferation, migration, and invasion, which could contribute to the development and progression of CLM.\nIn summary, the role of LIMT lncRNA in CLM is to act as a prognostic marker and potentially play a role in the regulation of cellular processes involved in the development and progression of CLM.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA (lncRNA-CLMAT3) is differentially expressed in colorectal liver metastasis (CLM) tissue compared to non-metastatic colorectal cancer (CRC) tissue.\n2. High expression of lncRNA-CLMAT3 is associated with poor prognosis in patients with CRC.\n3. Patients with high expression of lncRNA-CLMAT3 have shorter overall survival duration.\n4. There is an increased risk of liver and lymph node metastasis in patients with high expression of lncRNA-CLMAT3.\n5. lncRNA-CLMAT3 may regulate cellular processes such as cell proliferation, migration, and invasion in CLM.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA (lncRNA-CLMAT3) is differentially expressed in colorectal liver metastasis (CLM) tissue compared to non-metastatic colorectal cancer (CRC) tissue.",
      "High expression of lncRNA-CLMAT3 is associated with poor prognosis in patients with CRC.",
      "Patients with high expression of lncRNA-CLMAT3 have shorter overall survival duration.",
      "There is an increased risk of liver and lymph node metastasis in patients with high expression of lncRNA-CLMAT3.",
      "lncRNA-CLMAT3 may regulate cellular processes such as cell proliferation, migration, and invasion in CLM."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nSince the statements are specific scientific claims presumably taken from a credible research study or review of literature, and there is no contradicting information given, they are accepted as true. If these statements were part of a passage in a peer-reviewed article, they would have been based on findings from experiments or observations detailed within the study.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R/Bioconductor package used for performing SNP enrichment analysis is likely to be the \"oligo\" package. The document mentions the \"oligo Bioconductor package\" and highlights its ability to handle probe-level data and interface with advanced statistical tools under a simplified framework, which suggests that it is specifically designed for microarray data analysis, including SNP enrichment analysis. Additionally, the document provides a demonstration of the package's functionality by preprocessing data originated from three different designs, which further supports the conclusion that the \"oligo\" package is the most suitable option for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"oligo\" package is an R/Bioconductor package.\n2. The \"oligo\" package is used for performing SNP enrichment analysis.\n3. The \"oligo\" package is capable of handling probe-level data.\n4. The \"oligo\" package can interface with advanced statistical tools.\n5. The document demonstrates the \"oligo\" package's functionality with data from three different designs.",
    "llama-2-7b-chat-hf_fact": [
      "The \"oligo\" package is an R/Bioconductor package.",
      "The \"oligo\" package is used for performing SNP enrichment analysis.",
      "The \"oligo\" package is capable of handling probe-level data.",
      "The \"oligo\" package can interface with advanced statistical tools.",
      "The document demonstrates the \"oligo\" package's functionality with data from three different designs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The \"oligo\" package is primarily used for preprocessing and analyzing oligonucleotide array data, typically from Affymetrix and NimbleGen platforms.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the key players in radial glial specification to ependymal cells are:\n1. Pax3 and Pax7: These transcription factors are expressed in the dorsal ventricular zone (VZ) of the embryonic spinal cord and are involved in the specification of radial glial cells.\n2. Pax6: This transcription factor is expressed in the ventral VZ and is important for the generation of neurons in this region.\n3. Nkx2.2: This transcription factor is expressed in the more ventral VZ and is involved in the specification of radial glial cells.\n4. Astrocyte-specific glutamate transporter: This protein is expressed in radial glial cells and is involved in the regulation of glutamate transport.\n5. Ephrin-B1: This protein is expressed in dorsal radial fibers and is involved in the regulation of cell-cell interactions and the specification of radial glial cells.\nThese transcription factors and proteins play important roles in determining the fate of radial glial cells and the generation of ependymal cells in the spinal cord. The diversity of radial glial cells along the dorsoventral axis is thought to be important for the generation of distinct types of astrocytes in the central nervous system.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pax3 and Pax7 are expressed in the dorsal ventricular zone of the embryonic spinal cord and are involved in radial glial cell specification.\n2. Pax6 is a transcription factor expressed in the ventral ventricular zone important for neuron generation in that region.\n3. Nkx2.2 is a transcription factor involved in the specification of radial glial cells and is expressed in the more ventral ventricular zone.\n4. The astrocyte-specific glutamate transporter is involved in the regulation of glutamate transport and is expressed in radial glial cells.\n5. Ephrin-B1 is involved in cell-cell interactions and radial glial cell specification and is expressed in dorsal radial fibers.",
    "llama-2-7b-chat-hf_fact": [
      "Pax3 and Pax7 are expressed in the dorsal ventricular zone of the embryonic spinal cord and are involved in radial glial cell specification.",
      "Pax6 is a transcription factor expressed in the ventral ventricular zone important for neuron generation in that region.",
      "Nkx2.2 is a transcription factor involved in the specification of radial glial cells and is expressed in the more ventral ventricular zone.",
      "The astrocyte-specific glutamate transporter is involved in the regulation of glutamate transport and is expressed in radial glial cells.",
      "Ephrin-B1 is involved in cell-cell interactions and radial glial cell specification and is expressed in dorsal radial fibers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Nkx2.2 is a transcription factor involved in the specification of oligodendrocyte precursor cells and is expressed in the ventral ventricular zone, not radial glial cells.\n4. UNKNOWN\n5. UNKNOWN\n\nFor statements 4 and 5, while the stated functions of the astrocyte-specific glutamate transporter and ephrin-B1 are generally consistent with scientific understanding, without more context regarding the specific expressions in radial glial cells or dorsal radial fibers, the accuracy of these particular expressions cannot be conclusively determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, triple negative gliomas are characterized by the presence of CD133-positive cells, which are thought to be cancer stem cells. These cells are found in higher numbers in recurrent glioblastomas compared to primary tumors, and their presence is associated with longer survival after tumor recurrence. The study also found that the CD133-positive cell compartment of recurrent glioblastoma is composed of both cancer stem cells and nontumor neural stem cells, with the latter cells representing a significant proportion of the CD133-positive cell population. Additionally, the study found that endothelial CD133-positive/CD34-positive precursors do not contribute to the CD133-positive cell population.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the presence of CD133-positive cells.\n2. CD133-positive cells are found in higher numbers in recurrent glioblastomas compared to primary tumors.\n3. The presence of CD133-positive cells is associated with longer survival after tumor recurrence.\n4. Recurrent glioblastoma's CD133-positive cell compartment is composed of both cancer stem cells and nontumor neural stem cells.\n5. Endothelial CD133-positive/CD34-positive precursors do not contribute to the CD133-positive cell population in triple negative gliomas.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the presence of CD133-positive cells.",
      "CD133-positive cells are found in higher numbers in recurrent glioblastomas compared to primary tumors.",
      "The presence of CD133-positive cells is associated with longer survival after tumor recurrence.",
      "Recurrent glioblastoma's CD133-positive cell compartment is composed of both cancer stem cells and nontumor neural stem cells.",
      "Endothelial CD133-positive/CD34-positive precursors do not contribute to the CD133-positive cell population in triple negative gliomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Triple negative gliomas are indeed characterized by the presence of a subset of cells that express the stem cell marker CD133; these are often referred to as cancer stem-like cells or tumor-initiating cells.\n2. TRUE: Several studies have reported that CD133-positive cells are found in higher quantities in recurrent glioblastomas as compared to primary tumors, suggesting that these cells may be involved in therapy resistance and tumor recurrence.\n3. FALSE [correction]: The presence of CD133-positive cells is generally associated with poorer prognosis and shorter survival after tumor recurrence, not longer survival.\n4. UNKNOWN: Without specific research data or a clear consensus, the precise composition of the CD133-positive cell compartment in recurrent glioblastoma, and whether it includes both cancer stem cells and nontumor neural stem cells, cannot be determined.\n5. UNKNOWN: The statement about the contribution of endothelial CD133-positive/CD34-positive precursors to the CD133-positive cell population in triple negative gliomas is very specific and without additional context or data provided, it is difficult to determine the truth value. This would require specific scientific evidence to confirm or deny.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, TOPAZ1 appears to be a novel Top1 inhibitor identified through a combination of structure- and ligand-based molecular modeling methods. The study aimed to identify potential anticancer agents by using a combination of in silico and in vitro screening methods. The researchers used a pharmacophore model based on derivatives of the alkaloid camptothecin, which are known potent antitumor agents and the main group of Top1 inhibitors. The model was used for in silico screening of the National Cancer Institute (NCI) compound database, leading to the identification of a set of structurally diverse molecules. The study validated the strategy by observing that amongst the identified molecules are several known Top1 inhibitors and agents cytotoxic against human tumor cell lines. The potential of the untested hits to inhibit Top1 activity was further evaluated by docking into the binding site of a Top1-DNA complex, resulting in a selection of 10 compounds for biological testing. Although the tested compounds display only low in vitro antitumor activity, the approach has been successful in identifying structurally novel Top1 inhibitors worthy of further investigation as potential anticancer agents. Therefore, TOPAZ1 is a novel Top1 inhibitor identified through a combination of computational and experimental methods, with potential as an anticancer agent.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a novel Top1 inhibitor.\n2. The identification of TOPAZ1 involved structure- and ligand-based molecular modeling methods.\n3. The pharmacophore model used for identifying TOPAZ1 was based on derivatives of the alkaloid camptothecin.\n4. The National Cancer Institute (NCI) compound database was screened to identify TOPAZ1.\n5. Amongst the molecules identified through the study, several known Top1 inhibitors and cytotoxic agents against human tumor cell lines were found.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a novel Top1 inhibitor.",
      "The identification of TOPAZ1 involved structure- and ligand-based molecular modeling methods.",
      "The pharmacophore model used for identifying TOPAZ1 was based on derivatives of the alkaloid camptothecin.",
      "The National Cancer Institute (NCI) compound database was screened to identify TOPAZ1.",
      "Amongst the molecules identified through the study, several known Top1 inhibitors and cytotoxic agents against human tumor cell lines were found."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or source material to verify the statements about TOPAZ1 and its identification process, it is not possible to accurately classify the statements as true or false. These statements are very specific to a particular scientific study or literature, and without access to the relevant information, it is not feasible to provide corrections for any false statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the gene that controls the expression of GATA-1 isoforms is GATA-2. The document states that both GATA-2 and GATA-3 are expressed in adipocyte precursors and control the preadipocyte-to-adipocyte transition, and that the interaction between GATA factors and C/EBP factors is critical for the ability of GATA to suppress adipocyte differentiation. The document also mentions that GATA-2 and GATA-3 form protein complexes with CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPbeta, which are members of a family of transcription factors that are integral to adipogenesis. Therefore, it can be inferred that the gene that controls the expression of GATA-1 isoforms is GATA-2.",
    "llama-2-7b-chat-hf_fact_raw": "1. The gene GATA-2 controls the expression of GATA-1 isoforms.\n2. GATA-2 and GATA-3 are expressed in adipocyte precursors.\n3. GATA-2 and GATA-3 participate in the preadipocyte-to-adipocyte transition.\n4. The interaction between GATA factors and C/EBP factors is essential for GATA's ability to suppress adipocyte differentiation.\n5. GATA-2 and GATA-3 form protein complexes with CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPbeta.",
    "llama-2-7b-chat-hf_fact": [
      "The gene GATA-2 controls the expression of GATA-1 isoforms.",
      "GATA-2 and GATA-3 are expressed in adipocyte precursors.",
      "GATA-2 and GATA-3 participate in the preadipocyte-to-adipocyte transition.",
      "The interaction between GATA factors and C/EBP factors is essential for GATA's ability to suppress adipocyte differentiation.",
      "GATA-2 and GATA-3 form protein complexes with CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPbeta."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nGenetic statements regarding the specific roles and interactions of genes like GATA-2 and GATA-3 require specialized knowledge in molecular biology and are not usually known without specific study or research into those particular genes. Thus, the truthfulness of these statements cannot be assessed without access to relevant scientific literature or expertise in the field. However, statement 4 is a known principle in molecular biology where interactions between GATA factors and C/EBP factors are indeed important for certain cellular differentiation processes, including adipocyte differentiation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a method used in high-throughput sequencing of small RNAs (sRNA-seq) to discover and annotate microRNAs (miRNAs), endogenous short interfering RNAs (siRNAs), and Piwi-associated RNAs (piRNAs). It is a popular method for sRNA-seq data analysis, and one of the key steps in this process is alignment to a reference genome. However, sRNA-seq libraries often have a high proportion of reads that align to multiple genomic locations, making it difficult to determine their true origins. Commonly used sRNA-seq alignment methods result in either very low precision (choosing an alignment at random) or sensitivity (ignoring multi-mapping reads).\nTo address this challenge, the authors of the article describe and test an sRNA-seq alignment strategy that uses local genomic context to guide decisions on proper placements of multi-mapped sRNA-seq reads. This strategy, called local-weighting, outperforms other alignment strategies using three different plant genomes in tests using simulated sRNA-seq data. Experimental analyses with real sRNA-seq data also indicate superior performance of local-weighting methods for both plant miRNAs and heterochromatic siRNAs.\nThe local-weighting methods developed in the study are implemented as part of the sRNA-seq analysis program ShortStack, which is freely available under a general public license. Improved genome alignments of sRNA-seq data should increase the quality of downstream analyses and genome annotation efforts. In summary, MIRA-seq is a method used in sRNA-seq data analysis that uses local genomic context to guide the alignment of multi-mapped reads, resulting in improved genome alignments and quality of downstream analyses.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is used for high-throughput sequencing of small RNAs to identify microRNAs, endogenous short interfering RNAs, and Piwi-associated RNAs.\n2. One of the key steps in MIRA-seq is alignment to a reference genome.\n3. sRNA-seq libraries commonly contain reads that align to multiple genomic locations.\n4. The authors of an article propose an sRNA-seq alignment strategy called local-weighting that uses local genomic context for placing multi-mapped reads.\n5. The local-weighting methods for MIRA-seq are part of the ShortStack analysis program, which is available under a general public license.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is used for high-throughput sequencing of small RNAs to identify microRNAs, endogenous short interfering RNAs, and Piwi-associated RNAs.",
      "One of the key steps in MIRA-seq is alignment to a reference genome.",
      "sRNA-seq libraries commonly contain reads that align to multiple genomic locations.",
      "The authors of an article propose an sRNA-seq alignment strategy called local-weighting that uses local genomic context for placing multi-mapped reads.",
      "The local-weighting methods for MIRA-seq are part of the ShortStack analysis program, which is available under a general public license."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the indication of ARCALYST is not explicitly mentioned. However, the document describes the development and validation of a high-performance liquid chromatography method for the simultaneous determination of seven drugs, including hydrochlorothiazide, in their combined formulations. The drugs included in the study are:\n1. Hydrochlorothiazide\n2. Atenolol\n3. Amlodipine besylate\n4. Moexipril hydrochloride\n5. Valsartan\n6. Candesartan cilexetil\n7. Aliskiren hemifumarate\nThe method was validated according to ICH guidelines, and the results showed that the method was linear, accurate, and precise over the concentration ranges of the drugs in their combined formulations. Therefore, the developed method can be used for the quality control and routine analysis of these drugs in their pharmaceutical dosage forms. However, without additional information, it is not possible to determine the specific indication or purpose of ARCALYST.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human acrocentric chromosomes involved in Robertsonian translocations are:\n* i(13q)\n* i(14q)\n* i(21q)\nThese are the only acrocentric chromosomes that are specifically mentioned in the document as being involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 (i(13q)) is involved in Robertsonian translocations.\n2. Chromosome 14 (i(14q)) is involved in Robertsonian translocations.\n3. Chromosome 21 (i(21q)) is involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 (i(13q)) is involved in Robertsonian translocations.",
      "Chromosome 14 (i(14q)) is involved in Robertsonian translocations.",
      "Chromosome 21 (i(21q)) is involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Isodicentric chromosome 13 (i(13q)) is not typically involved in Robertsonian translocations. Robertsonian translocations typically involve chromosome 13, but not specifically the isodicentric chromosome 13 (i(13q)).\n2. FALSE [correction]: Isodicentric chromosome 14 (i(14q)) is not typically involved in Robertsonian translocations. Robertsonian translocations often involve chromosome 14, but not specifically the isodicentric chromosome 14 (i(14q)).\n3. TRUE: Chromosome 21 is indeed involved in Robertsonian translocations, which can lead to Down syndrome when combined with an additional chromosome 21.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R package that could be used for the identification of pediatric brain tumors is likely to be \"MRStoolbox\" or \"MRtoolbox\". These packages are specifically designed for analyzing and processing magnetic resonance (MR) images, including proton MR spectroscopy (MRS) data, which is mentioned in the document as a noninvasive and sensitive approach for diagnosing and monitoring pediatric brain tumors.\n\"MRStoolbox\" is a popular R package for analyzing MRS data, and it provides a wide range of functions for processing and analyzing MRS data, including data preprocessing, peak detection, and metabolite identification. It also provides tools for visualizing MRS data and comparing it to other types of imaging data.\n\"MRtoolbox\" is another R package that is specifically designed for analyzing and processing MR images, including MRS data. It provides a wide range of functions for processing and analyzing MR data, including data preprocessing, image registration, and visualization. It also provides tools for analyzing and interpreting MR data, including measures of tumor volume and metabolic activity.\nBoth of these packages are widely used in the field of MR imaging and have been used in numerous studies on pediatric brain tumors. They are well-documented and have a large user community, which can be helpful for users who are new to MRS analysis.\nIt's worth noting that the specific R package used will depend on the specific research question and the type of MRS data being analyzed. However, based on the information provided in the document, \"MRStoolbox\" or \"MRtoolbox\" are likely to be the most relevant and useful packages for identifying pediatric brain tumors using MRS data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"MRStoolbox\" R package is designed for analyzing and processing magnetic resonance spectroscopy (MRS) data.\n2. \"MRStoolbox\" provides functions for data preprocessing, peak detection, and metabolite identification.\n3. \"MRtoolbox\" is an R package designed for analyzing and processing magnetic resonance (MR) images, including MRS data.\n4. \"MRtoolbox\" offers functions for processing and analyzing MR data, including data preprocessing, image registration, and visualization.\n5. Both \"MRStoolbox\" and \"MRtoolbox\" have been used in studies on pediatric brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The \"MRStoolbox\" R package is designed for analyzing and processing magnetic resonance spectroscopy (MRS) data.",
      "\"MRStoolbox\" provides functions for data preprocessing, peak detection, and metabolite identification.",
      "\"MRtoolbox\" is an R package designed for analyzing and processing magnetic resonance (MR) images, including MRS data.",
      "\"MRtoolbox\" offers functions for processing and analyzing MR data, including data preprocessing, image registration, and visualization.",
      "Both \"MRStoolbox\" and \"MRtoolbox\" have been used in studies on pediatric brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: \"MRStoolbox\" is the correct name of the R package designed for analyzing and processing magnetic resonance spectroscopy (MRS) data, not \"MRtoolbox\".\n4. UNKNOWN: Without specific information about a package named \"MRtoolbox,\" it is not possible to confirm the functions it offers. Additionally, the previous statement's correction implies \"MRtoolbox\" may be an incorrect or non-existent package in this context.\n5. UNKNOWN: Without additional context or references, it is not possible to confirm if both \"MRStoolbox\" and a package referred to as \"MRtoolbox\" have been used in studies on pediatric brain tumors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, NEMO is a zinc finger protein.\nThe document mentions the identification of a new SUMO-binding protein called ZNF261, which contains a stretch of tandem zinc fingers called myeloproliferative and mental retardation (MYM)-type zinc fingers. The MYM-type zinc fingers from ZNF261 and ZNF198 are shown to be necessary and sufficient for SUMO-binding, and individual MYM-type zinc fingers function as SUMO-interacting motifs (SIMs). The document also mentions that the MYM-type zinc fingers from ZNF261 contain zinc, but that zinc is not required for SUMO-binding.\nTherefore, based on the information provided in the document, NEMO is a zinc finger protein, specifically a member of the MYM-type zinc fingers family, which are capable of binding to SUMO proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is identified as a zinc finger protein.\n2. A protein called ZNF261 has been identified as a SUMO-binding protein containing MYM-type zinc fingers.\n3. MYM-type zinc fingers are necessary and sufficient for SUMO-binding.\n4. Individual MYM-type zinc fingers can function as SUMO-interacting motifs (SIMs).\n5. Zinc contained in the MYM-type zinc fingers from ZNF261 is not necessary for SUMO-binding.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is identified as a zinc finger protein.",
      "A protein called ZNF261 has been identified as a SUMO-binding protein containing MYM-type zinc fingers.",
      "MYM-type zinc fingers are necessary and sufficient for SUMO-binding.",
      "Individual MYM-type zinc fingers can function as SUMO-interacting motifs (SIMs).",
      "Zinc contained in the MYM-type zinc fingers from ZNF261 is not necessary for SUMO-binding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MYM-type zinc fingers are necessary but not sufficient for SUMO-binding; additional context or sequences may be required for SUMO interaction.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that TFIIS does affect nucleosome positioning in plants. The study found that plant nucleosome depletion occurs on specific 6-mer motifs, and this sequence-specific nucleosome depletion is predictive of expression levels. The study also found that the 6-mer motifs enriched in genes responsive to treatment with the defense hormone jasmonate do not show significant changes in nucleosome occupancy, suggesting that these sites are potentially preconditioned to enable rapid response without changing chromatin state significantly. These findings suggest that TFIIS plays a role in regulating nucleosome positioning and gene expression in plants.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS affects nucleosome positioning in plants.\n2. Plant nucleosome depletion occurs on specific 6-mer motifs according to the study.\n3. Sequence-specific nucleosome depletion is predictive of expression levels in plants.\n4. The 6-mer motifs enriched in genes responsive to jasmonate treatment do not show significant changes in nucleosome occupancy.\n5. Sites enriched with 6-mer motifs are potentially preconditioned to enable a rapid response without significant chromatin state changes.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS affects nucleosome positioning in plants.",
      "Plant nucleosome depletion occurs on specific 6-mer motifs according to the study.",
      "Sequence-specific nucleosome depletion is predictive of expression levels in plants.",
      "The 6-mer motifs enriched in genes responsive to jasmonate treatment do not show significant changes in nucleosome occupancy.",
      "Sites enriched with 6-mer motifs are potentially preconditioned to enable a rapid response without significant chromatin state changes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe specificity of these statements requires expert knowledge in plant molecular biology and a review of the relevant study or studies being referred to. Without the context of the source material, it is not possible to confirm or correct these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it can be concluded that the origins of replication close to yeast centromeres fire late.\nThe study used a direct selection method to isolate centromeres from a genomic library of the yeast Kluyveromyces lactis. The method is based on the lethality at high copy number of the ochre-suppressing tRNA gene SUP11. By using this method, the researchers were able to isolate five different chromosomal fragments that confer mitotic stability to plasmids containing a replication origin of K. lactis (KARS). These fragments were found to hybridize to different chromosomes of K. lactis, indicating that five of the six centromeres of K. lactis have been isolated.\nHowever, the study also found that the KARS plasmids containing these fragments have a copy number of approximately one. This suggests that the origins of replication close to the centromeres are not firing early, as they are only able to replicate once per cell cycle. Instead, they are firing late, allowing the plasmids to maintain a stable copy number.\nIn summary, the information provided in Document-0 suggests that the origins of replication close to yeast centromeres fire late, consistent with the idea that centromeres are regions of the genome that are involved in the regulation of DNA replication and segregation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication close to yeast centromeres fire late.\n2. The study used a direct selection method to isolate centromeres from a genomic library of the yeast Kluyveromyces lactis.\n3. The lethality at high copy number of the ochre-suppressing tRNA gene SUP11 was the basis of the method used to isolate centromeres.\n4. The researchers isolated five different chromosomal fragments that confer mitotic stability to plasmids containing a replication origin of K. lactis.\n5. The KARS plasmids that contain these fragments have a copy number of approximately one.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication close to yeast centromeres fire late.",
      "The study used a direct selection method to isolate centromeres from a genomic library of the yeast Kluyveromyces lactis.",
      "The lethality at high copy number of the ochre-suppressing tRNA gene SUP11 was the basis of the method used to isolate centromeres.",
      "The researchers isolated five different chromosomal fragments that confer mitotic stability to plasmids containing a replication origin of K. lactis.",
      "The KARS plasmids that contain these fragments have a copy number of approximately one."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: In yeast, origins of replication that are close to centromeres tend to fire late in the S phase of the cell cycle.\n2. UNKNOWN: Without specific information about the study or its methods, it is impossible to verify the use of a direct selection method to isolate centromeres from a genomic library of the yeast Kluyveromyces lactis.\n3. UNKNOWN: The statement about the lethality at high copy number of the ochre-suppressing tRNA gene SUP11 being the basis of the method to isolate centromeres requires specific knowledge of the study's methodology, which is not provided.\n4. UNKNOWN: Similarly, without detailed information on the research and its findings, we cannot verify the accurate isolation of five different chromosomal fragments that confer mitotic stability to plasmids.\n5. UNKNOWN: The statement regarding the copy number of KARS plasmids that contain these fragments being approximately one cannot be verified without access to the specific research data or results.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the properties of mammalian GA-sequences:\n1. Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system (CNS) of vertebrates.\n2. GABA has also been reported in multiple cell types outside the CNS, including pulmonary neuroepithelial bodies (NEBs) in monkey lungs.\n3. The NEB microenvironment in mouse lungs expresses both GABAA and GABAB (R1 and R2) receptors.\n4. The vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are exclusively expressed in NEB cells.\n5. The GAD67-green fluorescent protein (GFP) knock-in mice allow for the direct loading of fluorescent functional probes into pulmonary NEBs without the need for prior live visualization.\n6. The present study revealed the presence of a GABAergic signaling pathway in the NEB microenvironment of mouse lungs.\n7. The GAD67-GFP mouse model will certainly boost future functional imaging and gene expression analysis of the mouse NEB microenvironment.\nIn summary, the properties of mammalian GA-sequences in the context of this study are related to the expression of GABA and its receptors in the pulmonary NEB microenvironment, and the potential of the GAD67-GFP mouse model for functional imaging and gene expression analysis of this microenvironment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system (CNS) of vertebrates.\n2. GABA is present in multiple cell types outside the CNS, such as pulmonary neuroepithelial bodies (NEBs) in monkey lungs.\n3. In mouse lungs, the NEB microenvironment expresses both GABAA and GABAB (R1 and R2) receptors.\n4. Vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are exclusively expressed in NEB cells.\n5. The GAD67-green fluorescent protein (GFP) knock-in mice allow for the direct loading of fluorescent functional probes into pulmonary NEBs.",
    "llama-2-7b-chat-hf_fact": [
      "Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system (CNS) of vertebrates.",
      "GABA is present in multiple cell types outside the CNS, such as pulmonary neuroepithelial bodies (NEBs) in monkey lungs.",
      "In mouse lungs, the NEB microenvironment expresses both GABAA and GABAB (R1 and R2) receptors.",
      "Vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are exclusively expressed in NEB cells.",
      "The GAD67-green fluorescent protein (GFP) knock-in mice allow for the direct loading of fluorescent functional probes into pulmonary NEBs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Gamma-aminobutyric acid (GABA) is indeed the main inhibitory neurotransmitter in the central nervous system of vertebrates.\n2. TRUE: GABA is present in various cell types outside the CNS, including neuroepithelial bodies in the lungs of several species, such as monkeys.\n3. TRUE: In mouse lungs, neuroepithelial bodies (NEBs) have been shown to express GABA receptors, including GABAA and GABAB subtypes.\n4. FALSE [correction]: Vesicular GABA transporter (VGAT) and glutamic acid decarboxylase 65/67 (GAD65/67) are not exclusively expressed in NEB cells. These enzymes are also present in other GABAergic neurons and cells throughout the body.\n5. TRUE: The GAD67-GFP knock-in mice model is used to study GABAergic neurons, and the insertion of the green fluorescent protein (GFP) allows for the visualization of GAD67 expression, which can facilitate the study of specific cells such as pulmonary NEBs. However, whether it allows for direct loading of fluorescent functional probes into these cells is unknown without specific context; if meant literally, this could be a misinterpretation of the purpose of GFP tagging.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 27 genes that are associated with the same phenotype in both humans and mice. These genes are referred to as \"orthologs\" and are located in the mouse genome. The document does not provide the exact number of Groucho-related genes (GRG) in the mouse genome, but it does mention that 262 unique genes were evaluated in the study. However, it is important to note that the study only focused on genes that were associated with a phenotype in both humans and mice, and not all genes in the mouse genome may have been included in the study. Therefore, the actual number of GRG in the mouse genome could be higher than the 27 genes identified in the study.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 27 genes associated with the same phenotype in both humans and mice located in the mouse genome.\n2. These genes are referred to as \"orthologs\".\n3. The study evaluated 262 unique genes.\n4. The study focused only on genes that were associated with a phenotype in both humans and mice.",
    "llama-2-7b-chat-hf_fact": [
      "There are 27 genes associated with the same phenotype in both humans and mice located in the mouse genome.",
      "These genes are referred to as \"orthologs\".",
      "The study evaluated 262 unique genes.",
      "The study focused only on genes that were associated with a phenotype in both humans and mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the RNA polymerase II subunit that carries RNA cleavage activity is Pol II. According to the document, Pol II is able to recover from backtracks by RNA cleavage, whereas Pol I recovers from shallow backtracks by 1D diffusion and from intermediary depths by RNA cleavage. Additionally, the document states that Pol II is fully protected through association with the cleavage stimulatory factor TFIIS, which enables rapid recovery from any depth by RNA cleavage. Therefore, the answer to the user's question is Pol II.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (Pol II) subunit carries RNA cleavage activity.\n2. Pol II can recover from backtracks by RNA cleavage.\n3. Pol I recovers from shallow backtracks by 1D diffusion and from intermediary depths by RNA cleavage.\n4. Pol II is associated with the cleavage stimulatory factor TFIIS.\n5. The presence of TFIIS enables Pol II to rapidly recover from any depth by RNA cleavage.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (Pol II) subunit carries RNA cleavage activity.",
      "Pol II can recover from backtracks by RNA cleavage.",
      "Pol I recovers from shallow backtracks by 1D diffusion and from intermediary depths by RNA cleavage.",
      "Pol II is associated with the cleavage stimulatory factor TFIIS.",
      "The presence of TFIIS enables Pol II to rapidly recover from any depth by RNA cleavage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The RNA polymerase II (Pol II) subunit itself does not carry out RNA cleavage activity. RNA cleavage during transcriptional elongation is assisted by additional factors such as TFIIS.\n2. TRUE\n3. FALSE [correction]: It is Pol II, not Pol I, that can recover from intermediary-depth backtracks through RNA cleavage, often aided by the factor TFIIS. Pol I's mechanisms for recovering from backtracks might be different and are less characterized.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genetic basis of Ohdo syndrome is not definitively established. However, the document suggests that Ohdo syndrome may be associated with genetic abnormalities on chromosome 3p, specifically a deletion or mutation of genetic material on this chromosome. The document also proposes a classification system for Ohdo syndrome, which includes five groups:\n1. Del(3p) syndrome: This group includes patients with a deletion of genetic material on chromosome 3p.\n2. BMRS, Ohdo type: This group includes patients with a phenotype similar to the original patients described by Ohdo, including blepharophimosis and mental retardation.\n3. BMRS SBBYS type: This group includes patients with distinctive dysmorphic features and inconstant anomalies, including heart defect, optic atrophy, deafness, hypoplastic teeth, cleft palate, joint limitations, and hypothyroidism.\n4. BMRS, MKB (Maat-Kievit-Brunner) type: This group includes patients with a coarse, triangular face, which is likely sex-linked.\n5. BMRS V (Verloes) type: This group includes patients with severe microcephaly, hypsarrhythmia, adducted thumbs, cleft palate, and abnormal genitalia, which is likely autosomal recessive.\nIt is important to note that the genetic basis of Ohdo syndrome is still not fully understood, and further research is needed to determine the underlying genetic causes of this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome may be associated with genetic abnormalities on chromosome 3p.\n2. Del(3p) syndrome, a classification of Ohdo syndrome, includes patients with a deletion of genetic material on chromosome 3p.\n3. BMRS SBBYS type of Ohdo syndrome includes patients with heart defect, optic atrophy, deafness, hypoplastic teeth, cleft palate, joint limitations, and hypothyroidism.\n4. BMRS, MKB (Maat-Kievit-Brunner) type of Ohdo syndrome is characterized by patients with a coarse, triangular face and is possibly sex-linked.\n5. BMRS V (Verloes) type of Ohdo syndrome includes patients with severe microcephaly, hypsarrhythmia, adducted thumbs, cleft palate, and abnormal genitalia, and is likely autosomal recessive.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome may be associated with genetic abnormalities on chromosome 3p.",
      "Del(3p) syndrome, a classification of Ohdo syndrome, includes patients with a deletion of genetic material on chromosome 3p.",
      "BMRS SBBYS type of Ohdo syndrome includes patients with heart defect, optic atrophy, deafness, hypoplastic teeth, cleft palate, joint limitations, and hypothyroidism.",
      "BMRS, MKB (Maat-Kievit-Brunner) type of Ohdo syndrome is characterized by patients with a coarse, triangular face and is possibly sex-linked.",
      "BMRS V (Verloes) type of Ohdo syndrome includes patients with severe microcephaly, hypsarrhythmia, adducted thumbs, cleft palate, and abnormal genitalia, and is likely autosomal recessive."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\nStatements 1 and 2 are true. Ohdo syndrome can be associated with genetic abnormalities, including those on chromosome 3p, and del(3p) syndrome is a classification within Ohdo syndrome characterized by a deletion on chromosome 3p.\n\nStatement 3 is true. The features listed are associated with the Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome (BPES), which is also associated with intellectual disability (SBBYS variant) within the Ohdo syndrome spectrum.\n\nAs for statements 4 and 5, the precise characterization of Maat-Kievit-Brunner (MKB) type and Verloes (V) type of Ohdo syndrome with those specific features is not as commonly detailed in general knowledge, and it would require specific knowledge or access to current genetic research or medical literature to confirm. The genetic inheritance patterns of these subtypes are also specialized knowledge, which necessitate accurate medical sources to confirm. Therefore, the verification of statements 4 and 5 as true or false would require specific expertise or access to up-to-date genetic or medical resources.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R/Bioconductor package developed for the analysis of psychiatric disease genes is called \"mgsa\". The package provides a simple and flexible application programming interface for applying the model-based gene set analysis (MGSA) algorithm, which can substantially reduce the number of redundant categories returned by gene-category analysis. The package is available as part of Bioconductor 2.8 and is released under the Artistic license 2.0.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"mgsa\" is an R/Bioconductor package developed for the analysis of psychiatric disease genes.\n2. The \"mgsa\" package uses the model-based gene set analysis (MGSA) algorithm.\n3. The MGSA algorithm aims to reduce the number of redundant categories returned by gene-category analysis.\n4. The \"mgsa\" package is available as part of Bioconductor version 2.8.\n5. The \"mgsa\" package is released under the Artistic License 2.0.",
    "llama-2-7b-chat-hf_fact": [
      "The \"mgsa\" is an R/Bioconductor package developed for the analysis of psychiatric disease genes.",
      "The \"mgsa\" package uses the model-based gene set analysis (MGSA) algorithm.",
      "The MGSA algorithm aims to reduce the number of redundant categories returned by gene-category analysis.",
      "The \"mgsa\" package is available as part of Bioconductor version 2.8.",
      "The \"mgsa\" package is released under the Artistic License 2.0."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The \"mgsa\" package availability cannot be determined for Bioconductor version 2.8 without knowing the package's release date or having specific archive information. Bioconductor version 2.8 was released around October 2010; without the exact release timing of \"mgsa\", it can't be confirmed if it was included in that version.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign in intracerebral hemorrhage refers to a specific type of hemorrhage that occurs within the brain tissue. It is characterized by a swirling or spiral pattern of blood within the hemorrhage, which can be seen on imaging studies such as CT or MRI.\nIn the context of vestibular schwannomas, which are non-cancerous tumors that develop in the inner ear, swirl sign is a rare occurrence. According to the information provided, intratumoral hemorrhage in vestibular schwannomas is rare, and symptoms often have an acute onset and include headache, nausea, vomiting, vertigo, and depressed consciousness.\nRepeated hemorrhage within a vestibular schwannoma is even less common, and there have only been a few reported cases in the medical literature. In the case described in the information provided, the patient experienced acute neurological deterioration due to repeated intratumoral hemorrhage inside a vestibular schwannoma, which was confirmed through CT and MRI imaging.\nIt is important to note that the swirl sign is not a diagnostic criterion for intracerebral hemorrhage, and its presence does not necessarily indicate the location or cause of the hemorrhage. A thorough medical evaluation and imaging studies are necessary to determine the underlying cause of hemorrhage and to develop an appropriate treatment plan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign in intracerebral hemorrhage is characterized by a swirling or spiral pattern of blood seen on imaging studies.\n2. Swirl sign can be identified using CT or MRI imaging techniques.\n3. Vestibular schwannomas are non-cancerous tumors that develop in the inner ear.\n4. Symptoms of acute onset like headache, nausea, vomiting, vertigo, and depressed consciousness can be associated with intratumoral hemorrhage in vestibular schwannomas.\n5. Intratumoral hemorrhage in vestibular schwannomas is a rare occurrence and repeated hemorrhage is even less common.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign in intracerebral hemorrhage is characterized by a swirling or spiral pattern of blood seen on imaging studies.",
      "Swirl sign can be identified using CT or MRI imaging techniques.",
      "Vestibular schwannomas are non-cancerous tumors that develop in the inner ear.",
      "Symptoms of acute onset like headache, nausea, vomiting, vertigo, and depressed consciousness can be associated with intratumoral hemorrhage in vestibular schwannomas.",
      "Intratumoral hemorrhage in vestibular schwannomas is a rare occurrence and repeated hemorrhage is even less common."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The swirl sign in intracerebral hemorrhage is indeed characterized by a heterogenous appearance with areas of different densities, often indicating a mix of blood at different stages of clotting, which can create a swirling or spiral pattern on imaging studies.\n2. TRUE: Swirl sign can be identified using both CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) techniques.\n3. TRUE: Vestibular schwannomas, also known as acoustic neuromas, are indeed non-cancerous, slow-growing tumors that develop on the main nerve leading from the inner ear to the brain (the vestibulocochlear nerve).\n4. TRUE: Symptoms such as acute headache, nausea, vomiting, vertigo, and depressed consciousness can be associated with intratumoral hemorrhage, including that in vestibular schwannomas, as the bleeding can increase intracranial pressure or affect the function of the inner ear and surrounding structures.\n5. TRUE: Intratumoral hemorrhage in vestibular schwannomas is considered a rare event, and repeated hemorrhage within these tumors is even rarer. This is reflected in the limited number of cases reported in the medical literature.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Arabidopsis ROF1 expression is induced by heat stress. The study shows that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain and localizes in the cytoplasm under normal conditions. However, exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent on the presence of the transcription factor HsfA2. The study also shows that ROF1 knockout plants exhibit collapse when exposed to high temperatures, while transgenic ROF1 over-expressors show better survival in response to high temperatures. Additionally, the study found that the level of expression of small HSPs regulated by HsfA2 is dramatically reduced in rof1 knockout mutants after exposure to high temperatures, which correlates well with the mutant phenotype. Based on these findings, it can be concluded that ROF1 plays a role in prolonging thermotolerance by sustaining the levels of small HSPs that are essential for survival at high temperatures.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. ROF1 binds heat shock proteins HSP90.1 through its tetratricopeptide repeat domain.\n3. The study observed nuclear localization of the ROF1-HSP90.1 complex upon exposure to heat stress.\n4. Plants with ROF1 knocked out exhibit collapse when exposed to high temperatures.\n5. Transgenic plants over-expressing ROF1 show improved survival when exposed to high temperatures.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "ROF1 binds heat shock proteins HSP90.1 through its tetratricopeptide repeat domain.",
      "The study observed nuclear localization of the ROF1-HSP90.1 complex upon exposure to heat stress.",
      "Plants with ROF1 knocked out exhibit collapse when exposed to high temperatures.",
      "Transgenic plants over-expressing ROF1 show improved survival when exposed to high temperatures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Arabidopsis ROF1 (At5g28540), also known as AtFKBP62, is a gene known to be induced by heat stress, suggesting this statement is correct. ROF1 is a co-chaperone involved in the response to heat stress.\n\n2. TRUE: ROF1 contains a tetratricopeptide repeat (TPR) domain known to be involved in the interaction with heat shock proteins such as HSP90, suggesting the statement is accurate.\n\n3. UNKNOWN: While it is known that ROF1 interacts with HSP90, the specific subcellular localization of the ROF1-HSP90.1 complex upon heat stress might vary and requires specific experimental evidence for confirmation. Since the statement provides a specific observation without citing this evidence, the truth cannot be determined without additional context.\n\n4. FALSE [correction]: Plants with ROF1 knocked out may exhibit increased sensitivity to heat stress, but the exact terminology used here, \"collapse,\" is not a standard scientific description of plant responses and is too vague without context. It is more accurate to say knockout plants may display impaired growth or survival under heat stress conditions.\n\n5. TRUE: Over-expression of certain genes like ROF1 that play a role in stress responses is a common genetic strategy to enhance plant survival under stressful conditions, such as high temperatures. Therefore, this statement is plausible and aligns with general scientific understanding of stress response mechanisms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the most common cause of hereditary renal amyloidosis is Ig amyloidosis, which accounts for approximately 85.9% of all renal amyloidosis cases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ig amyloidosis is the most common cause of hereditary renal amyloidosis.\n2. Ig amyloidosis accounts for approximately 85.9% of all renal amyloidosis cases.",
    "llama-2-7b-chat-hf_fact": [
      "Ig amyloidosis is the most common cause of hereditary renal amyloidosis.",
      "Ig amyloidosis accounts for approximately 85.9% of all renal amyloidosis cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common cause of hereditary renal amyloidosis is not Ig amyloidosis, but rather mutations in genes such as those encoding transthyretin (TTR), fibrinogen A alpha chain (AFib), or apolipoprotein A-I, which lead to hereditary forms of the disease.\n\n2. FALSE [correction]: The percentage 85.9% is very specific and without a source, it is hard to verify. Historically, Immunoglobulin light-chain (AL) amyloidosis is the most common type of systemic amyloidosis affecting the kidneys, but it is not a form of hereditary amyloidosis, and quoting such a precise percentage requires a reliable source.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the answer to the user's question is yes, the proteome of mice hippocampus has been analyzed as part of the Brain Proteome Project (BPP) initiative. The pilot phase of the BPP involved the study of the proteomes of three mouse samples from various developmental stages, in addition to human samples derived from biopsy and autopsy. The combined and centrally reprocessed data from these studies are now available for comparison with other proteomics studies, including a comparison of protein identifications and project organization between the HUPO BPP pilot and other studies such as the HUPO Plasma Proteome Project (PPP) pilot, a proteome of human blood platelets, and a recently published comprehensive mouse proteome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of mice hippocampus has been analyzed as part of the Brain Proteome Project (BPP).\n2. The Brain Proteome Project's pilot phase included the study of three mouse samples from various developmental stages.\n3. The Brain Proteome Project also involved human samples derived from biopsy and autopsy.\n4. Data from the Brain Proteome Project studies have been centrally reprocessed and are available for comparison with other proteomics studies.\n5. The Brain Proteome Project data have been compared with other projects, like the HUPO Plasma Proteome Project (PPP) pilot, a proteome of human blood platelets, and a comprehensive mouse proteome study.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of mice hippocampus has been analyzed as part of the Brain Proteome Project (BPP).",
      "The Brain Proteome Project's pilot phase included the study of three mouse samples from various developmental stages.",
      "The Brain Proteome Project also involved human samples derived from biopsy and autopsy.",
      "Data from the Brain Proteome Project studies have been centrally reprocessed and are available for comparison with other proteomics studies.",
      "The Brain Proteome Project data have been compared with other projects, like the HUPO Plasma Proteome Project (PPP) pilot, a proteome of human blood platelets, and a comprehensive mouse proteome study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE – The Brain Proteome Project (BPP) has included analysis of the proteome of various parts of the mouse brain, including the hippocampus.\n2. UNKNOWN – Without specific details from the BPP documentation, the exact number and developmental stages of the mouse samples used in the pilot phase cannot be confirmed.\n3. TRUE – The Brain Proteome Project has indeed involved human samples, including those derived from biopsy and autopsy, to better understand the human brain proteome and its alterations in neurodegenerative diseases.\n4. TRUE – Data from the Brain Proteome Project and other related projects are typically made available for reprocessing and comparison to aid in further research and enhance the depth of analysis across studies in the field.\n5. UNKNOWN – Though it is likely that data from the BPP have been compared with data from other proteomics projects, we would need specific references to confirm whether these exact comparisons with the named projects (HUPO Plasma Proteome Project - PPP, a proteome of human blood platelets, and a comprehensive mouse proteome study) have been made.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, mouse chromosomes are not acrocentric. The document states that mouse chromosomes are characterized by metacentric chromosomes formed by Robertsonian fusions and whole-arm reciprocal translocations. Acrocentric chromosomes, on the other hand, are characterized by a centromere that is located near the center of the chromosome. Therefore, mouse chromosomes do not meet the definition of acrocentric.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are characterized by metacentric chromosomes.\n2. Mouse chromosomes are formed by Robertsonian fusions and whole-arm reciprocal translocations.\n3. Acrocentric chromosomes have centromeres that are located near one end of the chromosome.\n4. Mouse chromosomes do not meet the definition of acrocentric.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are characterized by metacentric chromosomes.",
      "Mouse chromosomes are formed by Robertsonian fusions and whole-arm reciprocal translocations.",
      "Acrocentric chromosomes have centromeres that are located near one end of the chromosome.",
      "Mouse chromosomes do not meet the definition of acrocentric."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are characterized by acrocentric chromosomes.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mouse chromosomes do meet the definition of acrocentric, as their centromeres are located near one end of the chromosome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is CRS-207. The document mentions a phase II trial by Le et al. (Abstract #177) that found the addition of CRS-207 to GVAX improves survival in patients being treated with GVAX.",
    "llama-2-7b-chat-hf_fact_raw": "1. The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is named CRS-207.\n2. A phase II trial involving CRS-207 indicated that adding CRS-207 to GVAX improves survival in patients treated with GVAX.\n3. The trial referenced is by Le et al. and is associated with an Abstract #177.",
    "llama-2-7b-chat-hf_fact": [
      "The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is named CRS-207.",
      "A phase II trial involving CRS-207 indicated that adding CRS-207 to GVAX improves survival in patients treated with GVAX.",
      "The trial referenced is by Le et al. and is associated with an Abstract #177."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CRS-207 is not an siRNA-based drug; it is a vaccine that consists of attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin.\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the HPG pore appears to be a toolkit for exploring and analyzing nanopore sequencing data. The toolkit is designed to be scalable and can run on both individual computers and in the Hadoop distributed computing framework, allowing for easy management of large amounts of data expected from extensive use of nanopore technologies in the future. The HPG pore is available on GitHub at <http://github.com/opencb/hpg-pore>.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data.\n2. The toolkit is scalable.\n3. The HPG pore can run on individual computers.\n4. The HPG pore can also run in the Hadoop distributed computing framework.\n5. The HPG pore is available on GitHub at the provided URL.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data.",
      "The toolkit is scalable.",
      "The HPG pore can run on individual computers.",
      "The HPG pore can also run in the Hadoop distributed computing framework.",
      "The HPG pore is available on GitHub at the provided URL."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is an research project focused on the analysis of the genomes of 959 species of free-living marine nematodes. The project aims to develop and apply molecular identification tools, specifically targeting the COI gene, to solve the problem of identifying these difficult-to-diagnose nematodes. The project involves the amplification and sequencing of the COI gene in 41 nematode species from a wide phylogenetic range, with the goal of identifying a reliable DNA barcoding gap that can be used to distinguish between different species. The study found that the I3-M11 partition of the COI gene outperformed the universal M1-M6 primers in terms of amplification success and produced a higher number of bidirectional COI sequences. The project's findings suggest that the I3-M11 partition can reliably identify a wide range of marine nematodes, but that a strict scrutiny of the obtained sequences is necessary to avoid confusion caused by contamination, nuclear pseudogenes, and endosymbionts.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative is focused on the analysis of the genomes of 959 species of free-living marine nematodes.\n2. The initiative aims to develop molecular identification tools targeting the COI gene.\n3. The project involves the amplification and sequencing of the COI gene in 41 nematode species.\n4. The study identified that the I3-M11 partition of the COI gene outperformed the universal M1-M6 primers in amplification success and in producing bidirectional COI sequences.\n5. The findings indicate that the I3-M11 partition can be used to reliably identify a wide range of marine nematodes.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative is focused on the analysis of the genomes of 959 species of free-living marine nematodes.",
      "The initiative aims to develop molecular identification tools targeting the COI gene.",
      "The project involves the amplification and sequencing of the COI gene in 41 nematode species.",
      "The study identified that the I3-M11 partition of the COI gene outperformed the universal M1-M6 primers in amplification success and in producing bidirectional COI sequences.",
      "The findings indicate that the I3-M11 partition can be used to reliably identify a wide range of marine nematodes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative is focused on the analysis of the genomes of 959 species of nematodes, but not all of them are necessarily free-living marine species. The initiative includes diverse types of nematodes.\n2. FALSE [correction]: While the initiative may involve the development of molecular identification tools, it is not specified that targeting the COI gene is the aim of the entire initiative. The COI gene is commonly used in molecular identification, but the statement overgeneralizes the aim of the initiative.\n3. UNKNOWN: Without specific information regarding the number of nematode species the project is targeting for COI gene amplification and sequencing, it's not possible to confirm the accuracy of the number 41.\n4. UNKNOWN: This statement requires specific knowledge from the research findings of the 959 Nematode Genomes initiative, which are not provided.\n5. UNKNOWN: Similar to statement 4, without specific information from the research findings, it's not possible to confirm the reliability of the I3-M11 partition for identifying marine nematodes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that has been developed for analyzing Non-invasive prenatal testing (NIPT) data is likely to be \"niphtools\". This package provides a set of tools for the analysis of NIPT data, including quality control, sample classification, and genetic risk assessment.\nThe package was developed by the University of California, San Diego, and is widely used in the field of prenatal genetics. It has been specifically designed to handle the unique challenges of NIPT data, including the high dimensionality of the data and the need to account for maternal cell contamination.\nThe \"niphtools\" package includes a range of functions for data preprocessing, including filtering, cleaning, and normalization, as well as functions for genetic risk assessment, such as calculating the probability of a chromosomal abnormality based on the NIPT results. It also provides tools for visualizing the results of NIPT tests, including plots of the probability of a chromosomal abnormality over time.\nIn summary, based on the information provided, the R package that has been developed for analyzing NIPT data is likely to be \"niphtools\".",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"niphtools\" has been developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. \"niphtools\" provides tools for quality control, sample classification, and genetic risk assessment of NIPT data.\n3. The package was developed by the University of California, San Diego.\n4. The package is used in the field of prenatal genetics.\n5. \"niphtools\" includes functions for data preprocessing, such as filtering, cleaning, and normalization.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"niphtools\" has been developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "\"niphtools\" provides tools for quality control, sample classification, and genetic risk assessment of NIPT data.",
      "The package was developed by the University of California, San Diego.",
      "The package is used in the field of prenatal genetics.",
      "\"niphtools\" includes functions for data preprocessing, such as filtering, cleaning, and normalization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder that is characterized by a combination of physical and developmental abnormalities. The syndrome is named after Dr. John Achenbach, who first described it in 1978.\nThe main features of Achenbach's syndrome include:\n1. Coarse facial appearance: Individuals with Achenbach's syndrome may have a large head, a prominent forehead, and a wide nasal bridge.\n2. Hepatosplenomegaly: Enlargement of the liver and spleen is a common finding in Achenbach's syndrome.\n3. Hirsutism: Excessive hair growth, particularly on the face and body, is a characteristic feature of the syndrome.\n4. Gingival fibromatosis: Individuals with Achenbach's syndrome may develop abnormal growth of gum tissue, leading to dental problems.\n5. Small joint hyperextensibility: Joints, such as the hands and feet, may be overly flexible, leading to joint pain and mobility issues.\n6. Hypoplasia of the finger- and toenails: The nails of individuals with Achenbach's syndrome may be thin and brittle, and may break easily.\n7. Intellectual deficit: While some individuals with Achenbach's syndrome may have intellectual disability, the degree of impairment can vary.\n8. Cardiomyopathy and aortic root and arch dilatation: In some cases, Achenbach's syndrome can lead to heart problems, including cardiomyopathy and dilatation of the aortic root and arch.\nAchenbach's syndrome is caused by mutations in the PTK2B gene, which is involved in cell signaling pathways. The syndrome is usually diagnosed in infancy or early childhood, and the symptoms can vary in severity and progression over time. Treatment options for Achenbach's syndrome may include medications to manage symptoms, such as joint pain and dental problems, as well as monitoring and management of any associated heart problems.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is a rare genetic disorder first described by Dr. John Achenbach in 1978.\n2. Achenbach's syndrome is characterized by coarse facial appearance, hepatosplenomegaly, hirsutism, gingival fibromatosis, small joint hyperextensibility, hypoplasia of the finger- and toenails, and intellectual deficit.\n3. Individuals with Achenbach's syndrome may have a large head, a prominent forehead, and a wide nasal bridge.\n4. The syndrome can lead to heart problems, including cardiomyopathy and dilatation of the aortic root and arch.\n5. Achenbach's syndrome is caused by mutations in the PTK2B gene.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is a rare genetic disorder first described by Dr. John Achenbach in 1978.",
      "Achenbach's syndrome is characterized by coarse facial appearance, hepatosplenomegaly, hirsutism, gingival fibromatosis, small joint hyperextensibility, hypoplasia of the finger- and toenails, and intellectual deficit.",
      "Individuals with Achenbach's syndrome may have a large head, a prominent forehead, and a wide nasal bridge.",
      "The syndrome can lead to heart problems, including cardiomyopathy and dilatation of the aortic root and arch.",
      "Achenbach's syndrome is caused by mutations in the PTK2B gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a genetic disorder. It was first described in 1958 and is actually a benign condition characterized by sudden bruising of the hand or fingers without any preceding injury or trauma.\n2. FALSE [correction]: The described characteristics do not pertain to Achenbach's syndrome. These features seem to describe a different condition, which could potentially be a genetic syndrome, but they are not associated with Achenbach's syndrome.\n3. UNKNOWN: The statement is likely referring to another condition, as Achenbach's syndrome generally involves paroxysmal hand hematoma and does not typically include the described facial features.\n4. FALSE [correction]: Achenbach's syndrome is not associated with heart problems like cardiomyopathy and dilatation of the aortic root and arch. The symptoms of Achenbach's syndrome are typically restricted to the hands and do not involve the heart.\n5. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the PTK2B gene. It is not a genetic disorder; the cause of Achenbach's syndrome is not well understood but is thought to possibly be due to microvascular injury in the hands.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm used for detection of long repeat expansions is RepMaestro. RepMaestro is a software that adapts existing in-memory-enhanced suffix array (SA) algorithms to enable them to scale efficiently to large genomic sequences that are disk-resident. The document mentions that RepMaestro has been used to detect supermaximal repeats, maximal unique matches (MuMs), and pairwise branching tandem repeats in large genome sequences, and that it has been shown to scale efficiently to large genome sequences that other repeat detection algorithms could not process due to memory constraints.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepMaestro is an algorithm used for detection of long repeat expansions.\n2. RepMaestro adapts existing in-memory-enhanced suffix array (SA) algorithms for scalability.\n3. The algorithm is designed to scale efficiently to large genomic sequences that are disk-resident.\n4. RepMaestro can detect supermaximal repeats, maximal unique matches (MuMs), and pairwise branching tandem repeats in large genome sequences.\n5. RepMaestro can process large genome sequences that other repeat detection algorithms cannot due to memory constraints.",
    "llama-2-7b-chat-hf_fact": [
      "RepMaestro is an algorithm used for detection of long repeat expansions.",
      "RepMaestro adapts existing in-memory-enhanced suffix array (SA) algorithms for scalability.",
      "The algorithm is designed to scale efficiently to large genomic sequences that are disk-resident.",
      "RepMaestro can detect supermaximal repeats, maximal unique matches (MuMs), and pairwise branching tandem repeats in large genome sequences.",
      "RepMaestro can process large genome sequences that other repeat detection algorithms cannot due to memory constraints."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nNote: The fourth statement regarding the specific types of repeats RepMaestro can detect is very specific and without additional context from the actual documentation or paper describing the algorithm, it would be difficult to verify. Hence, the response is \"UNKNOWN\".",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, neuroligin-3 promotes the growth of several types of high-grade gliomas (HGG), including:\n1. Adult and pediatric glioblastoma (GBM)\n2. Anaplastic oligodendroglioma\n3. Diffuse intrinsic pontine glioma (DIPG)\nThe document suggests that neuroligin-3 promotes glioma proliferation through the PI3K-mTOR pathway, and that its secretion from neurons and oligodendrocyte precursor cells is mediated by the ADAM10 sheddase. The study also shows that patient-derived orthotopic xenografts of paediatric GBM, DIPG, and adult GBM fail to grow in Nlgn3 knockout mice, and that inhibitors of ADAM10 can robustly block HGG xenograft growth.\nTherefore, based on the information provided in the document, neuroligin-3 appears to promote the growth of several types of HGG, including adult and pediatric GBM, anaplastic oligodendroglioma, and DIPG.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth of several types of high-grade gliomas.\n2. Neuroligin-3 is implicated in the growth of adult and pediatric glioblastoma.\n3. Neuroligin-3 is associated with the growth of anaplastic oligodendroglioma.\n4. Neuroligin-3 contributes to the proliferation of diffuse intrinsic pontine glioma (DIPG).\n5. Inhibitors of ADAM10 can block the growth of high-grade glioma xenografts.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth of several types of high-grade gliomas.",
      "Neuroligin-3 is implicated in the growth of adult and pediatric glioblastoma.",
      "Neuroligin-3 is associated with the growth of anaplastic oligodendroglioma.",
      "Neuroligin-3 contributes to the proliferation of diffuse intrinsic pontine glioma (DIPG).",
      "Inhibitors of ADAM10 can block the growth of high-grade glioma xenografts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the approximate size of gas vesicles in streptomycetes is not explicitly stated. However, the document does mention that gas vesicles are \"fluffy mycelial pellets with long hyphae\" and that their size can be affected by the overexpression of the gvp3234 gene.\nTherefore, based on the available information, it can be estimated that the size of gas vesicles in streptomycetes is likely to be in the range of a few hundred nanometers to a few micrometers in diameter. However, this is only an estimate, and the actual size of gas vesicles in streptomycetes may vary depending on various factors such as the specific species of streptomycete, the expression level of the gvp genes, and the growth conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles can be described as \"fluffy mycelial pellets with long hyphae.\"\n2. The size of gas vesicles in streptomycetes may be affected by the overexpression of the gvp3234 gene.\n3. The estimated size range of gas vesicles in streptomycetes is a few hundred nanometers to a few micrometers in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles can be described as \"fluffy mycelial pellets with long hyphae.\"",
      "The size of gas vesicles in streptomycetes may be affected by the overexpression of the gvp3234 gene.",
      "The estimated size range of gas vesicles in streptomycetes is a few hundred nanometers to a few micrometers in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles are not described as \"fluffy mycelial pellets with long hyphae.\" They are protein-shelled structures that provide buoyancy to aquatic microorganisms.\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the BET proteins that have been identified as novel therapeutic targets for cancer and inflammation:\n1. Brd4 (Bromodomain-Containing Protein 4)\n2. Brd2 (Bromodomain-Containing Protein 2)\n3. Brd3 (Bromodomain-Containing Protein 3)\n4. Brdt (Bromodomain-Containing Protein T)\nThese proteins are part of the BET (Bromodomain and Extra-Terminal) protein family, which are known to play a crucial role in regulating gene expression by reading the chromatin structure. The document highlights the potential of targeting these proteins for cancer and inflammation, but also notes that the consequences of sustained BET protein inhibition in normal tissues are poorly characterized.",
    "llama-2-7b-chat-hf_fact_raw": "1. Brd4 is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.\n2. Brd2 is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.\n3. Brd3 is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.\n4. Brdt is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.\n5. BET proteins are known to regulate gene expression by reading the chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "Brd4 is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.",
      "Brd2 is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.",
      "Brd3 is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.",
      "Brdt is a bromodomain-containing protein identified as a novel therapeutic target for cancer and inflammation.",
      "BET proteins are known to regulate gene expression by reading the chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBrd4, Brd2, Brd3, and Brdt are all members of the BET (bromodomain and extra-terminal domain) protein family. BET proteins, including these, have been identified as potential therapeutic targets for various diseases, including cancer and inflammation, because of their role in regulating gene expression through chromatin interactions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm developed for prediction of protein subcellular localization using deep learning is the Nearest Neighbor Algorithm (NNA).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MULTOVL appears to be a term used to describe the combination of two compounds: betulinic acid and benzalkonium cation. The document explains that betulinic acid is a natural antiviral agent that has been investigated for its potential to inhibit the replication of retroviruses, including Murine leukemia virus (MuLV). The authors of the document synthesized ionic derivatives of betulinic acid and tested their activity against MuLV, with the goal of improving the water solubility of the compounds and enhancing their antiviral potency.\nOne of the derivatives tested, containing the benzalkonium cation, was found to inhibit the production of virus in media and decrease the amount of viral structural protein Gag in cells. However, the same derivative also inhibited the growth of mouse fibroblast cells, suggesting that it may be limiting virus production through the inhibition of cell metabolism rather than directly targeting the virus.\nThe document highlights the differences in viral maturation between MuLV and human immunodeficiency virus (HIV), which may explain why the betulinic acid compounds had a minimal impact on Gag processing and release in 43D cells. Overall, MULTOVL appears to be a term used to describe the combination of betulinic acid and benzalkonium cation, and its potential as an antiviral agent against MuLV.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is a combination of betulinic acid and benzalkonium cation.\n2. Betulinic acid is investigated for its potential to inhibit the replication of retroviruses, including Murine leukemia virus (MuLV).\n3. Derivatives of betulinic acid were synthesized to improve water solubility and enhance antiviral potency.\n4. A derivative containing benzalkonium cation was found to inhibit the production of the MuLV virus and decrease the amount of viral structural protein Gag in cells.\n5. The same derivative that inhibited MuLV production also inhibited the growth of mouse fibroblast cells.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is a combination of betulinic acid and benzalkonium cation.",
      "Betulinic acid is investigated for its potential to inhibit the replication of retroviruses, including Murine leukemia virus (MuLV).",
      "Derivatives of betulinic acid were synthesized to improve water solubility and enhance antiviral potency.",
      "A derivative containing benzalkonium cation was found to inhibit the production of the MuLV virus and decrease the amount of viral structural protein Gag in cells.",
      "The same derivative that inhibited MuLV production also inhibited the growth of mouse fibroblast cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, it appears that GDF15 can be a useful biomarker for predicting the risk of major bleeding in patients with atrial fibrillation (AF) who are on oral anticoagulant treatment. The study found that patients with higher levels of GDF15 (>1,800 ng/L) had a higher risk of major bleeding compared to those with lower levels (<1,200 ng/L). The study also found that GDF15 improved the predictive accuracy of two commonly used bleeding risk scores, HAS-BLED and ORBIT.\nThe study did not examine the relationship between GDF15 and stroke outcomes, so it is unclear whether GDF15 can be used as a biomarker for predicting the risk of stroke in patients with AF. However, the study did find that GDF15 was independently associated with all-cause mortality in patients with AF, suggesting that it may be a useful biomarker for predicting overall mortality risk in this population.\nIn summary, based on the information provided in the article, GDF15 appears to be a useful biomarker for predicting the risk of major bleeding in patients with AF on oral anticoagulant treatment, but it is unclear whether it can be used as a biomarker for predicting the risk of stroke in this population. Further research is needed to confirm these findings and to determine the potential clinical utility of GDF15 as a biomarker for predicting bleeding and mortality risk in patients with AF.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 can be a useful biomarker for predicting the risk of major bleeding in patients with atrial fibrillation who are on oral anticoagulant treatment.\n2. Patients with higher levels of GDF15 (>1,800 ng/L) had a higher risk of major bleeding compared to those with lower levels (<1,200 ng/L).\n3. GDF15 improved the predictive accuracy of the bleeding risk scores HAS-BLED and ORBIT.\n4. GDF15 was independently associated with all-cause mortality in patients with atrial fibrillation.\n5. The study did not examine the relationship between GDF15 and stroke outcomes.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 can be a useful biomarker for predicting the risk of major bleeding in patients with atrial fibrillation who are on oral anticoagulant treatment.",
      "Patients with higher levels of GDF15 (>1,800 ng/L) had a higher risk of major bleeding compared to those with lower levels (<1,200 ng/L).",
      "GDF15 improved the predictive accuracy of the bleeding risk scores HAS-BLED and ORBIT.",
      "GDF15 was independently associated with all-cause mortality in patients with atrial fibrillation.",
      "The study did not examine the relationship between GDF15 and stroke outcomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - GDF15 is researched in various studies as a biomarker that could be helpful in predicting major bleeding in patients with atrial fibrillation on oral anticoagulant therapy.\n2. UNKNOWN - The specific threshold levels for GDF15 mentioned here (greater than 1,800 ng/L and less than 1,200 ng/L) may be based on study-specific findings, but without a specific study as a reference, it's uncertain whether these exact numbers are accurate.\n3. UNKNOWN - While it's plausible that GDF15 could have improved the predictive accuracy of bleeding risk scores like HAS-BLED and ORBIT, the statement lacks context and specific study information, so it cannot be definitively deemed true or false without additional details.\n4. UNKNOWN - The statement that GDF15 was independently associated with all-cause mortality in patients with atrial fibrillation is plausible since biomarkers like GDF15 are often studied for such associations, but again, it cannot be verified without specific evidence or source material.\n5. UNKNOWN - The statement about the study does not provide enough information to determine its truthfulness. Without access to the study itself, one cannot confirm whether the relationship between GDF15 and stroke outcomes was examined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that recursive splicing is more common in short introns. The document mentions that cryptic noncoding cassettes are much more common in large (>1 kb) retained introns than they are in small retained introns or in nonretained introns. This suggests that the splicing machinery is more likely to recognize and retain introns that are shorter in length, leading to a higher frequency of recursive splicing events.\nAdditionally, the document describes the discovery of new splice junctions in the SF3B1 splicing factor gene, which are found in nonsense-mediated decay (NMD)-inhibited cells. These splice junctions connect constitutive exons 4 and 5 to highly conserved cryptic cassette exons within the intron, and promote intron retention. The fact that these cryptic exons are more common in large retained introns suggests that they are also more common in short introns.\nOverall, the information provided in the document suggests that recursive splicing is more common in short introns, and that the splicing machinery is more likely to recognize and retain introns that are shorter in length.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Cryptic noncoding cassettes are much more common in large (>1 kb) retained introns than in small retained introns or nonretained introns.\n3. The splicing machinery is more likely to recognize and retain introns that are shorter in length.\n4. New splice junctions were discovered in the SF3B1 splicing factor gene in NMD-inhibited cells.\n5. These new splice junctions connect constitutive exons 4 and 5 to highly conserved cryptic cassette exons within the intron and promote intron retention.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Cryptic noncoding cassettes are much more common in large (>1 kb) retained introns than in small retained introns or nonretained introns.",
      "The splicing machinery is more likely to recognize and retain introns that are shorter in length.",
      "New splice junctions were discovered in the SF3B1 splicing factor gene in NMD-inhibited cells.",
      "These new splice junctions connect constitutive exons 4 and 5 to highly conserved cryptic cassette exons within the intron and promote intron retention."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. TRUE\n3. FALSE [correction]: The splicing machinery is more likely to recognize and correctly splice out introns that are shorter in length, whereas longer introns might be more likely to be retained due to the complexity of splicing them.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "The TALE-iD method is used for efficiently producing monoclonal cells with specific gene mutations in a simple and rapid manner. Specifically, the method involves using integrated TALE nuclease technology and high-throughput cell cloning approaches to generate monoclonal cells with desired gene mutations, such as the mTOR mutant 293T cell lines obtained within 2 months of using the method.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for producing monoclonal cells with specific gene mutations.\n2. The method involves using integrated TALE nuclease technology.\n3. High-throughput cell cloning approaches are used in the TALE-iD method.\n4. The TALE-iD method can obtain specific mutant cell lines, such as mTOR mutant 293T cells, within 2 months.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for producing monoclonal cells with specific gene mutations.",
      "The method involves using integrated TALE nuclease technology.",
      "High-throughput cell cloning approaches are used in the TALE-iD method.",
      "The TALE-iD method can obtain specific mutant cell lines, such as mTOR mutant 293T cells, within 2 months."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the Lisp framework that has been developed for image processing is Taverna. The document mentions that the develop environment for the Geneva University Hospitals is based on Taverna workflow engine, and that it is being used with a medical imaging application on the hospitals' internal Grid cluster. Therefore, it can be inferred that Taverna is a suitable framework for image processing in the context of Grid computing.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there are 454 distinct genes in Saccharomyces cerevisiae that are the result of an ancient whole genome duplication. This is calculated by subtracting the number of out-of-frame, antisense, and intergenic genomic fragments (162) from the total number of fragments identified (714). Of the 454 genes, 91 are of unknown function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae has 454 genes that resulted from an ancient whole genome duplication.\n2. The total number of genomic fragments identified in Saccharomyces cerevisiae was 714.\n3. Out of the genomic fragments identified, 162 were out-of-frame, antisense, and intergenic.\n4. Among the 454 genes resulting from the whole genome duplication, 91 genes are of unknown function.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae has 454 genes that resulted from an ancient whole genome duplication.",
      "The total number of genomic fragments identified in Saccharomyces cerevisiae was 714.",
      "Out of the genomic fragments identified, 162 were out-of-frame, antisense, and intergenic.",
      "Among the 454 genes resulting from the whole genome duplication, 91 genes are of unknown function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Saccharomyces cerevisiae underwent an ancient whole genome duplication event, but the exact number of genes resulting from this event is not 454. It's estimated that yeast has thousands of genes, and the duplication affected most of them.\n2. UNKNOWN: Without specific information regarding a study or context in which \"genomic fragments\" were identified, it is impossible to confirm or correct this statement.\n3. UNKNOWN: Again, without context or a source, it's not possible to confirm the number of genomic fragments identified or characterize them as out-of-frame, antisense, and intergenic.\n4. UNKNOWN: While it is true that some genes remain of unknown function in many organisms, including Saccharomyces cerevisiae, without specific context or reference to a study, it is impossible to verify the exact number of genes of unknown function resulting from the whole genome duplication.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the complex that is bound by estrogen-related receptor β (Esrrb) is the estrogen receptor (ER) itself. The document states that 70% of breast cancers express ER, and that many of these tumors become refractory to inhibition of estrogen action in the metastatic setting. This suggests that the ER is a key player in the development and progression of breast cancer, and that understanding how it functions is crucial for developing effective treatments.\nThe document also identifies mutations in the LBD of ESR1, which affect the ligand-binding domain of the receptor, in 14 of 80 cases of metastatic ER-positive breast tumors. These mutations, which include p.Tyr537Ser, p.Tyr537Asn, and p.Asp538Gly alterations, are shown to favor the agonist conformation of the receptor, leading to increased activity and resistance to hormonal therapy.\nTherefore, based on the information provided in the document, the complex that is bound by Esrrb is the ER, specifically the LBD of the receptor, which is affected by mutations that lead to increased activity and resistance to hormonal therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is bound by the estrogen receptor (ER).\n2. 70% of breast cancers express the estrogen receptor (ER).\n3. Mutations in the ligand-binding domain (LBD) of ESR1 are identified in 14 out of 80 cases of metastatic ER-positive breast tumors.\n4. Mutations such as p.Tyr537Ser, p.Tyr537Asn, and p.Asp538Gly can lead to increased activity and resistance to hormonal therapy in the ER.\n5. These mutations favor the agonist conformation of the estrogen receptor.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is bound by the estrogen receptor (ER).",
      "70% of breast cancers express the estrogen receptor (ER).",
      "Mutations in the ligand-binding domain (LBD) of ESR1 are identified in 14 out of 80 cases of metastatic ER-positive breast tumors.",
      "Mutations such as p.Tyr537Ser, p.Tyr537Asn, and p.Asp538Gly can lead to increased activity and resistance to hormonal therapy in the ER.",
      "These mutations favor the agonist conformation of the estrogen receptor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Estrogen-related receptor β (Esrrb) is not bound by the estrogen receptor (ER); rather, it is a related receptor that can be regulated independently of estrogens.\n2. TRUE\n3. UNKNOWN (without specific data or references, it's unclear if these numbers are accurate)\n4. TRUE (mutations in the LBD of ESR1 such as the ones listed are known to affect the activity of the receptor and can lead to resistance to hormone therapy)\n5. TRUE (mutations in the estrogen receptor that lead to an agonist conformation are known to favor activity associated with agonists, potentially leading to resistance to antagonist hormonal therapies)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ZCCHC17 appears to play a role in regulating the activity of cGAS, an enzyme that senses double-stranded DNA in the cytosol and triggers an innate immune response. Specifically, ZCCHC17 is identified as a positive regulator of cytosolic DNA- and DNA virus-triggered signaling, and is shown to directly bind to double-stranded DNA and enhance the binding of cGAS to dsDNA. The study suggests that ZCCHC17 is important for efficient innate immune response to cytosolic DNA and DNA virus, and that its deficiency leads to inhibition of downstream effector genes and increased susceptibility to viral infection. Therefore, the role of ZCCHC17 can be summarized as follows:\nRole of ZCCHC17:\n* Positive regulator of cytosolic DNA- and DNA virus-triggered signaling\n* Enhances the binding of cGAS to double-stranded DNA\n* Important for efficient innate immune response to cytosolic DNA and DNA virus\n* Essential for proper activation of downstream effector genes and immune response\nIn summary, ZCCHC17 plays a crucial role in regulating the activity of cGAS and enhancing the immune response to cytosolic DNA and DNA virus.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is identified as a positive regulator of cytosolic DNA- and DNA virus-triggered signaling.\n2. ZCCHC17 directly binds to double-stranded DNA.\n3. ZCCHC17 enhances the binding of cGAS to double-stranded DNA.\n4. The deficiency of ZCCHC17 leads to inhibition of downstream effector genes.\n5. The deficiency of ZCCHC17 increases susceptibility to viral infections.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is identified as a positive regulator of cytosolic DNA- and DNA virus-triggered signaling.",
      "ZCCHC17 directly binds to double-stranded DNA.",
      "ZCCHC17 enhances the binding of cGAS to double-stranded DNA.",
      "The deficiency of ZCCHC17 leads to inhibition of downstream effector genes.",
      "The deficiency of ZCCHC17 increases susceptibility to viral infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context given, the statements about ZCCHC17 appear to be consistent with what we might expect if ZCCHC17 is a positive regulator of responses to cytosolic DNA and DNA viruses. Thus, these statements are marked as true. However, without specific academic or scientific references provided to verify each point, the truth of these statements depends on the original context from which they were extracted. If these statements are indeed accurate to the cited research, then they are true. If there are nuances or specific details omitted from these condensed points, it could affect their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following proteins form the nuclear pore basket in human cells:\n1. Nup153\n2. POM121\n3. p62\n4. CAN/Nup214\n5. gp210/Tpr\nThese proteins are involved in the sequential assembly of the nuclear pore complex during nuclear envelope reformation, with POM121 and p62 associating with chromatin towards the end of anaphase, followed by the assembly of the remaining proteins in the sequence CAN/Nup214, gp210/Tpr, and Nup153. These findings support a model in which it is POM121 rather than gp210 that defines initial membrane-associated NPC assembly intermediates.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nup153 is one of the proteins that form the nuclear pore basket in human cells.\n2. POM121 is one of the proteins that form the nuclear pore basket in human cells.\n3. p62 is one of the proteins that form the nuclear pore basket in human cells.\n4. CAN/Nup214 is one of the proteins that form the nuclear pore basket in human cells.\n5. gp210, also known as Tpr, is one of the proteins that form the nuclear pore basket in human cells.",
    "llama-2-7b-chat-hf_fact": [
      "Nup153 is one of the proteins that form the nuclear pore basket in human cells.",
      "POM121 is one of the proteins that form the nuclear pore basket in human cells.",
      "p62 is one of the proteins that form the nuclear pore basket in human cells.",
      "CAN/Nup214 is one of the proteins that form the nuclear pore basket in human cells.",
      "gp210, also known as Tpr, is one of the proteins that form the nuclear pore basket in human cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Nup153 is indeed one of the proteins involved in forming the nuclear pore complex and is associated with the nuclear basket.\n2. FALSE [correction]: POM121 is a transmembrane protein of the nuclear pore complex but is not typically described as forming the nuclear pore basket.\n3. UNKNOWN: The statement is vague as \"p62\" could refer to different proteins. In terms of the nuclear pore complex, it often refers to Nup62, which is part of the central channel, not the nuclear basket.\n4. TRUE: CAN/Nup214 is part of the cytoplasmic filaments that extend from the nuclear pore; however, in some descriptions, it might be considered associated with the basket structure since the filaments and basket are connected.\n5. FALSE [correction]: gp210 is a transmembrane nucleoporin known to be involved in the nuclear pore complex but Tpr, not gp210, is associated with the nuclear basket. Tpr is a distinct protein from gp210.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, gepotidacin is a topoisomerase inhibitor that belongs to the second generation of camptothecins. Specifically, it is a modified lactone ring-containing camptothecin derivative that shows promise as an anticancer agent. The document does not provide specific information on the mechanism of action of gepotidacin, but it suggests that it may have improved potency and selectivity compared to earlier generations of camptothecins, such as topotecan and irinotecan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. Gepotidacin belongs to the second generation of camptothecins.\n3. Gepotidacin contains a modified lactone ring structure.\n4. Gepotidacin is explored as an anticancer agent.\n5. Gepotidacin is compared to earlier generations of camptothecins, such as topotecan and irinotecan, in terms of potency and selectivity.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "Gepotidacin belongs to the second generation of camptothecins.",
      "Gepotidacin contains a modified lactone ring structure.",
      "Gepotidacin is explored as an anticancer agent.",
      "Gepotidacin is compared to earlier generations of camptothecins, such as topotecan and irinotecan, in terms of potency and selectivity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Gepotidacin does not belong to the second generation of camptothecins; it is a novel triazaacenaphthylene antibacterial agent being developed for the treatment of bacterial infections.\n3. UNKNOWN\n4. FALSE [correction]: Gepotidacin is being developed for the treatment of bacterial infections, not as an anticancer agent.\n5. FALSE [correction]: Since gepotidacin is not a camptothecin, it is not compared to camptothecins like topotecan and irinotecan in terms of potency and selectivity; those are anticancer drugs, whereas gepotidacin is an antibacterial agent.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a powerful tool for managing and analyzing genetic variants from massively parallel sequencing (MPS) projects. It is designed to handle very large datasets and allows for rapid analysis using simple commands in R. The system includes functional annotations, making it suitable for identifying disease-causing mutations in human exome- (WES) or whole-genome sequencing (WGS) projects.\nOne of the key features of Canvas SPW is its built-in filtering function, which enables advanced comparative analysis of variant distribution between groups of samples. This allows for the detection of candidate causative mutations within family structures and genome-wide association by sequencing. The system is highly scalable, as demonstrated by importing the individual variant calls from all 1092 individuals in the 1000 Genomes Project, resulting in over 4.4 billion SNPs and indels in total.\nCanvas SPW is a local server-based system, which means that it can be installed and run on a user's own computer or server, rather than relying on a cloud-based service. This makes it a flexible and cost-effective option for researchers who need to analyze large-scale WGS projects.\nThe system is accessible through a user-friendly interface, which allows users to easily import and analyze their data. The database URL is provided as a reference for users who want to learn more about the system and how to use it.\nIn summary, Canvas SPW is a powerful tool for managing and analyzing genetic variants from MPS projects, with a built-in filtering function that enables advanced comparative analysis and scalability that can handle large-scale WGS projects. It is a local server-based system that can be installed and run on a user's own computer or server, making it a flexible and cost-effective option for researchers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is designed to manage and analyze genetic variants from massively parallel sequencing (MPS) projects.\n2. It includes functional annotations for identifying disease-causing mutations in human exome sequencing (WES) or whole-genome sequencing (WGS) projects.\n3. Canvas SPW features a built-in filtering function for advanced comparative analysis of variant distribution between sample groups.\n4. The system successfully imported individual variant calls from all 1092 individuals in the 1000 Genomes Project, including over 4.4 billion SNPs and indels.\n5. Canvas SPW is a local server-based system that can be installed and operated on a user's own computer or server.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is designed to manage and analyze genetic variants from massively parallel sequencing (MPS) projects.",
      "It includes functional annotations for identifying disease-causing mutations in human exome sequencing (WES) or whole-genome sequencing (WGS) projects.",
      "Canvas SPW features a built-in filtering function for advanced comparative analysis of variant distribution between sample groups.",
      "The system successfully imported individual variant calls from all 1092 individuals in the 1000 Genomes Project, including over 4.4 billion SNPs and indels.",
      "Canvas SPW is a local server-based system that can be installed and operated on a user's own computer or server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The 1000 Genomes Project identified over 88 million variants, including SNPs and indels, not 4.4 billion.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some STING agonists that were investigated for the treatment of acute pulmonary edema due to scorpion sting:\n1. Prazosin hydrochloride: A vasodilator that was investigated for its role in alleviating refractory myocardial failure due to scorpion sting.\n2. Sodium nitroprusside: A vasodilator that was also investigated for its potential in treating acute pulmonary edema due to scorpion sting.\n3. Nifedipine: A calcium channel blocker that was investigated for its ability to reduce the symptoms of acute pulmonary edema in patients with scorpion sting.\nIt is important to note that these are just some of the STING agonists that were investigated in the study, and the results may not be applicable to all patients. Additionally, it is crucial to consult with a medical professional before administering any medication, especially in severe cases of scorpion sting.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prazosin hydrochloride was investigated for its role in treating refractory myocardial failure due to scorpion sting.\n2. Sodium nitroprusside was investigated for its potential in treating acute pulmonary edema due to scorpion sting.\n3. Nifedipine was investigated for its ability to reduce symptoms of acute pulmonary edema in patients with scorpion sting.",
    "llama-2-7b-chat-hf_fact": [
      "Prazosin hydrochloride was investigated for its role in treating refractory myocardial failure due to scorpion sting.",
      "Sodium nitroprusside was investigated for its potential in treating acute pulmonary edema due to scorpion sting.",
      "Nifedipine was investigated for its ability to reduce symptoms of acute pulmonary edema in patients with scorpion sting."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nUnfortunately, without more context or specific references, it is impossible to verify the accuracy of these statements. They are quite specific to medical treatments and research outcomes that could indeed have occurred, but without access to the relevant medical literature or studies, their truth cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided in the document, here is a description of the SLIC-CAGE:\nThe SLIC-CAGE is an olfactometric cage designed to study olfactory perception in unrestrained rats. The cage consists of two compartments: an upper expansion chamber (B) and a lower stimulation chamber (A) with a perforated metal plate. The compartments are divided by a metal plate with a parabolic shape, which creates a laminar flow of air in the cage. This flow is suitable for long duration exposures of animals to odours.\nTo flatten the parabolic front of the air flow, a new distribution of holes was calculated for the metal plate. This resulted in a partially turbulent air flow in the stimulation chamber (A), which creates some fluctuations in the time-course of stimulations. However, the amplitude and delay of the signals are reasonably constant in all parts of the cage floor.\nThe SLIC-CAGE can be used for a variety of purposes beyond its original intended use, such as behavioral studies. The cage provides a controlled environment for studying olfactory perception and behavior in unrestrained animals, allowing researchers to observe and measure the animals' responses to different odors in a naturalistic setting.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SLIC-CAGE is designed to study olfactory perception in unrestrained rats.\n2. It consists of two compartments: an upper expansion chamber and a lower stimulation chamber with a perforated metal plate.\n3. The compartments are divided by a metal plate with a parabolic shape to create a laminar flow of air.\n4. A partially turbulent air flow is created in the stimulation chamber due to a new distribution of holes calculated for the metal plate.\n5. The SLIC-CAGE can also be used for behavioral studies in addition to studying olfactory perception.",
    "llama-2-7b-chat-hf_fact": [
      "The SLIC-CAGE is designed to study olfactory perception in unrestrained rats.",
      "It consists of two compartments: an upper expansion chamber and a lower stimulation chamber with a perforated metal plate.",
      "The compartments are divided by a metal plate with a parabolic shape to create a laminar flow of air.",
      "A partially turbulent air flow is created in the stimulation chamber due to a new distribution of holes calculated for the metal plate.",
      "The SLIC-CAGE can also be used for behavioral studies in addition to studying olfactory perception."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The compartments are divided by a metal plate which is not specified to have a parabolic shape in the given statements; this detail cannot be verified without additional context.\n4. UNKNOWN: Without additional context, it is unclear whether the air flow is partially turbulent or laminar. The statement does not provide enough information to determine the nature of the air flow.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, LEM-3 (14-3-3gamma) plays important roles in the growth and survival of hematopoietic progenitor cells. Specifically, the document states that overexpression of 14-3-3gamma in Ba/F3 cells abrogated dependence on IL-3 and was associated with activation of PI3K and MAPK signaling cascades. This suggests that 14-3-3gamma promotes survival and growth of hematopoietic progenitor cells through the activation of distinct signaling pathways. Additionally, the document notes that the up-regulation of Bax and Bad was seen with the ablation of 14-3-3gamma, resulting in cell death. These results suggest that deregulated expression of 14-3-3gamma may contribute to malignant transformation, possibly providing a new target for therapeutic intervention in hematopoietic neoplasms. Therefore, the roles of LEM-3 (14-3-3gamma) in hematopoietic progenitor cells are related to its ability to promote survival and growth, and its potential involvement in malignant transformation.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 (14-3-3gamma) is involved in the growth and survival of hematopoietic progenitor cells.\n2. Overexpression of 14-3-3gamma in Ba/F3 cells results in independence from interleukin-3 (IL-3).\n3. Activation of PI3K and MAPK signaling cascades is associated with overexpression of 14-3-3gamma.\n4. Ablation of 14-3-3gamma leads to up-regulation of Bax and Bad, resulting in cell death.\n5. Deregulated expression of 14-3-3gamma may contribute to malignant transformation in hematopoietic neoplasms.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 (14-3-3gamma) is involved in the growth and survival of hematopoietic progenitor cells.",
      "Overexpression of 14-3-3gamma in Ba/F3 cells results in independence from interleukin-3 (IL-3).",
      "Activation of PI3K and MAPK signaling cascades is associated with overexpression of 14-3-3gamma.",
      "Ablation of 14-3-3gamma leads to up-regulation of Bax and Bad, resulting in cell death.",
      "Deregulated expression of 14-3-3gamma may contribute to malignant transformation in hematopoietic neoplasms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The specific role of LEM-3 (14-3-3gamma) in the growth and survival of hematopoietic progenitor cells requires specific context from biological research that is not provided in this statement.\n2. UNKNOWN: Whether overexpression of 14-3-3gamma in Ba/F3 cells results in independence from interleukin-3 (IL-3) would need to be confirmed by specific scientific studies, which are not provided here.\n3. UNKNOWN: The association between the activation of PI3K and MAPK signaling cascades and the overexpression of 14-3-3gamma is a specific detail that must be validated with scientific research, not provided in this context.\n4. UNKNOWN: The statement about the ablation of 14-3-3gamma leading to up-regulation of Bax and Bad, resulting in cell death, requires substantiation from biological research, which is not provided.\n5. UNKNOWN: Whether deregulated expression of 14-3-3gamma may contribute to malignant transformation in hematopoietic neoplasms is a statement that needs to be supported by peer-reviewed studies, of which none have been cited here.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the releases of tmVar are:\n1. TMZ (temozolomide) - concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ)\n2. BEV (bevacizumab) - after Food and Drug Administration (FDA) approval\nThe document mentions the administration of TMZ concomitant with RT and adjuvant TMZ for newly diagnosed GBM, and then BEV for recurrent GBM after respective FDA approval. Therefore, the releases of tmVar mentioned in the document are TMZ and BEV.",
    "llama-2-7b-chat-hf_fact_raw": "1. Temozolomide (TMZ) is used concomitantly with radiotherapy-temozolomide (RT-TMZ) and as an adjuvant treatment.\n2. Bevacizumab (BEV) is used for recurrent glioblastoma multiforme (GBM) after FDA approval.",
    "llama-2-7b-chat-hf_fact": [
      "Temozolomide (TMZ) is used concomitantly with radiotherapy-temozolomide (RT-TMZ) and as an adjuvant treatment.",
      "Bevacizumab (BEV) is used for recurrent glioblastoma multiforme (GBM) after FDA approval."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "The database of somatic mutations in normal cells is the \"normal skin\" sampled in the study described in the provided information. According to the study, ultradeep sequencing of 74 cancer genes was performed on small biopsies of normal skin from 234 individuals, and the results showed that somatic mutations accumulate in normal cells, with an average of two to six mutations per megabase per cell, similar to that seen in many cancers. Additionally, the study found that multiple cancer genes are under strong positive selection even in physiologically normal skin, including key drivers of cutaneous squamous cell carcinomas. The study also observed variability in the driver landscape among individuals and the sizes of clonal expansions across genes. Therefore, the database of somatic mutations in normal cells is the collection of mutations observed in the normal skin samples analyzed in the study.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultradeep sequencing of 74 cancer genes was performed on small biopsies of normal skin from 234 individuals in the study.\n2. The study found that somatic mutations accumulate in normal cells, with an average of two to six mutations per megabase per cell.\n3. The study indicated that these rates of mutation accumulation in normal cells are similar to those seen in many cancers.\n4. Multiple cancer genes, including key drivers of cutaneous squamous cell carcinomas, were found to be under strong positive selection in physiologically normal skin according to the study.\n5. The study observed variability in the driver landscape among individuals and the sizes of clonal expansions across genes.",
    "llama-2-7b-chat-hf_fact": [
      "Ultradeep sequencing of 74 cancer genes was performed on small biopsies of normal skin from 234 individuals in the study.",
      "The study found that somatic mutations accumulate in normal cells, with an average of two to six mutations per megabase per cell.",
      "The study indicated that these rates of mutation accumulation in normal cells are similar to those seen in many cancers.",
      "Multiple cancer genes, including key drivers of cutaneous squamous cell carcinomas, were found to be under strong positive selection in physiologically normal skin according to the study.",
      "The study observed variability in the driver landscape among individuals and the sizes of clonal expansions across genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince no specific study details are provided, it is impossible to verify the accuracy of the statements related to the hypothetical study's findings without additional context or references.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are graph kernel libraries available implemented in Java. The paper you provided mentions a new Open Source Java library called JTT (Java Time-Triggered) that is specifically designed for the simulation of embedded control systems. JTT is based on the ideas and architecture of TrueTime, a toolbox of MATLAB devoted to this topic, and allows Java programmers to simulate the performance of control processes that run in a real-time environment.\nJTT provides a graph kernel that enables the simulation of complex systems by modeling them as graphs, where nodes represent processes and edges represent communication between them. This allows for the efficient simulation of systems with many interacting components, such as those found in embedded control systems.\nThe library is designed to be easy to use, with a simple and intuitive API that can be accessed by both pure Java programmers and EJS (Easy Java Simulations) users. EJS is a popular modeling and authoring tool that allows instructors, students, and researchers with less programming capabilities to create advanced interactive simulations in Java.\nJTT is available online at <http://lab.dia.uned.es/jtt>, where you can find more information and examples of how to use the library.",
    "llama-2-7b-chat-hf_fact_raw": "1. JTT is an Open Source Java library for the simulation of embedded control systems.\n2. JTT is based on the architecture of TrueTime, a MATLAB toolbox.\n3. JTT uses a graph kernel to simulate complex systems where nodes represent processes and edges represent communication.\n4. JTT has an API that is accessible for pure Java programmers and EJS users.\n5. JTT is available online at <http://lab.dia.uned.es/jtt>.",
    "llama-2-7b-chat-hf_fact": [
      "JTT is an Open Source Java library for the simulation of embedded control systems.",
      "JTT is based on the architecture of TrueTime, a MATLAB toolbox.",
      "JTT uses a graph kernel to simulate complex systems where nodes represent processes and edges represent communication.",
      "JTT has an API that is accessible for pure Java programmers and EJS users.",
      "JTT is available online at <http://lab.dia.uned.es/jtt>."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: As of my knowledge cutoff in April 2023, I cannot verify the availability of JTT at that specific URL since I do not have browsing capabilities. Users interested in JTT should search for the library in a web browser or appropriate repositories for the most current information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the four advances integrated into the SHERLOCKv2 platform are:\n1. Multiplexing: The platform allows for increased multiplexing, meaning it can analyze multiple genetic targets simultaneously, which is important for precision medicine.\n2. Automation: The platform is fully automated and programmable, reducing the need for human manipulation and contamination risk.\n3. High sensitivity: The platform is capable of detecting very small amounts of RNA, corresponding to less than one cell, making it highly sensitive.\n4. Speed: The platform is fast, with the ability to perform RNA purification, reverse transcription, and amplification in a matter of hours, rather than days or weeks.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform can analyze multiple genetic targets simultaneously.\n2. The platform is fully automated and programmable.\n3. The platform can detect amounts of RNA corresponding to less than one cell.\n4. The platform can perform RNA purification, reverse transcription, and amplification in a matter of hours.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform can analyze multiple genetic targets simultaneously.",
      "The platform is fully automated and programmable.",
      "The platform can detect amounts of RNA corresponding to less than one cell.",
      "The platform can perform RNA purification, reverse transcription, and amplification in a matter of hours."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) version 2 is an updated version of the CRISPR-based diagnostic tool that can analyze multiple genetic targets simultaneously.\n2. UNKNOWN: The detail provided is insufficient to confirm whether SHERLOCKv2 is fully automated and programmable as it could refer to specific configurations or iterations of the platform that may or may not have these capabilities.\n3. TRUE: SHERLOCKv2 and similar CRISPR-based diagnostic platforms are known for their high sensitivity and can detect very small amounts of nucleic acids, which could include amounts corresponding to less than one cell.\n4. TRUE: CRISPR-based platforms like SHERLOCKv2 are typically capable of performing the necessary steps of RNA purification, reverse transcription, and amplification within a short time frame, which is commonly a matter of hours.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a frequent itemset mining algorithm that was introduced in a research paper titled \"A New Efficient Algorithm for Mining Frequent Closed Itemsets\" by Jiawei Han, Meng Xia, and Divesh Srivastava. The algorithm is designed to efficiently mine frequent closed itemsets (FCIs) from large datasets.\nThe bartender algorithm works by using a novel compound frequent itemset tree (CFIT) to facilitate fast growth and efficient pruning of the search space. The CFIT is a data structure that represents the frequent itemsets in a compact and efficient manner, allowing for fast querying and pruning of the search space. The algorithm also employs a hybrid approach that adapts search strategies, representations of projected transaction subsets, and projecting methods to the characteristics of the dataset.\nThe bartender algorithm has several key features that make it efficient and effective:\n1. Efficient local pruning: The algorithm uses a novel pruning strategy that reduces the size of the search space by pruning the subspaces that are unlikely to contain frequent itemsets.\n2. Global subsumption checking: The algorithm performs global subsumption checking to identify frequent itemsets that are subsumed by larger frequent itemsets, reducing the number of itemsets that need to be considered.\n3. Fast hashing methods: The algorithm uses fast hashing methods to quickly identify frequent itemsets that are likely to be frequent.\n4. Balanced overhead: The algorithm balances the overhead of search space growth and pruning, ensuring that the algorithm is efficient and scalable.\nThe bartender algorithm has been shown to outperform other frequent itemset mining algorithms, including CHARM, CLOSET, and MAFIA, in terms of efficiency and scalability. The algorithm has been applied to a variety of datasets, including real-world datasets, and has demonstrated excellent performance in mining frequent closed itemsets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm was introduced in a research paper titled \"A New Efficient Algorithm for Mining Frequent Closed Itemsets\" by authors Jiawei Han, Meng Xia, and Divesh Srivastava.\n2. The bartender algorithm is designed to mine frequent closed itemsets from large datasets.\n3. It uses a compound frequent itemset tree (CFIT) for fast querying and efficient pruning of the search space.\n4. The bartender algorithm employs a hybrid approach that adapts search strategies, representations of projected transaction subsets, and projecting methods to the dataset characteristics.\n5. The bartender algorithm has been demonstrated to outperform other frequent itemset mining algorithms such as CHARM, CLOSET, and MAFIA in terms of efficiency and scalability.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm was introduced in a research paper titled \"A New Efficient Algorithm for Mining Frequent Closed Itemsets\" by authors Jiawei Han, Meng Xia, and Divesh Srivastava.",
      "The bartender algorithm is designed to mine frequent closed itemsets from large datasets.",
      "It uses a compound frequent itemset tree (CFIT) for fast querying and efficient pruning of the search space.",
      "The bartender algorithm employs a hybrid approach that adapts search strategies, representations of projected transaction subsets, and projecting methods to the dataset characteristics.",
      "The bartender algorithm has been demonstrated to outperform other frequent itemset mining algorithms such as CHARM, CLOSET, and MAFIA in terms of efficiency and scalability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The \"BIDE\" algorithm was introduced in the research paper titled \"A New Efficient Algorithm for Mining Frequent Closed Itemsets\" by authors Jiawei Han, Jian Pei, and Yiwen Yin. The bartender algorithm is not mentioned in this context, and the authors listed are not associated with the bartender algorithm.\n2. FALSE [correction]: As the bartender algorithm is not the subject of the stated paper, this statement cannot be confirmed as true or false without additional context about the bartender algorithm. Nonetheless, the described function is typical of algorithms in frequent itemset mining.\n3. UNKNOWN: Without specific information about the bartender algorithm, it is unclear whether it uses a compound frequent itemset tree (CFIT).\n4. UNKNOWN: The details of how the bartender algorithm operates are not provided in the given context, making it impossible to determine the truthfulness of this statement.\n5. UNKNOWN: Without empirical evidence or a relevant source that verifies the performance claim, the statement regarding the bartender algorithm outperforming others such as CHARM, CLOSET, and MAFIA cannot be validated.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several web-based pedigree editors available that can help with cleaning raw datasets of bad data points, including:\n1. VIPER (Visual Pedigree Explorer): This is a software tool that integrates an inheritance-checking algorithm with a novel space-efficient pedigree visualization, allowing users to explore and identify inheritance inconsistencies in the context of the pedigree structure.\n2. Pedigree-R: This is a web-based tool that allows users to visualize and edit pedigrees, including the ability to identify and correct errors in the pedigree structure.\n3. GenoViz: This is a web-based tool that provides a visual interface for exploring and analyzing genetic data, including the ability to identify and correct errors in the genotype data.\n4. Pedigree-Genius: This is a web-based tool that provides a comprehensive solution for cleaning and organizing genetic data, including the ability to identify and correct errors in the pedigree structure.\n5. Genetic Pedigree Analyzer: This is a web-based tool that provides a user-friendly interface for analyzing and cleaning genetic data, including the ability to identify and correct errors in the pedigree structure.\nIt's worth noting that these are just a few examples of web-based pedigree editors available, and there may be other tools available that can help with cleaning raw datasets of bad data points.",
    "llama-2-7b-chat-hf_fact_raw": "1. VIPER (Visual Pedigree Explorer) is a software tool that integrates an inheritance-checking algorithm with pedigree visualization.\n2. Pedigree-R is a web-based tool that allows users to visualize and edit pedigrees.\n3. GenoViz is a web-based tool designed for exploring and analyzing genetic data.\n4. Pedigree-Genius is a web-based tool for cleaning and organizing genetic data.\n5. Genetic Pedigree Analyzer is a web-based tool that offers an interface for analyzing and cleaning genetic data.",
    "llama-2-7b-chat-hf_fact": [
      "VIPER (Visual Pedigree Explorer) is a software tool that integrates an inheritance-checking algorithm with pedigree visualization.",
      "Pedigree-R is a web-based tool that allows users to visualize and edit pedigrees.",
      "GenoViz is a web-based tool designed for exploring and analyzing genetic data.",
      "Pedigree-Genius is a web-based tool for cleaning and organizing genetic data.",
      "Genetic Pedigree Analyzer is a web-based tool that offers an interface for analyzing and cleaning genetic data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GenoViz is not a web-based tool; it is a software toolkit for creating interactive graphical genomics applications.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several curated databases of spider-venom toxins that can be used for research purposes:\n1. ArachnoServer: A web portal that provides access to a comprehensive relational database of spider toxins, including the precursor prediction tool (SpiderP). The database contains information on the venom peptides of over 100 species of spiders, and the tool can be used to predict the mature toxin sequence directly from toxin transcripts.\n2. ToxinDB: A database of toxins from various sources, including spider venom. The database contains information on the structure, function, and evolution of toxins, as well as tools for predicting toxin sequences and functions.\n3. VenomDB: A database of venom peptides and proteins from various organisms, including spiders. The database contains information on the structure, function, and evolution of venom peptides and proteins, as well as tools for predicting venom sequences and functions.\n4. SpiderToxinDB: A database of spider toxins and their precursors, including information on the structure, function, and evolution of the toxins. The database also contains tools for predicting toxin sequences and functions.\nThese databases can be used to identify and characterize novel spider-venom toxins, understand their structure and function, and develop new pharmacological tools and therapies.",
    "llama-2-7b-chat-hf_fact_raw": "1. ArachnoServer is a comprehensive database of spider toxins, which includes a precursor prediction tool named SpiderP.\n2. ArachnoServer's database provides information on venom peptides of over 100 species of spiders.\n3. ToxinDB is a database that contains information on toxins from various sources, including spider venom.\n4. VenomDB is a database that includes venom peptides and proteins from a variety of organisms, such as spiders.\n5. SpiderToxinDB is a database specifically for spider toxins and their precursors, providing structure, function, and evolutionary information.",
    "llama-2-7b-chat-hf_fact": [
      "ArachnoServer is a comprehensive database of spider toxins, which includes a precursor prediction tool named SpiderP.",
      "ArachnoServer's database provides information on venom peptides of over 100 species of spiders.",
      "ToxinDB is a database that contains information on toxins from various sources, including spider venom.",
      "VenomDB is a database that includes venom peptides and proteins from a variety of organisms, such as spiders.",
      "SpiderToxinDB is a database specifically for spider toxins and their precursors, providing structure, function, and evolutionary information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout more context on SpiderToxinDB, I cannot accurately determine the veracity of the last statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no conclusive evidence to suggest that Axitinib prolongs survival of Pancreatic Cancer patients. The document is focused on the safety profile of Axitinib in patients with metastatic Renal Cell Carcinoma (mRCC) and other advanced solid tumors, and does not provide any data or analysis specifically related to Pancreatic Cancer.\nWhile the document does mention that Axitinib is an approved treatment for advanced RCC, it does not provide any information on its efficacy in treating other types of cancer, including Pancreatic Cancer. Therefore, it is not possible to draw any conclusions about the potential benefits of Axitinib in prolonging the survival of Pancreatic Cancer patients based on the information provided in the document.\nIt is important to note that the safety and efficacy of any cancer treatment should be evaluated through rigorous clinical trials and peer-reviewed publications, and should not be based solely on retrospective analyses or small-scale studies. If you have any further questions or concerns, please feel free to ask.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no conclusive evidence that Axitinib prolongs the survival of patients with Pancreatic Cancer based on the mentioned document.\n2. The document primarily discusses the safety profile of Axitinib in patients with metastatic Renal Cell Carcinoma (mRCC) and other advanced solid tumors.\n3. The document does not provide any data or analysis specific to the treatment of Pancreatic Cancer with Axitinib.\n4. Axitinib is an approved treatment for advanced Renal Cell Carcinoma (RCC).\n5. The efficacy of cancer treatments should be evaluated through rigorous clinical trials and peer-reviewed publications.",
    "llama-2-7b-chat-hf_fact": [
      "There is no conclusive evidence that Axitinib prolongs the survival of patients with Pancreatic Cancer based on the mentioned document.",
      "The document primarily discusses the safety profile of Axitinib in patients with metastatic Renal Cell Carcinoma (mRCC) and other advanced solid tumors.",
      "The document does not provide any data or analysis specific to the treatment of Pancreatic Cancer with Axitinib.",
      "Axitinib is an approved treatment for advanced Renal Cell Carcinoma (RCC).",
      "The efficacy of cancer treatments should be evaluated through rigorous clinical trials and peer-reviewed publications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (This is context-dependent and without the document, we cannot verify the truth of the statement.)\n2. UNKNOWN (Without the actual document, we cannot confirm what the primary discussion is about.)\n3. UNKNOWN (The availability of data or analysis specific to Pancreatic Cancer with Axitinib treatment cannot be confirmed without the document.)\n4. TRUE (Axitinib is indeed an approved treatment for advanced Renal Cell Carcinoma (RCC) by the FDA.)\n5. TRUE (The efficacy of cancer treatments is generally evaluated through rigorous clinical trials and the findings are often disseminated through peer-reviewed publications.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, MLP regulates F-actin dynamics through protein interaction with the Nephrin-Nck-N-WASP signaling pathway. The document states that the Nephrin-Nck-N-WASP signaling pathway is phase-separated on lipid bilayers, which increases the membrane dwell time of N-WASP and Arp2/3 complex, consequently increasing actin assembly. This suggests that MLP interacts with the Nephrin-Nck-N-WASP signaling pathway in a way that regulates F-actin dynamics.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through interaction with the Nephrin-Nck-N-WASP signaling pathway.\n2. The Nephrin-Nck-N-WASP signaling pathway is phase-separated on lipid bilayers.\n3. The membrane dwell time of N-WASP and Arp2/3 complex is increased by the phase separation of the Nephrin-Nck-N-WASP pathway.\n4. Increased membrane dwell time of N-WASP and Arp2/3 complex leads to an increase in actin assembly.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through interaction with the Nephrin-Nck-N-WASP signaling pathway.",
      "The Nephrin-Nck-N-WASP signaling pathway is phase-separated on lipid bilayers.",
      "The membrane dwell time of N-WASP and Arp2/3 complex is increased by the phase separation of the Nephrin-Nck-N-WASP pathway.",
      "Increased membrane dwell time of N-WASP and Arp2/3 complex leads to an increase in actin assembly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n\nThese statements involve specialized, technical knowledge in the field of cell biology and biochemistry. Without the specific context or passage that these statements are extracted from, I cannot verify the accuracy of the first three statements. However, generally speaking, the fourth statement is based on a common understanding within the field that an increased membrane dwell time of N-WASP and the Arp2/3 complex can lead to an increase in actin assembly, as these proteins are involved in actin nucleation and polymerization.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are at least three pseudokinases in the human kinome:\n1. Low molecular weight kininogen (LMWK): The document states that a purified preparation of LMWK has been obtained from human blood plasma, and the kinin content per 1 mg of the preparation is 14--16 micrograms of bradykinin. This indicates that LMWK is a pseudokinase that is present in human blood plasma.\n2. High molecular weight kininogen: The document mentions that immunoelectrophoretic studies of the antiserum to LMWK revealed three precipitation arcs with human plasma, including one that is assumed to be formed with a high molecular weight form of kininogen. This suggests that there is at least one pseudokinase with a higher molecular weight than LMWK.\n3. Prekallikrein: The document also mentions that immunoelectrophoretic studies of the antiserum to LMWK revealed one precipitation arc that is assumed to be formed with a high molecular weight kininogen complex with prekallikrein. This suggests that there is at least one pseudokinase that is involved in the complex with prekallikrein.\nTherefore, based on the information provided, there are at least three pseudokinases in the human kinome: LMWK, high molecular weight kininogen, and prekallikrein.",
    "llama-2-7b-chat-hf_fact_raw": "1. Low molecular weight kininogen (LMWK) is a pseudokinase present in human blood plasma.\n2. High molecular weight kininogen is identified as another pseudokinase through immunoelectrophoretic studies.\n3. Prekallikrein is involved in a complex with high molecular weight kininogen and is identified as a pseudokinase.\n\nNote: These statements are derived from the context provided, but factual accuracy regarding pseudokinases and the human kinome would require verification from a scientific source or research study. The terms \"pseudokinase\" and \"kininogen\" have specific meanings in biochemistry, and it should be confirmed with the relevant scientific literature whether the substances mentioned are indeed classified as pseudokinases within the human kinome.",
    "llama-2-7b-chat-hf_fact": [
      "Low molecular weight kininogen (LMWK) is a pseudokinase present in human blood plasma.",
      "High molecular weight kininogen is identified as another pseudokinase through immunoelectrophoretic studies.",
      "Prekallikrein is involved in a complex with high molecular weight kininogen and is identified as a pseudokinase.",
      "te: These statements are derived from the context provided, but factual accuracy regarding pseudokinases and the human kinome would require verification from a scientific source or research study. The terms \"pseudokinase\" and \"kininogen\" have specific meanings in biochemistry, and it should be confirmed with the relevant scientific literature whether the substances mentioned are indeed classified as pseudokinases within the human kinome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Low molecular weight kininogen (LMWK) is not a pseudokinase. It is actually a protein involved in the kallikrein-kinin system.\n2. FALSE [correction]: High molecular weight kininogen (HMWK) is not a pseudokinase. Like LMWK, HMWK is also a protein involved in blood clotting and inflammation processes, not a pseudokinase.\n3. FALSE [correction]: Prekallikrein is not a pseudokinase. It is a proenzyme (precursor to an enzyme) which, when combined with high molecular weight kininogen, plays a role in inflammation and blood pressure regulation. It is part of the kallikrein-kinin system and can be converted to an active enzyme called kallikrein.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are three apoE mimetics:\n1. Mimetite: Pb(10)(As(5+)O(4))(6)(Cl(2 - x)O(x/2))\n2. Finnemanite: Pb(10)(As(3+)O(3))(6)Cl(2)\n3. Clinomimetite: Pb(10)(As(4+)O(4))(6)Cl(2)\nNote: The term \"apoE mimetics\" refers to compounds that mimic the structure and properties of the apolipoprotein E (apoE) protein, which plays a crucial role in lipid metabolism and is associated with various diseases. The three compounds listed above are examples of apoE mimetics that have been identified in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mimetite is a compound with the chemical formula Pb(10)(As(5+)O(4))(6)(Cl(2 - x)O(x/2)).\n2. Finnemanite has the chemical formula Pb(10)(As(3+)O(3))(6)Cl(2).\n3. Clinomimetite is a compound with the chemical formula Pb(10)(As(4+)O(4))(6)Cl(2).\n4. ApoE mimetics are compounds that mimic the structure and properties of apolipoprotein E.",
    "llama-2-7b-chat-hf_fact": [
      "Mimetite is a compound with the chemical formula Pb(10)(As(5+)O(4))(6)(Cl(2 - x)O(x/2)).",
      "Finnemanite has the chemical formula Pb(10)(As(3+)O(3))(6)Cl(2).",
      "Clinomimetite is a compound with the chemical formula Pb(10)(As(4+)O(4))(6)Cl(2).",
      "ApoE mimetics are compounds that mimic the structure and properties of apolipoprotein E."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mimetite is a compound with the chemical formula Pb5(AsO4)3Cl.\n2. TRUE\n3. FALSE [correction]: Clinomimetite is a mistake and seems to be an incorrect or not officially recognized mineral name. The closest recognized mineral would be clinoclase, with the chemical formula Cu3(AsO4)(OH)3, but that is not related to mimetite by formula.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are no significant sex differences in SAMHD1 activity in children with attention deficit hyperactivity disorder (ADHD). The study found that both male and female children with ADHD had similar levels of primary and secondary symptomatology, including impulsivity, inattention, overactivity, learning problems, externalizing symptoms, internalizing symptoms, peer relationship difficulties, and self-perceptions. These findings conflict with prior reports in the literature that suggested there may be sex differences in the expression of ADHD symptoms. The study suggests that these conflicting results may be due to differences in inclusion criteria used in previous studies. The lack of significant sex differences in SAMHD1 activity in children with ADHD has implications for understanding the long-term outcome of ADHD in girls.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are no significant sex differences in SAMHD1 activity in children with ADHD according to the study referenced.\n2. The study found similar levels of ADHD symptoms, such as impulsivity and inattention, in both male and female children.\n3. The study mentioned observed no significant sex differences in peer relationship difficulties and self-perceptions in children with ADHD.\n4. Previous reports suggested there might be sex differences in the expression of ADHD symptoms, which conflicts with the findings of the referenced study.\n5. The study implies that variations in inclusion criteria among different studies may account for conflicting results regarding sex differences in ADHD symptom expression.",
    "llama-2-7b-chat-hf_fact": [
      "There are no significant sex differences in SAMHD1 activity in children with ADHD according to the study referenced.",
      "The study found similar levels of ADHD symptoms, such as impulsivity and inattention, in both male and female children.",
      "The study mentioned observed no significant sex differences in peer relationship difficulties and self-perceptions in children with ADHD.",
      "Previous reports suggested there might be sex differences in the expression of ADHD symptoms, which conflicts with the findings of the referenced study.",
      "The study implies that variations in inclusion criteria among different studies may account for conflicting results regarding sex differences in ADHD symptom expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nWithout the specifics of the study or additional context about its findings, it is not possible to accurately determine the truth of statements 1, 2, 3, and 5. However, statement 4 is generally accurate as it has been a common theme in ADHD research to investigate potential sex differences in symptom expression, and the suggestion of a conflict with the referenced study implies knowledge of previous research trends.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that RUNX2 does not inhibit astrocyte differentiation. In fact, the document suggests that RUNX2 may play a role in the development and progression of glioblastoma, a type of brain cancer.\nThe document mentions that Emx2, a gene that normally antagonizes cortico-cerebral astrogenesis by inhibiting proliferation of astrocyte progenitors, can be overexpressed in glioblastoma cells to collapse these cells. The document also suggests that the antioncogenic activity of Emx2 originates from its impact on at least six metabolic nodes, which accounts for the robustness of its effect.\nThere is no mention in the document of RUNX2 inhibiting astrocyte differentiation, and the focus of the document is on the potential of Emx2 as a novel tool for therapy of glioblastoma and prevention of its recurrencies. Therefore, based on the information provided in the document, it can be concluded that RUNX2 does not inhibit astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 does not inhibit astrocyte differentiation according to the document.\n2. RUNX2 may be involved in the development and progression of glioblastoma.\n3. Emx2 can antagonize cortico-cerebral astrogenesis by inhibiting the proliferation of astrocyte progenitors.\n4. Overexpression of Emx2 in glioblastoma cells can lead to the collapse of these cells.\n5. The antioncogenic activity of Emx2 is linked to its impact on at least six metabolic nodes.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 does not inhibit astrocyte differentiation according to the document.",
      "RUNX2 may be involved in the development and progression of glioblastoma.",
      "Emx2 can antagonize cortico-cerebral astrogenesis by inhibiting the proliferation of astrocyte progenitors.",
      "Overexpression of Emx2 in glioblastoma cells can lead to the collapse of these cells.",
      "The antioncogenic activity of Emx2 is linked to its impact on at least six metabolic nodes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nI cannot verify the accuracy of these statements without the specific document they are based on. The scientific assertions require information or evidence from that document to ascertain their validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the Cobb-Stainsby excision arthroplasty would be performed in the shoulder joint, specifically in the glenohumeral joint. The procedure involves creating portals in the shoulder and using arthroscopic instruments to resect osteophytes, alter the version of the glenoid, and create microfractures on the glenoid surface. The interposition membrane/tissue is then introduced into the joint through the anterior cannula and aligned with the glenoid rim. Anterior sutures are rerouted through the anterior capsular-labral tissue, and intra-articular nonsliding knots are used to anchor the interposition tissue to the anterior glenoid labrum and capsule. Posterior sutures are knotted intra-articularly or tied extra-articularly, and the proximal and distal posterior sutures are retrieved subcutaneously through the skin tract of the posterior portal. The stability of the interposition tissue is assessed through movement of the glenohumeral joint through its entire range of motion.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a procedure performed on the shoulder joint.\n2. Specifically, the Cobb-Stainsby excision arthroplasty targets the glenohumeral joint.\n3. The procedure involves resecting osteophytes and altering the version of the glenoid.\n4. An interposition membrane/tissue is introduced into the glenohumeral joint during the procedure.\n5. The stability of the interposition tissue in a Cobb-Stainsby excision arthroplasty is assessed by moving the glenohumeral joint through its entire range of motion.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a procedure performed on the shoulder joint.",
      "Specifically, the Cobb-Stainsby excision arthroplasty targets the glenohumeral joint.",
      "The procedure involves resecting osteophytes and altering the version of the glenoid.",
      "An interposition membrane/tissue is introduced into the glenohumeral joint during the procedure.",
      "The stability of the interposition tissue in a Cobb-Stainsby excision arthroplasty is assessed by moving the glenohumeral joint through its entire range of motion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a procedure performed on the hip joint, not the shoulder joint.\n2. FALSE [correction]: Since the Cobb-Stainsby excision arthroplasty is performed on the hip joint, it does not target the glenohumeral joint which is in the shoulder. It targets the hip joint.\n3. UNKNOWN: Without specific details related to the Cobb-Stainsby procedure for the hip joint, it’s unclear whether resecting osteophytes and altering the version of the glenoid are steps involved. These could be elements of other types of joint arthroplasty but not necessarily the Cobb-Stainsby excision arthroplasty.\n4. TRUE: During a Cobb-Stainsby excision arthroplasty, an interposition membrane or tissue, such as a fascia lata or synthetic material, is introduced to prevent bone-to-bone contact and to create a pseudo-joint.\n5. TRUE: The stability of the interposition tissue in a Cobb-Stainsby excision arthroplasty is indeed assessed by moving the joint through its entire range of motion, which is a standard practice to check the success of such procedures.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the study, it appears that overexpression of GRHL2 (Growth Differentiation Factor 11) does lead to EMT (Epithelial-Mesenchymal Transition) in oral cancer cells.\nThe study found that GDF11 and ROS (Reactive Oxygen Species) were overexpressed in patients with metastatic oral cancer, and that GDF11 induction in SCC-9 cells led to altered expression of EMT-related markers and cell migration. The study also found that treatment with the powerful antioxidant N-acetylcysteine inhibited GDF11-induced EMT and cell migration.\nTherefore, based on the findings of this study, it can be concluded that GRHL2 overexpression leads to EMT in oral cancer cells, and that this process is associated with ROS involvement.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of GRHL2 leads to EMT in oral cancer cells according to the study referenced.\n2. GRHL2 is also known as Growth Differentiation Factor 11 (GDF11).\n3. Patients with metastatic oral cancer showed overexpression of GDF11 and Reactive Oxygen Species (ROS).\n4. GDF11 induction in SCC-9 cells altered the expression of EMT-related markers and cell migration.\n5. Treatment with N-acetylcysteine inhibited GDF11-induced EMT and cell migration in the study.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of GRHL2 leads to EMT in oral cancer cells according to the study referenced.",
      "GRHL2 is also known as Growth Differentiation Factor 11 (GDF11).",
      "Patients with metastatic oral cancer showed overexpression of GDF11 and Reactive Oxygen Species (ROS).",
      "GDF11 induction in SCC-9 cells altered the expression of EMT-related markers and cell migration.",
      "Treatment with N-acetylcysteine inhibited GDF11-induced EMT and cell migration in the study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: GRHL2 is not known as Growth Differentiation Factor 11 (GDF11). GRHL2 stands for Grainyhead-like transcription factor 2, and GDF11 is a different protein.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe accuracy of statements relating to specific scientific studies can vary, and without access to the referenced study, it's not possible to confirm the claims about GRHL2 and EMT in oral cancer cells, the expression of GDF11 and ROS in metastatic oral cancer patients, the effects of GDF11 induction in SCC-9 cells, or the treatment outcomes with N-acetylcysteine. However, the correction for statement 2 was provided based on known scientific terminology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in lung cancer:\n1. Tobacco (T)\n2. Areca nut (AN)\nThe study found that urine concentrates (UCs) prepared from T/AN chewers caused elevated chromosome aberration (CA) and sister chromatid exchange (SCE) frequencies in Chinese hamster ovary (CHO) cells, indicating that the mutagens/carcinogens in tobacco and areca nut might be playing a causative role in cancer of the urinary bladder as well as lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tobacco has been implicated in lung cancer.\n2. Areca nut has been implicated in lung cancer.\n3. A study found that urine concentrates from tobacco/areca nut chewers caused elevated chromosome aberration frequencies in Chinese hamster ovary cells.\n4. A study found that urine concentrates from tobacco/areca nut chewers caused elevated sister chromatid exchange frequencies in Chinese hamster ovary cells.\n5. The mutagens/carcinogens in tobacco and areca nut might play a causative role in cancer of the urinary bladder as well as lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Tobacco has been implicated in lung cancer.",
      "Areca nut has been implicated in lung cancer.",
      "A study found that urine concentrates from tobacco/areca nut chewers caused elevated chromosome aberration frequencies in Chinese hamster ovary cells.",
      "A study found that urine concentrates from tobacco/areca nut chewers caused elevated sister chromatid exchange frequencies in Chinese hamster ovary cells.",
      "The mutagens/carcinogens in tobacco and areca nut might play a causative role in cancer of the urinary bladder as well as lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, GPR151 is an orphan G protein-coupled receptor that has been found to have anti-HIV-1 activity. Specifically, several shortened peptide analogues of the N-terminal domain of GPR1, including sulfated derivatives, were prepared and evaluated for their anti-HIV-1 activity. The results showed that these compounds, particularly the sulfated derivatives, exhibited potent inhibitory activity against a broad range of HIV-1 strains, including T cell-tropic, dual cell-tropic, and brain-derived (BT) cell-tropic HIV-1 strains.\nGPR151 is a member of the G protein-coupled receptor (GPCR) family, which plays a crucial role in various physiological processes, including signal transduction and regulation of gene expression. Orphan GPCRs, like GPR151, are GPCRs that do not have a well-defined endogenous ligand or a clear physiological function, making them an attractive target for drug discovery.\nThe discovery of GPR151's anti-HIV-1 activity suggests that it may be a promising target for the development of new HIV-1 therapies. Further research is needed to fully understand the mechanism of action of GPR151 and its potential as an anti-HIV-1 drug target.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan G protein-coupled receptor.\n2. Peptide analogues of the N-terminal domain of GPR1 have shown anti-HIV-1 activity.\n3. Sulfated derivatives of these peptides have potent inhibitory activity against a broad range of HIV-1 strains.\n4. G protein-coupled receptors are involved in signal transduction and regulation of gene expression.\n5. GPR151 is being investigated as a potential target for HIV-1 therapy development.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan G protein-coupled receptor.",
      "Peptide analogues of the N-terminal domain of GPR1 have shown anti-HIV-1 activity.",
      "Sulfated derivatives of these peptides have potent inhibitory activity against a broad range of HIV-1 strains.",
      "G protein-coupled receptors are involved in signal transduction and regulation of gene expression.",
      "GPR151 is being investigated as a potential target for HIV-1 therapy development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Peptide analogues of the N-terminal domain of chemokines, like CXCR4 and CCR5, have shown anti-HIV-1 activity, not specifically GPR1.\n3. TRUE – Assuming this statement is related to the aforementioned peptide analogues and their derivatives, it's true that sulfated derivatives of chemokine receptor peptides have potent inhibitory activity against a range of HIV-1 strains.\n4. TRUE\n5. UNKNOWN – While GPR151 is a G protein-coupled receptor, there isn't enough information provided in the statement to confirm if it is specifically being investigated as a target for HIV-1 therapy development.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n* Reassortant B/USSR/60/69-based vaccine influenza viruses Victoria and Yamagata.\nThese are the two attenuated live viruses that are included in the quadrivalent LAIV (qLAIV) vaccine. The vaccine is safe and reactogenic in adult volunteers, and it induces an immune response to both the Victoria and Yamagata lineages following administration.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains reassortant B/USSR/60/69-based vaccine influenza viruses from the Victoria and Yamagata lineages.\n2. The Fluzone intradermal quadrivalent vaccine is a quadrivalent live attenuated influenza vaccine (qLAIV).\n3. The vaccine is considered safe and reactogenic in adult volunteers according to Document-0.\n4. The vaccine induces an immune response to both the Victoria and Yamagata lineages after administration.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains reassortant B/USSR/60/69-based vaccine influenza viruses from the Victoria and Yamagata lineages.",
      "The Fluzone intradermal quadrivalent vaccine is a quadrivalent live attenuated influenza vaccine (qLAIV).",
      "The vaccine is considered safe and reactogenic in adult volunteers according to Document-0.",
      "The vaccine induces an immune response to both the Victoria and Yamagata lineages after administration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine is an inactivated vaccine, not a live attenuated influenza vaccine (qLAIV).\n3. UNKNOWN (as Document-0 is not provided)\n4. TRUE (assuming the statement is based on standard expectations for a quadrivalent influenza vaccine)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus is rs5754217 (UBE2L3).",
    "llama-2-7b-chat-hf_fact_raw": "1. The part of the TNFR2 gene associated with Systemic Lupus Erythematosus is indicated as rs5754217.\n2. The gene UBE2L3 is connected with the genetic association of rs5754217 in Systemic Lupus Erythematosus.",
    "llama-2-7b-chat-hf_fact": [
      "The part of the TNFR2 gene associated with Systemic Lupus Erythematosus is indicated as rs5754217.",
      "The gene UBE2L3 is connected with the genetic association of rs5754217 in Systemic Lupus Erythematosus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The gene associated with the genetic marker rs5754217 in Systemic Lupus Erythematosus is TNFAIP3, not UBE2L3. UBE2L3 is associated with another genetic marker for the disease.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is currently no vaccine available for peanut allergy. The document states that oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) are two approaches that have been studied for their potential to induce desensitization and tolerance to peanuts in individuals with peanut allergy. However, the safety of these approaches is still uncertain, and more research is needed to determine if the potential benefits outweigh the risks.\nThe document does not mention any vaccine for peanut allergy, and the focus of the study is on evaluating the efficacy and safety of OIT and SLIT. While the study shows a statistically significant benefit of peanut immunotherapy in patients with peanut allergy, the findings are based on a small number of randomized controlled trials and more research is needed to confirm these results and establish the safety and efficacy of peanut immunotherapy.\nTherefore, based on the information provided in the document, there is currently no vaccine available for peanut allergy, and further research is needed to determine the safety and efficacy of immunotherapy approaches for this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. Oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) are approaches being studied to treat peanut allergies.\n3. The safety of OIT and SLIT for peanut allergies is still uncertain.\n4. More research is needed to confirm the efficacy and establish the safety of peanut immunotherapy.\n5. The findings regarding the benefit of peanut immunotherapy are based on a small number of randomized controlled trials.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "Oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) are approaches being studied to treat peanut allergies.",
      "The safety of OIT and SLIT for peanut allergies is still uncertain.",
      "More research is needed to confirm the efficacy and establish the safety of peanut immunotherapy.",
      "The findings regarding the benefit of peanut immunotherapy are based on a small number of randomized controlled trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff date in 2023, a vaccine called Palforzia has been approved by the FDA for the treatment of peanut allergies in children.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mouse Fxy gene is located on the distal portion of the short arm of the Y chromosome. Specifically, it is located at p12-p13 on the short arm of the Y chromosome in mice.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the Y chromosome.\n2. It is situated on the distal portion of the short arm of the Y chromosome in mice.\n3. The specific chromosomal position of the mouse Fxy gene is at p12-p13.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the Y chromosome.",
      "It is situated on the distal portion of the short arm of the Y chromosome in mice.",
      "The specific chromosomal position of the mouse Fxy gene is at p12-p13."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse Fxy gene is located on the X chromosome, not the Y chromosome.\n2. UNKNOWN\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of N-methylimidazolium modified magnetic particles (MIm-MPs) for solid phase extraction of genomic DNA from genetically modified soybeans. The positively charged MIm-MPs are able to adsorb negatively charged DNA through strong electrostatic interactions. The DNA is then eluted from the MIm-MPs using phosphate buffer, which has a stronger electrostatic interaction with the MPs than the DNA. The method does not use any harmful reagents such as phenol, chloroform, or isopropanol, and is able to achieve high yields (10.4 μg DNA per 30 mg sample) and high quality (A260/A280=1.82) of DNA. The developed method allows for quick and high quality extraction of DNA templates, as well as fast and high resolution detection of duplex PCR products using a sieving capillary electrophoresis method.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) uses N-methylimidazolium modified magnetic particles (MIm-MPs) for solid phase extraction of DNA.\n2. The MIm-MPs in MPE-seq adsorb negatively charged DNA through electrostatic interactions.\n3. DNA is eluted from the MIm-MPs using a phosphate buffer in the MPE-seq method.\n4. MPE-seq does not utilize harmful reagents like phenol, chloroform, or isopropanol.\n5. MPE-seq achieves high yields of DNA, with 10.4 μg DNA per 30 mg sample, and produces high quality DNA with an A260/A280 ratio of 1.82.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) uses N-methylimidazolium modified magnetic particles (MIm-MPs) for solid phase extraction of DNA.",
      "The MIm-MPs in MPE-seq adsorb negatively charged DNA through electrostatic interactions.",
      "DNA is eluted from the MIm-MPs using a phosphate buffer in the MPE-seq method.",
      "MPE-seq does not utilize harmful reagents like phenol, chloroform, or isopropanol.",
      "MPE-seq achieves high yields of DNA, with 10.4 μg DNA per 30 mg sample, and produces high quality DNA with an A260/A280 ratio of 1.82."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA sequencing (MPE-seq) is not a method for DNA extraction; it actually refers to a DNA footprinting technique that uses the compound methidiumpropyl-EDTA to cleave DNA.\n2. UNKNOWN (due to the first statement being incorrect, this statement pertains to a potentially fictional process and cannot be verified without the correct context)\n3. UNKNOWN (similar to statement 2, the context of the process is based on the incorrect statement 1, making the validity of this statement unclear)\n4. UNKNOWN (again, this is related to the false premise mentioned in statement 1, thus the truthfulness of this statement cannot be ascertained)\n5. UNKNOWN (since the method described is not accurately depicted, the details provided here about yield and quality of DNA cannot be verified)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the programming language used for implementing GWAR is X10.",
    "llama-2-7b-chat-hf_fact_raw": "1. The programming language used for implementing GWAR is X10.",
    "llama-2-7b-chat-hf_fact": [
      "The programming language used for implementing GWAR is X10."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The programming language used for implementing Generalized Watershed Assessment of Erosion Risk (GWAR) is uncertain as the acronym \"GWAR\" is not standard for a specific programming language or application. Without additional context, the programming language cannot be confirmed. If \"GWAR\" is intended to refer to a different, specific concept or system, additional context would be needed for an accurate assessment.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no evidence to suggest that xaliproden (dextromethorphan) improves the prognosis of amyotrophic lateral sclerosis (ALS). In fact, the study found that treatment with dextromethorphan did not result in an improvement in 12-month survival in ALS patients. The study was a randomized, double-blind, placebo-controlled trial in which 45 ALS patients were treated with either dextromethorphan (150 mg daily) or a placebo for 12 months. At the end of the treatment period, the rates of disease progression and survival were similar in both groups, except for a less pronounced rate of decline in the ability scores for the lower extremities in the dextromethorphan group. Therefore, based on the results of this study, it appears that xaliproden is not effective in improving the prognosis of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no evidence to suggest that xaliproden (incorrectly referred to as dextromethorphan in the answer) improves the prognosis of amyotrophic lateral sclerosis (ALS).\n2. A study found that dextromethorphan did not improve 12-month survival in ALS patients.\n3. The study mentioned was a randomized, double-blind, placebo-controlled trial.\n4. In the study, 45 ALS patients were treated with either dextromethorphan (150 mg daily) or a placebo for 12 months.\n5. At the end of the treatment period, there was a less pronounced rate of decline in the ability scores for the lower extremities in the dextromethorphan group.",
    "llama-2-7b-chat-hf_fact": [
      "There is no evidence to suggest that xaliproden (incorrectly referred to as dextromethorphan in the answer) improves the prognosis of amyotrophic lateral sclerosis (ALS).",
      "A study found that dextromethorphan did not improve 12-month survival in ALS patients.",
      "The study mentioned was a randomized, double-blind, placebo-controlled trial.",
      "In the study, 45 ALS patients were treated with either dextromethorphan (150 mg daily) or a placebo for 12 months.",
      "At the end of the treatment period, there was a less pronounced rate of decline in the ability scores for the lower extremities in the dextromethorphan group."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: It is possible that xaliproden is the drug in question and not dextromethorphan.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement seems to suggest that xaliproden, rather than dextromethorphan, should be the drug associated with the ALS prognosis study, but without additional context or data to clarify this point, statements 2 to 5 are difficult to verify and are thus marked as unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the transgenes in the LiPS-A3S line are inserted into chromosome 1. The document states that the introduction of transgenes in Dictyostelium discoideum typically results in the integration of the transformation vector into the genome at one or a few insertion sites as tandem arrays of approximately 100 copies. However, exceptions exist, such as extrachromosomal vectors that do not integrate into chromosomes, and vectors containing resistance markers such as blasticidin, which integrate as single copies at one or a few sites.\nIn the case of the LiPS-A3S line, the transgenes are inserted into chromosome 1, as indicated by the statement that \"low copy number vector inserts display typical euchromatic features while high copy number insertions are enriched for modifications associate with heterochromatin.\" This suggests that the transgenes in the LiPS-A3S line are integrated into the chromosome at multiple sites, with the higher copy number insertions showing characteristics of heterochromatin.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line has transgenes inserted into chromosome 1.\n2. In Dictyostelium discoideum, transgenes typically integrate into the genome as tandem arrays of approximately 100 copies.\n3. Transgenes in Dictyostelium discoideum can also integrate as single copies if vectors with resistance markers are used.\n4. Vectors containing blasticidin resistance markers integrate into the genome as single copies at one or a few sites.\n5. High copy number insertions of transgenes display features associated with heterochromatin.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line has transgenes inserted into chromosome 1.",
      "In Dictyostelium discoideum, transgenes typically integrate into the genome as tandem arrays of approximately 100 copies.",
      "Transgenes in Dictyostelium discoideum can also integrate as single copies if vectors with resistance markers are used.",
      "Vectors containing blasticidin resistance markers integrate into the genome as single copies at one or a few sites.",
      "High copy number insertions of transgenes display features associated with heterochromatin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout specific knowledge of the LiPS-A3S line or the particular details of its construction, it isn't possible to confirm or deny the statement about transgenes being inserted into chromosome 1 of that line. However, the other statements regarding Dictyostelium discoideum's typical transgene integration patterns, use of resistance markers for single-copy integration, and the behavior of high copy number insertions align with general knowledge on genetic engineering in this organism. If the given statements are taken from a reputable source discussing these topics, they are likely accurate.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several deep learning tools that can be used for predicting drug synergy:\n1. HNMDRP (Heterogeneous Network-based Drug Response Prediction): This is a novel method proposed in the study that incorporates heterogeneity relationships among cell lines, drugs, and targets to predict drug responses. The tool can be found at <https://github.com/USTC-HIlab/HNMDRP>.\n2. DeepDrug: This is a deep learning framework for predicting drug responses based on genomic, chemical, and clinical data. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug responses. The tool can be found at <https://github.com/BroadInstitute/DeepDrug>.\n3. DrugNet: This is a deep learning tool for predicting drug-target interactions and drug responses. It uses a graph convolutional neural network (GCNN) to predict drug-target interactions and a multi-task learning framework to predict drug responses. The tool can be found at <https://github.com/BioUber/DrugNet>.\n4. Drug2Drug: This is a deep learning tool for predicting drug-drug interactions and predicting drug responses. It uses a combination of CNNs and RNNs to predict drug-drug interactions and a multi-task learning framework to predict drug responses. The tool can be found at <https://github.com/BioUber/Drug2Drug>.\n5. DRUG-ML: This is a deep learning tool for predicting drug responses based on genomic, chemical, and clinical data. It uses a combination of CNNs and RNNs to predict drug responses and can handle complex relationships between drug targets and drug responses. The tool can be found at <https://github.com/BroadInstitute/DRUG-ML>.\nThese are just a few examples of the many deep learning tools available for predicting drug synergy. It's important to evaluate each tool based on the specific needs of the problem you are trying to solve and the data you have available.",
    "llama-2-7b-chat-hf_fact_raw": "1. HNMDRP (Heterogeneous Network-based Drug Response Prediction) is a method that uses heterogeneity relationships among cell lines, drugs, and targets to predict drug responses.\n2. DeepDrug is a deep learning framework that predicts drug responses using genomic, chemical, and clinical data with CNNs and RNNs.\n3. DrugNet is a tool that uses a graph convolutional neural network to predict drug-target interactions and a multi-task learning framework to predict drug responses.\n4. Drug2Drug predicts drug-drug interactions and drug responses using a combination of CNNs and RNNs and a multi-task learning framework.\n5. DRUG-ML is a deep learning tool that predicts drug responses based on genomic, chemical, and clinical data, combining CNNs and RNNs to handle complex relationships.",
    "llama-2-7b-chat-hf_fact": [
      "HNMDRP (Heterogeneous Network-based Drug Response Prediction) is a method that uses heterogeneity relationships among cell lines, drugs, and targets to predict drug responses.",
      "DeepDrug is a deep learning framework that predicts drug responses using genomic, chemical, and clinical data with CNNs and RNNs.",
      "DrugNet is a tool that uses a graph convolutional neural network to predict drug-target interactions and a multi-task learning framework to predict drug responses.",
      "Drug2Drug predicts drug-drug interactions and drug responses using a combination of CNNs and RNNs and a multi-task learning framework.",
      "DRUG-ML is a deep learning tool that predicts drug responses based on genomic, chemical, and clinical data, combining CNNs and RNNs to handle complex relationships."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Drug2Drug predicts drug-drug interactions using a combination of CNNs and RNNs and a multi-task learning framework; it does not predict drug responses.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the cloud-based platform that has been developed for comparing GWAS (Genome-Wide Association Studies) is G-CIEMS (Grid-Catchment Integrated Environmental Modeling System). G-CIEMS is a geographical information system (GIS) based platform that allows for the comparison of GWAS results with environmental data, such as air and water quality, to better understand the potential environmental factors that may be contributing to the observed genetic variations. The platform uses a spatially resolved and geo-referenced dynamic multimedia environmental fate model to simulate the distribution of chemicals in the environment, and can provide explicit information on the distribution of chemicals in the environment. The document highlights the advantages of using G-CIEMS, including its ability to provide more accurate exposure estimation with distribution information, using generally available data sources for a wide range of chemicals.",
    "llama-2-7b-chat-hf_fact_raw": "1. G-CIEMS (Grid-Catchment Integrated Environmental Modeling System) is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).\n2. G-CIEMS is a geographical information system (GIS) based platform.\n3. The platform allows for the comparison of GWAS results with environmental data.\n4. G-CIEMS uses a spatially resolved and geo-referenced dynamic multimedia environmental fate model.\n5. G-CIEMS can simulate the distribution of chemicals in the environment.",
    "llama-2-7b-chat-hf_fact": [
      "G-CIEMS (Grid-Catchment Integrated Environmental Modeling System) is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).",
      "G-CIEMS is a geographical information system (GIS) based platform.",
      "The platform allows for the comparison of GWAS results with environmental data.",
      "G-CIEMS uses a spatially resolved and geo-referenced dynamic multimedia environmental fate model.",
      "G-CIEMS can simulate the distribution of chemicals in the environment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: G-CIEMS (Grid-Catchment Integrated Environmental Modeling System) is a platform developed for simulating the distribution and fate of chemicals in the environment, not for comparing Genome-Wide Association Studies (GWAS).\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it appears that CMB305 (a five-drug regimen consisting of adriamycin, T.I.C.-mustard, and methotrexate) has been used in the chemotherapeutic management of sarcomas, specifically leiomyosarcoma and fibrosarcoma. However, the document does not provide any definitive answer to whether CMB305 is effective against sarcomas or not.\nThe document mentions that remissions were achieved with each of the three regimens used in the study (methotrexate alone, five-drug regimen, and adriamycin, T.I.C.-mustard, and methotrexate), but does not provide any information on the response rates or the duration of remissions. It also suggests that sensitivity to drugs should be assessed earlier in the disease and proposes a randomized study of methotrexate versus combination chemotherapy in particular sarcoma subgroups, such as leiomyosarcoma and fibrosarcoma.\nTherefore, based on the information provided in Document-0, it is unclear whether CMB305 is effective against sarcomas, and further research is needed to determine its efficacy in this context.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a chemotherapeutic regimen that includes adriamycin, T.I.C.-mustard, and methotrexate.\n2. CMB305 has been used in the management of leiomyosarcoma and fibrosarcoma.\n3. Document-0 mentions that remissions were achieved with the use of CMB305.\n4. The document suggests that sensitivity to drugs should be assessed earlier in the disease for sarcomas.\n5. There is a proposal for a randomized study of methotrexate versus combination chemotherapy in sarcoma subgroups such as leiomyosarcoma and fibrosarcoma.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a chemotherapeutic regimen that includes adriamycin, T.I.C.-mustard, and methotrexate.",
      "CMB305 has been used in the management of leiomyosarcoma and fibrosarcoma.",
      "Document-0 mentions that remissions were achieved with the use of CMB305.",
      "The document suggests that sensitivity to drugs should be assessed earlier in the disease for sarcomas.",
      "There is a proposal for a randomized study of methotrexate versus combination chemotherapy in sarcoma subgroups such as leiomyosarcoma and fibrosarcoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific details of CMB305, its composition, the medical context in which it's used, the outcomes it has yielded in clinical practice, and the contents of \"Document-0,\" it's not possible to confirm the accuracy of these statements. Additionally, the statement regarding a proposal for a randomized study would require access to the research plans or literature to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the manifestations of the Saint's Triad are:\n1. Low energy availability: This can lead to a range of symptoms, including fatigue, weakness, and decreased athletic performance.\n2. Menstrual dysfunction: This can include irregular or absent menstrual periods, as well as symptoms such as cramping, bloating, and mood changes.\n3. Low bone mineral density: This can increase the risk of osteoporosis and fractures, and can be detected through bone density tests.\nIt is important to note that these manifestations are interrelated and can have a cumulative impact on an athlete's health. Early detection and management of the Saint's Triad is crucial to preventing serious long-term negative health outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. One manifestation of the Saint's Triad is low energy availability, which may result in fatigue, weakness, and decreased athletic performance.\n2. Menstrual dysfunction, including irregular or absent menstrual periods, is a manifestation of the Saint's Triad.\n3. Low bone mineral density, which can increase the risk of osteoporosis and fractures, is part of the Saint's Triad.\n4. The manifestations of the Saint's Triad are interrelated and can affect an athlete's health cumulatively.\n5. Early detection and management of the Saint's Triad is essential to prevent serious long-term negative health outcomes.",
    "llama-2-7b-chat-hf_fact": [
      "One manifestation of the Saint's Triad is low energy availability, which may result in fatigue, weakness, and decreased athletic performance.",
      "Menstrual dysfunction, including irregular or absent menstrual periods, is a manifestation of the Saint's Triad.",
      "Low bone mineral density, which can increase the risk of osteoporosis and fractures, is part of the Saint's Triad.",
      "The manifestations of the Saint's Triad are interrelated and can affect an athlete's health cumulatively.",
      "Early detection and management of the Saint's Triad is essential to prevent serious long-term negative health outcomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct term is the \"Female Athlete Triad,\" not the \"Saint's Triad.\"\n2. FALSE [correction]: It is called the \"Female Athlete Triad,\" not the \"Saint's Triad,\" but menstrual dysfunction is indeed one of its manifestations.\n3. FALSE [correction]: It is part of the \"Female Athlete Triad,\" not the \"Saint's Triad,\" and low bone mineral density is indeed a component of it.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, overexpression of LY6K is associated with a better prognosis for non-small cell lung cancer patients.\nThe document states that cyclin D1 overexpression in non-small cell lung cancer specimens correlates with short-term patient survival and may have prognostic relevance. The study found that 50% of the specimens had cyclin D1 overexpression, and this was associated with a significant difference in mean survival time and five-year survival rate compared to specimens without overexpression. There was no significant correlation between cyclin D1 overexpression and histological grading, tumor stage or TNM status.\nTherefore, based on the information provided in the document, it can be concluded that overexpression of LY6K (cyclin D1) in non-small cell lung cancer is associated with a better prognosis for patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with a better prognosis for non-small cell lung cancer patients.\n2. Cyclin D1 overexpression in non-small cell lung cancer specimens correlates with short-term patient survival.\n3. 50% of non-small cell lung cancer specimens had cyclin D1 overexpression.\n4. There was a significant difference in mean survival time and five-year survival rate for patients whose non-small cell lung cancer specimens had cyclin D1 overexpression compared to those without.\n5. There was no significant correlation between cyclin D1 overexpression and histological grading, tumor stage, or TNM status in non-small cell lung cancer patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with a better prognosis for non-small cell lung cancer patients.",
      "Cyclin D1 overexpression in non-small cell lung cancer specimens correlates with short-term patient survival.",
      "50% of non-small cell lung cancer specimens had cyclin D1 overexpression.",
      "There was a significant difference in mean survival time and five-year survival rate for patients whose non-small cell lung cancer specimens had cyclin D1 overexpression compared to those without.",
      "There was no significant correlation between cyclin D1 overexpression and histological grading, tumor stage, or TNM status in non-small cell lung cancer patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is typically associated with a poor prognosis for non-small cell lung cancer patients.\n2. TRUE\n3. UNKNOWN (Insufficient data provided to assess the correctness of the percentage)\n4. TRUE (This appears consistent with the notion that overexpression of Cyclin D1 correlates with a worse prognosis, implying a significant difference in survival outcomes)\n5. UNKNOWN (While the statement may be true, without context from the specific study or source, the correlation cannot be determined as definitively true or false)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following CDK targets are dephosphorylated during cytokinesis:\n1. Eco1: DDK phosphorylates Eco1, creating a phosphodegron that is recognized by the ubiquitin ligase SCFCdc4.\n2. Mcm2-7 replicative helicase: DDK phosphorylates the Mcm2-7 replicative helicase, initiating DNA replication.\n3. Cohesin acetyltransferase Eco1: DDK phosphorylates Eco1, leading to its degradation.\nIt is worth noting that the timing of Eco1 phosphorylation and potentially that of other DDK substrates is determined in part by sequestration of DDK at unfired replication origins during S phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. CDK phosphorylates the protein Eco1 during cytokinesis.\n2. DDK phosphorylation creates a phosphodegron on Eco1 that is recognized by the ubiquitin ligase SCFCdc4.\n3. The Mcm2-7 replicative helicase is phosphorylated by DDK, which is associated with the initiation of DNA replication.\n4. Phosphorylation of Eco1 by DDK leads to its degradation.\n5. The timing of Eco1 phosphorylation and potentially that of other DDK substrates is influenced by the sequestration of DDK at unfired replication origins during the S phase.",
    "llama-2-7b-chat-hf_fact": [
      "CDK phosphorylates the protein Eco1 during cytokinesis.",
      "DDK phosphorylation creates a phosphodegron on Eco1 that is recognized by the ubiquitin ligase SCFCdc4.",
      "The Mcm2-7 replicative helicase is phosphorylated by DDK, which is associated with the initiation of DNA replication.",
      "Phosphorylation of Eco1 by DDK leads to its degradation.",
      "The timing of Eco1 phosphorylation and potentially that of other DDK substrates is influenced by the sequestration of DDK at unfired replication origins during the S phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE: The Mcm2-7 replicative helicase is indeed phosphorylated by DDK (Dbf4-dependent kinase), and this phosphorylation event is associated with the initiation of DNA replication.\n4. FALSE [correction]: It is CDK (Cyclin-dependent kinase), not DDK, that phosphorylates Eco1 leading to its recognition by SCFCdc4 and subsequent degradation.\n5. TRUE: The timing of Eco1 phosphorylation and potentially that of other DDK substrates can indeed be influenced by sequestration of DDK at unfired replication origins during S phase, as this dictates the availability of DDK to other substrates during the cell cycle.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Xanamem appears to be a compound that is derived from the biosynthesis of Xiamycin A (XMA) and oxiamycin (OXM) by a marine-derived Streptomyces sp. The biosynthetic gene cluster for XMA/OXM was identified through partial genome sequencing, and 18 genes were proposed to be involved in the biosynthesis of these compounds. The xia gene cluster was targeted for disruption to probe the encoded functions in XMA/OXM biosynthesis, and the disruption of xiaK, which encodes an aromatic ring hydroxylase, led to the production of indosespene and a minor amount of XMA. Feeding indosespene to XMA/OXM nonproducing mutants revealed indosespene as a common precursor for XMA/OXM biosynthesis. Additionally, the flavin-dependent oxygenase XiaI was biochemically characterized in vitro to convert indosespene to XMA, revealing an unusual oxidative cyclization strategy tailoring indolosesquiterpene biosynthesis. Therefore, Xanamem can be inferred to be a compound that is derived from the biosynthesis of XMA and OXM, and its biosynthesis involves a complex interplay of genes and enzymes involved in terpene synthesis, oxidoreductases, and regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is derived from the biosynthesis of Xiamycin A (XMA) and oxiamycin (OXM).\n2. The biosynthetic gene cluster for XMA/OXM was identified through partial genome sequencing.\n3. A total of 18 genes were proposed to be involved in the biosynthesis of XMA and OXM.\n4. The disruption of the gene xiaK in the biosynthetic pathway led to the production of indosespene and Xiamycin A (XMA).\n5. XiaI is a flavin-dependent oxygenase that was biochemically characterized to convert indosespene to Xiamycin A (XMA).",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is derived from the biosynthesis of Xiamycin A (XMA) and oxiamycin (OXM).",
      "The biosynthetic gene cluster for XMA/OXM was identified through partial genome sequencing.",
      "A total of 18 genes were proposed to be involved in the biosynthesis of XMA and OXM.",
      "The disruption of the gene xiaK in the biosynthetic pathway led to the production of indosespene and Xiamycin A (XMA).",
      "XiaI is a flavin-dependent oxygenase that was biochemically characterized to convert indosespene to Xiamycin A (XMA)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The disruption of the gene xiaK in the biosynthetic pathway led to the halt in the production of indosespene and Xiamycin A (XMA), not to their production.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the Hof1-Cyk3 interaction in yeast is to facilitate cytokinesis through the recruitment of Hof1 to the bud neck. The interaction between Hof1 and Cyk3 is critical for cytokinesis, as the Vrp1 fragment unable to interact with yeast WASP (Las17/Bee1) retains function in Hof1 recruitment but not in polarization of the cortical actin cytoskeleton. The Vrp1 HOT domain, which consists of three tandem proline-rich motifs flanked by serines, binds to the Hof1 SH3 domain and counteracts its inhibitory effect on cytokinesis. Therefore, the Hof1-Cyk3 interaction plays a crucial role in the proper execution of cytokinesis in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction facilitates cytokinesis in yeast through the recruitment of Hof1 to the bud neck.\n2. The interaction between Hof1 and Cyk3 is critical for the process of cytokinesis.\n3. The Vrp1 fragment that cannot interact with yeast WASP (Las17/Bee1) can still function in Hof1 recruitment but not in the polarization of the cortical actin cytoskeleton.\n4. The Vrp1 HOT domain binds to the Hof1 SH3 domain.\n5. The Hof1 SH3 domain has an inhibitory effect on cytokinesis that is counteracted by the Vrp1 HOT domain.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction facilitates cytokinesis in yeast through the recruitment of Hof1 to the bud neck.",
      "The interaction between Hof1 and Cyk3 is critical for the process of cytokinesis.",
      "The Vrp1 fragment that cannot interact with yeast WASP (Las17/Bee1) can still function in Hof1 recruitment but not in the polarization of the cortical actin cytoskeleton.",
      "The Vrp1 HOT domain binds to the Hof1 SH3 domain.",
      "The Hof1 SH3 domain has an inhibitory effect on cytokinesis that is counteracted by the Vrp1 HOT domain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Hof1 SH3 domain does not have an inhibitory effect on cytokinesis; it is typically involved in protein-protein interactions that facilitate processes like cytokinesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in gastric cancer:\n1. HLA-A02 and/or -A24 alleles: These are the HLA alleles that were found to be present in the majority of the patients with gastric adenocarcinoma in the study. HLA alleles are responsible for presenting antigens to T cells, and the presence of these alleles in patients with gastric cancer suggests that T cells may play a role in the immune response to the disease.\n2. Gastric cancer antigens: The study found that a specific type-1 T cell response to gastric cancer antigens was detectable in 17 out of 20 patients with gastric adenocarcinoma. This suggests that T cells may recognize and respond to specific antigens present on gastric cancer cells.\n3. Cancer peptides: The study found that most of the cancer peptide-specific T cells expressed a Th1/Tc1 profile and cytotoxic activity against target cells. This suggests that T cells may recognize and respond to specific peptides present on gastric cancer cells.\nOverall, the study suggests that T cells may play a role in the immune response to gastric cancer, and that specific TCRs may be involved in recognizing and responding to gastric cancer antigens. However, the study also suggests that the activity and number of cancer peptide-specific Th1/Tc1 cells may need to be enhanced through vaccination or other means in order to effectively combat gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the passage, the Lupus Severity Index (LSI) refers to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). The SLEDAI is the most commonly used measure of disease activity for children with systemic lupus erythematosus (SLE), and it is used to assess the severity of disease activity over time. However, the passage highlights a limitation of the SLEDAI in capturing the severity of headaches, which are a common symptom of SLE in children. Specifically, the passage notes that only 6% of all headache episodes were treated with narcotics and thus considered for the measurement of disease activity in the SLEDAI. This suggests that the SLEDAI may not accurately capture the severity of headaches in children with SLE, which could impact the overall estimation of disease activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) refers to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).\n2. The SLEDAI is used to measure disease activity for children with systemic lupus erythematosus (SLE).\n3. The SLEDAI assesses the severity of disease activity over time.\n4. Headaches are a common symptom of systemic lupus erythematosus (SLE) in children.\n5. Only 6% of headache episodes treated with narcotics are considered in the SLEDAI for the measurement of disease activity.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) refers to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).",
      "The SLEDAI is used to measure disease activity for children with systemic lupus erythematosus (SLE).",
      "The SLEDAI assesses the severity of disease activity over time.",
      "Headaches are a common symptom of systemic lupus erythematosus (SLE) in children.",
      "Only 6% of headache episodes treated with narcotics are considered in the SLEDAI for the measurement of disease activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Lupus Severity Index (LSI) is not equivalent to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). They are different tools used for measuring disease activity in SLE patients.\n2. TRUE\n3. TRUE: The SLEDAI can be used to assess the severity of disease activity over time in patients with SLE.\n4. TRUE: Headaches can be a symptom of systemic lupus erythematosus (SLE), although they are not specific to the disease and can be caused by other conditions as well.\n5. FALSE [correction]: The statement regarding exactly 6% of headache episodes treated with narcotics being considered in the SLEDAI is too specific without additional context or validation. The SLEDAI scores specific clinical manifestations and laboratory results; it does not quantify the percentage of headache episodes treated in a particular way.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, de novo mutations in ZSWIM6 can cause Mowat-Wilson syndrome (MWS). Specifically, nonsense mutations, frameshift mutations, and deletions in ZEB2 at 2q22 can lead to MWS. The ZEB2 protein, consisting of 1,214 amino acids, is encoded by ZSWIM6. The document reports 13 nonsense and 27 frameshift mutations in ZEB2 from 40 newly identified MWS patients in Japan, and finds that the frequencies of microcephaly, Hirschsprung disease, and urogenital/renal anomalies are lower than previously reported in other studies. The study also demonstrates that the cellular level of the longest form of the mutant ZEB2 protein is remarkably low, suggesting that the 3'-end frameshift mutation of ZEB2 causes MWS due to ZEB2 instability. Therefore, de novo mutations in ZSWIM6 can cause MWS, and the specific mutations in ZEB2 can lead to the development of this syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 can cause Mowat-Wilson syndrome (MWS).\n2. Nonsense mutations, frameshift mutations, and deletions in ZEB2 at 2q22 can lead to Mowat-Wilson syndrome.\n3. The ZEB2 protein is encoded by ZSWIM6 and consists of 1,214 amino acids.\n4. A study identified 13 nonsense and 27 frameshift mutations in ZEB2 among 40 newly identified Mowat-Wilson syndrome patients in Japan.\n5. The study reported lower frequencies of microcephaly, Hirschsprung disease, and urogenital/renal anomalies in Japanese MWS patients compared to previous reports.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 can cause Mowat-Wilson syndrome (MWS).",
      "Nonsense mutations, frameshift mutations, and deletions in ZEB2 at 2q22 can lead to Mowat-Wilson syndrome.",
      "The ZEB2 protein is encoded by ZSWIM6 and consists of 1,214 amino acids.",
      "A study identified 13 nonsense and 27 frameshift mutations in ZEB2 among 40 newly identified Mowat-Wilson syndrome patients in Japan.",
      "The study reported lower frequencies of microcephaly, Hirschsprung disease, and urogenital/renal anomalies in Japanese MWS patients compared to previous reports."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in ZEB2, not ZSWIM6, can cause Mowat-Wilson Syndrome (MWS).\n2. TRUE\n3. FALSE [correction]: The ZEB2 protein is not encoded by ZSWIM6; it is encoded by the ZEB2 gene and consists of 1,214 amino acids.\n4. UNKNOWN (Without access to the specific study, the details about the number and types of mutations found in Japanese MWS patients cannot be confirmed.)\n5. UNKNOWN (Similarly, without the specific study, data regarding the frequency of symptoms in Japanese MWS patients cannot be confirmed.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS). The article discusses the correlation between the various Koos grades of VS and their respective tumor volumes, and suggests that VS Koos Grade IV tumors are limited in size because all of the patients in the study were eligible for radiosurgery. The article also introduces an additional VS Grade V for large VS with tumor volumes greater than 6 cubic centimeters that may not be eligible for radiosurgery. Therefore, the answer to the user's question is: VS.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify vestibular schwannoma (VS).\n2. The article suggests a correlation between Koos grades of VS and their respective tumor volumes.\n3. Vestibular schwannoma (VS) Koos Grade IV tumors are limited in size.\n4. All patients with Koos Grade IV tumors in the study were eligible for radiosurgery.\n5. An additional VS Grade V is introduced for large vestibular schwannomas with tumor volumes greater than 6 cubic centimeters that may not be eligible for radiosurgery.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify vestibular schwannoma (VS).",
      "The article suggests a correlation between Koos grades of VS and their respective tumor volumes.",
      "Vestibular schwannoma (VS) Koos Grade IV tumors are limited in size.",
      "All patients with Koos Grade IV tumors in the study were eligible for radiosurgery.",
      "An additional VS Grade V is introduced for large vestibular schwannomas with tumor volumes greater than 6 cubic centimeters that may not be eligible for radiosurgery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Vestibular schwannoma (VS) Koos Grade IV tumors are not limited in size; they are the largest tumors in the classification, often involving brain structures beyond the internal auditory canal.\n4. UNKNOWN\n5. FALSE [correction]: The Koos Classification system only has four grades (I-IV) for vestibular schwannoma; there is no Grade V in the Koos Classification system.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the in vivo effects of AZD8601 (a MEK1/2 inhibitor) are as follows:\n1. Inhibition of ERK1/2 phosphorylation: AZD8601 completely inhibited ERK1/2 phosphorylation in vivo, as demonstrated by immunoblotting analysis.\n2. Limited activity against tumor xenografts: AZD8601 had limited activity against the tumor xenografts tested in vivo, with only BT-40 xenografts (harboring constitutively activated BRAF) showing significant sensitivity to the drug.\n3. No objective responses: There were no objective responses observed in any of the tumor xenograft models tested.\nOverall, the document suggests that AZD8601 has limited activity against solid tumors in vivo, but may be more effective against BRAF-mutated tumors. However, further studies are needed to confirm these findings and to determine the optimal dosing and scheduling regimen for AZD8601 in clinical settings.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a MEK1/2 inhibitor.\n2. AZD8601 completely inhibited ERK1/2 phosphorylation in vivo, as shown by immunoblotting analysis.\n3. AZD8601 had limited activity against the tumor xenografts tested, except BT-40 xenografts with activated BRAF mutation, where it showed significant sensitivity.\n4. No objective responses were observed in the tumor xenograft models tested with AZD8601.\n5. AZD8601 may be more effective against BRAF-mutated tumors.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a MEK1/2 inhibitor.",
      "AZD8601 completely inhibited ERK1/2 phosphorylation in vivo, as shown by immunoblotting analysis.",
      "AZD8601 had limited activity against the tumor xenografts tested, except BT-40 xenografts with activated BRAF mutation, where it showed significant sensitivity.",
      "No objective responses were observed in the tumor xenograft models tested with AZD8601.",
      "AZD8601 may be more effective against BRAF-mutated tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a MEK1/2 inhibitor; instead, it is an investigational mRNA-based therapy designed to produce vascular endothelial growth factor A (VEGF-A) for regenerative medicine.\n2. UNKNOWN (Without a clear passage or reference, it is impossible to confirm or deny whether AZD8601 inhibited ERK1/2 phosphorylation in vivo without the specific context or study results.)\n3. UNKNOWN (Again, without additional context or data, the activity of AZD8601 against tumor xenografts and specifically the BT-40 xenografts cannot be assessed.)\n4. UNKNOWN (Without proper context or research data, we cannot ascertain the objective responses in tumor xenograft models treated with AZD8601.)\n5. UNKNOWN (As AZD8601 is not a MEK1/2 inhibitor and the previous statements are unclear or incorrect, the efficacy of AZD8601 against BRAF-mutated tumors cannot be determined without specific data or a relevant study.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, SAHFS (Subarachnoid Haemorrhage-related Out-of-Hospital Cardiac Arrests) are created due to the rupture of blood vessels in the brain, leading to bleeding in the subarachnoid space. This can occur due to various reasons such as head injury, aneurysm rupture, or other causes.\nThe article suggests that the mechanisms of circulatory collapse in patients with subarachnoid haemorrhage (SAH) are not well understood, but it is known that these patients can experience sudden collapse, witnessed by others, and may have an initial cardiac rhythm of asystole or pulseless electrical activity. Despite resuscitation efforts, the patients may not survive to hospital discharge.\nThe article also highlights that the frequency of SAH in patients with all causes of out-of-hospital cardiac arrest (OHCA) is about 6%, and in resuscitated patients, it is about 15%. The article also notes that the initial cardiac rhythm revealed no ventricular fibrillation (VF) even though half of the patients had a witnessed arrest.\nIn summary, SAHFS are created due to the rupture of blood vessels in the brain, leading to bleeding in the subarachnoid space. The mechanisms of circulatory collapse in these patients are not well understood, and despite resuscitation efforts, the patients may not survive to hospital discharge.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS are caused by the rupture of blood vessels in the brain, leading to bleeding in the subarachnoid space.\n2. The rupture can occur due to reasons such as head injury or aneurysm rupture.\n3. Patients with subarachnoid haemorrhage can experience sudden collapse and may have an initial cardiac rhythm of asystole or pulseless electrical activity.\n4. The frequency of SAH among all causes of out-of-hospital cardiac arrest is approximately 6%.\n5. In resuscitated patients, the frequency of SAH is about 15%.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS are caused by the rupture of blood vessels in the brain, leading to bleeding in the subarachnoid space.",
      "The rupture can occur due to reasons such as head injury or aneurysm rupture.",
      "Patients with subarachnoid haemorrhage can experience sudden collapse and may have an initial cardiac rhythm of asystole or pulseless electrical activity.",
      "The frequency of SAH among all causes of out-of-hospital cardiac arrest is approximately 6%.",
      "In resuscitated patients, the frequency of SAH is about 15%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Subarachnoid hemorrhage (SAH) occurs when there is bleeding into the subarachnoid space—the area between the arachnoid membrane and the pia mater surrounding the brain, which can be caused by the rupture of blood vessels in the brain.\n2. TRUE: The rupture leading to SAH can indeed occur for various reasons, with trauma (head injury) and aneurysm rupture being two common causes.\n3. TRUE: Patients with a subarachnoid hemorrhage may experience a sudden collapse, and it is possible for them to have an initial cardiac rhythm of asystole (no heartbeat) or pulseless electrical activity (organized electrical activity without a pulse).\n4. UNKNOWN: The specific frequency of SAH among all causes of out-of-hospital cardiac arrest (OHCA) can vary depending on the study and population, and the given percentage is a very specific figure that requires data to either confirm or correct. Without the specific dataset or source, the veracity of the 6% figure cannot be determined.\n5. UNKNOWN: Similar to Statement 4, the frequency of SAH in resuscitated patients after OHCA would require specific data for confirmation. The percentage provided is very specific and cannot be confirmed without the appropriate source.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the PDZ domain in SATB1 is not directly mentioned. However, since SATB1 is a protein that contains a PDZ domain, it is likely that it also functions as a protein interaction domain, binding to the carboxy-terminal amino acids of binding partners, heterodimerizing with other PDZ domains, and binding phosphoinositides, similar to other PDZ domain-containing proteins.\nThe document focuses on the function of the PDZ domain-containing protein LNX1, which is a RING domain-containing E3 ubiquitin ligase that functions as a scaffold for a multi-protein complex. The study identifies direct binding partners of LNX1 using a human protein array and bioinformatic analysis, and identifies six novel LNX1 binding partners, including KCNA4, PAK6, PLEKHG5, PKC-alpha1, TYK2, and PBK.\nTherefore, based on the information provided in the document, it can be inferred that the PDZ domain in SATB1, like other PDZ domain-containing proteins, is involved in protein interaction and clustering of transmembrane proteins, and may play a role in signaling pathways, although the specific function of the PDZ domain in SATB1 is not directly addressed in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. SATB1 contains a PDZ domain.\n2. PDZ domains typically function as protein interaction domains.\n3. PDZ domains often bind to the carboxy-terminal amino acids of their binding partners.\n4. LNX1, a protein that contains a PDZ domain, is a RING domain-containing E3 ubiquitin ligase.\n5. The study identified six novel LNX1 binding partners, including KCNA4, PAK6, PLEKHG5, PKC-alpha1, TYK2, and PBK.",
    "llama-2-7b-chat-hf_fact": [
      "SATB1 contains a PDZ domain.",
      "PDZ domains typically function as protein interaction domains.",
      "PDZ domains often bind to the carboxy-terminal amino acids of their binding partners.",
      "LNX1, a protein that contains a PDZ domain, is a RING domain-containing E3 ubiquitin ligase.",
      "The study identified six novel LNX1 binding partners, including KCNA4, PAK6, PLEKHG5, PKC-alpha1, TYK2, and PBK."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SATB1 does not contain a PDZ domain; it is known for its homeodomain-like DNA-binding domain.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS technique is based on the principles of yoga, which is a holistic system of liberation that aims to help individuals discriminate between their ego-self and pure consciousness. The BLISS technique is a form of yoga-like therapy that utilizes a variety of special techniques to restore optimal homeostasis in the body and mind. These techniques are not found in other self-regulatory somatopsychic approaches, and they have been shown to be effective in treating a wide range of psychosomatic and psychiatric disorders.\nThe effectiveness of the BLISS technique can be understood in terms of neurophysiological theory, which suggests that yoga practice can influence the brain's neural pathways and promote a state of relaxation and well-being. The technique involves a combination of physical postures, breathing exercises, and meditation, which work together to regulate the body's physiological processes and promote a sense of calm and inner peace.\nIn summary, the BLISS technique is based on the principles of yoga and utilizes a holistic approach to restore optimal homeostasis in the body and mind. Its effectiveness can be understood through the lens of neurophysiological theory, which suggests that yoga practice can have a profound impact on the brain's neural pathways and promote a state of relaxation and well-being.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is based on the principles of yoga.\n2. Yoga is a holistic system that aims to help individuals differentiate between the ego-self and pure consciousness.\n3. The BLISS technique includes unique methods distinct from other self-regulatory somatopsychic approaches.\n4. Techniques involved in the BLISS method include physical postures, breathing exercises, and meditation.\n5. The BLISS technique is designed to influence the brain's neural pathways and promote relaxation and well-being.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is based on the principles of yoga.",
      "Yoga is a holistic system that aims to help individuals differentiate between the ego-self and pure consciousness.",
      "The BLISS technique includes unique methods distinct from other self-regulatory somatopsychic approaches.",
      "Techniques involved in the BLISS method include physical postures, breathing exercises, and meditation.",
      "The BLISS technique is designed to influence the brain's neural pathways and promote relaxation and well-being."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are 3 NK3R antagonists:\n1. Compound 2: Ac-Trp-N(CH3)CH(CH3)Ph with S-configuration at the C-terminus. This compound exhibited pA2 values of 7.0, 4.2, and 4.4 on NK-1, NK-2, and NK-3 sites, respectively.\n2. Compound 1: 3,5-bis(trifluoromethyl)benzyl ester of N-acetyl-L-Tryptophan (IV). This compound was used as a starting point for the study and showed moderate antagonist activity on tachykinin NK-1 receptors.\n3. Compound 9: Z-Trp-N(CH3)CH(CH3)Ph. This compound is an amidic derivative of N-acetyl-L-Tryptophan and showed moderate antagonist activity on tachykinin NK-1 receptors.\nIt is important to note that the activity of these compounds on other receptors or in different tissues may not be the same as their activity on NK3R receptors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Compound 2, described as Ac-Trp-N(CH3)CH(CH3)Ph with S-configuration at the C-terminus, exhibited pA2 values of 7.0 on NK-1, 4.2 on NK-2, and 4.4 on NK-3 sites.\n2. Compound 1 is identified as the 3,5-bis(trifluoromethyl)benzyl ester of N-acetyl-L-Tryptophan (IV) and showed moderate antagonist activity on tachykinin NK-1 receptors.\n3. Compound 9 is described as Z-Trp-N(CH3)CH(CH3)Ph, an amidic derivative of N-acetyl-L-Tryptophan, and displayed moderate antagonist activity on tachykinin NK-1 receptors.",
    "llama-2-7b-chat-hf_fact": [
      "Compound 2, described as Ac-Trp-N(CH3)CH(CH3)Ph with S-configuration at the C-terminus, exhibited pA2 values of 7.0 on NK-1, 4.2 on NK-2, and 4.4 on NK-3 sites.",
      "Compound 1 is identified as the 3,5-bis(trifluoromethyl)benzyl ester of N-acetyl-L-Tryptophan (IV) and showed moderate antagonist activity on tachykinin NK-1 receptors.",
      "Compound 9 is described as Z-Trp-N(CH3)CH(CH3)Ph, an amidic derivative of N-acetyl-L-Tryptophan, and displayed moderate antagonist activity on tachykinin NK-1 receptors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without the proper literature or scientific data, the specific activities of compounds on NK-1, NK-2, and NK-3 sites cannot be confirmed. The pA2 values are specific experimental results that would need to be verified with the appropriate studies.\n2. UNKNOWN: Compound 1 is identified with a specific chemical name and its activity on tachykinin NK-1 receptors; however, without additional information or a reliable source, the veracity of the statement regarding its antagonist activity cannot be ascertained.\n3. UNKNOWN: The description of Compound 9 as an amidic derivative of N-acetyl-L-Tryptophan and its activity on tachykinin NK-1 receptors cannot be verified without further context or scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is K-(d-1-Nal)-FwLL-NH(2).",
    "llama-2-7b-chat-hf_fact_raw": "1. K-(d-1-Nal)-FwLL-NH(2) is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "K-(d-1-Nal)-FwLL-NH(2) is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout further information about the compound K-(d-1-Nal)-FwLL-NH(2) or access to relevant medical or pharmaceutical literature, it is not possible to determine the truthfulness of the statement that it is \"the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\" This is a very specific statement that would require validation from scientific research or clinical trial data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protective efficacy of Vaxchora against moderate to severe cholera is not well established. The study conducted in Lima, Peru, found that a single dose of ciprofloxacin did not prevent the acquisition of Vibrio cholerae O1 infection nor the development of diarrhea among household contacts of bacteriologically confirmed index cases. While a subgroup of household contacts with positive baseline stool cultures showed a reduction in the bacterial load and a trend towards prevention of diarrhea among ciprofloxacin recipients, the overall results did not demonstrate a significant protective effect of ciprofloxacin against moderate to severe cholera. Therefore, it cannot be concluded that Vaxchora, which is a similar drug to ciprofloxacin, would be effective in preventing moderate to severe cholera.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protective efficacy of Vaxchora against moderate to severe cholera is not well established.\n2. A study in Lima, Peru, found that a single dose of ciprofloxacin did not prevent the acquisition of Vibrio cholerae O1 infection.\n3. The same study noted that ciprofloxacin did not prevent the development of diarrhea among household contacts of bacteriologically confirmed cholera cases.\n4. There was a reduction in bacterial load and a trend towards prevention of diarrhea among a subgroup with positive baseline stool cultures who received ciprofloxacin.\n5. The overall results of the study did not show a significant protective effect of ciprofloxacin against moderate to severe cholera.",
    "llama-2-7b-chat-hf_fact": [
      "The protective efficacy of Vaxchora against moderate to severe cholera is not well established.",
      "A study in Lima, Peru, found that a single dose of ciprofloxacin did not prevent the acquisition of Vibrio cholerae O1 infection.",
      "The same study noted that ciprofloxacin did not prevent the development of diarrhea among household contacts of bacteriologically confirmed cholera cases.",
      "There was a reduction in bacterial load and a trend towards prevention of diarrhea among a subgroup with positive baseline stool cultures who received ciprofloxacin.",
      "The overall results of the study did not show a significant protective effect of ciprofloxacin against moderate to severe cholera."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without information regarding the efficacy of Vaxchora, it's impossible to determine the truthfulness of this statement.\n2. UNKNOWN: The truth of this statement depends on the specific results of the study conducted in Lima, Peru. Without access to the study, the truth cannot be verified.\n3. UNKNOWN: Similar to statement 2, without access to the study, the veracity of the statement about ciprofloxacin's effect on the development of diarrhea among household contacts cannot be ascertained.\n4. UNKNOWN: The statement suggests specific findings from the study that could be true, but without the study data or results, it cannot be verified.\n5. UNKNOWN: This statement summarizes the outcome of the study. However, without the actual study results or data, it cannot be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first cholera vaccine approved in the US is the bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India). The vaccine has been shown to provide protection against cholera for up to 5 years in a slum area of Kolkata, India, with an estimated cumulative protective efficacy of 65% (95% CI 52-74; p<00001) during the 5-year follow-up period.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US is the bivalent killed whole-cell oral cholera vaccine.\n2. Shantha Biotechnics, located in Hyderabad, India, is the manufacturer of this vaccine.\n3. The vaccine has been shown to provide protection against cholera for up to 5 years.\n4. An estimated cumulative protective efficacy of 65% for this vaccine was observed during a 5-year follow-up period in a slum area of Kolkata, India.\n5. The protective efficacy falls within a 95% confidence interval (CI) of 52-74.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US is the bivalent killed whole-cell oral cholera vaccine.",
      "Shantha Biotechnics, located in Hyderabad, India, is the manufacturer of this vaccine.",
      "The vaccine has been shown to provide protection against cholera for up to 5 years.",
      "An estimated cumulative protective efficacy of 65% for this vaccine was observed during a 5-year follow-up period in a slum area of Kolkata, India.",
      "The protective efficacy falls within a 95% confidence interval (CI) of 52-74."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine licensed for use in the United States is Vaxchora, which is a live, attenuated oral cholera vaccine.\n2. UNKNOWN: Without specific information about which vaccine is being referenced, it is impossible to confirm if Shantha Biotechnics is the manufacturer. If the statement refers to Vaxchora, then the statement is false as Vaxchora is manufactured by PaxVax.\n3. UNKNOWN: While some cholera vaccines provide protection that may last for several years, without specific information on the vaccine being referenced and considering different cholera vaccines have varying durations of protection, it is not possible to confirm the duration of protection for the vaccine mentioned in the statement.\n4. UNKNOWN: Without evidence from specific studies or trials, the statement regarding the cumulative protective efficacy of a specific vaccine during a follow-up period in Kolkata cannot be confirmed.\n5. UNKNOWN: The protective efficacy and confidence interval stated cannot be confirmed without clear data or references to the specific study that produced these results, and since the vaccine has not been precisely identified, the claim remains unsubstantiated.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not specifically mentioned. However, the document does mention that CVID is a genetic disorder, and that the high percentages of pediatric patients with CVID in Iran may be due to the considerable prevalence of parental consanguinity in the region and an underlying genetic background.\nTherefore, based on the information provided, it can be inferred that monogenic causes of CVID in Europeans are likely to be related to genetic mutations or variations that are inherited from one or both parents. However, the specific genetic causes of CVID are not specified in the document.\nIt is important to note that CVID is a complex disorder that can have multiple causes, including both genetic and environmental factors. The specific cause of CVID in an individual patient may depend on a variety of factors, including their family history, medical history, and environmental exposures.\nIn summary, while the document does not provide specific information on the most common monogenic cause of CVID in Europeans, it suggests that genetic factors play a significant role in the development of this disorder. Further research is needed to identify the specific genetic causes of CVID and to develop effective treatments for this condition.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is not associated with the four Interferon-induced helicase C domain 1 (IFIH1) single nucleotide polymorphisms (SNPs) analyzed in the study. The study found that there was no association between IFIH1 SNPs and SLE in the sample of 337 patients with SLE and 373 healthy individuals from southeast and northeast Brazil. However, a meta-analysis of peer-reviewed articles from 2008 to 2015 and data from this study indicated an association between one of the IFIH1 SNPs, rs1990760, and SLE onset. This is the first association analysis on IFIH1 polymorphisms and SLE susceptibility in Brazilian populations.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene in Systemic Lupus Erythematosus (SLE) is not associated with the IFIH1 single nucleotide polymorphisms analyzed in a study.\n2. The study sample consisted of 337 patients with SLE and 373 healthy individuals from southeast and northeast Brazil.\n3. The meta-analysis reviewed peer-reviewed articles from 2008 to 2015.\n4. The meta-analysis found an association between the IFIH1 SNP, rs1990760, and the onset of SLE.\n5. The study represents the first association analysis on IFIH1 polymorphisms and SLE susceptibility in Brazilian populations.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene in Systemic Lupus Erythematosus (SLE) is not associated with the IFIH1 single nucleotide polymorphisms analyzed in a study.",
      "The study sample consisted of 337 patients with SLE and 373 healthy individuals from southeast and northeast Brazil.",
      "The meta-analysis reviewed peer-reviewed articles from 2008 to 2015.",
      "The meta-analysis found an association between the IFIH1 SNP, rs1990760, and the onset of SLE.",
      "The study represents the first association analysis on IFIH1 polymorphisms and SLE susceptibility in Brazilian populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nReason: There is not enough information provided to confirm or refute these statements' accuracy. Each statement details specific findings and characteristics of a study, and without access to the actual research, their veracity cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a newly developed, validated elbow-specific score that assesses the outcome of total elbow arthroplasty. The LES consists of a patient-answered questionnaire (PAQ) and a clinical assessment. The purpose of the study was to determine whether the PAQ portion of the LES could be used independently as a postal questionnaire for the assessment of outcome after total elbow arthroplasty, and to correlate the LES with the Mayo Elbow Performance Score (MEPS). The study found that there was an excellent response rate to the postal questionnaire (98%) and 44 elbows were available for clinical review. Good correlation was shown between the LES and the MEPS (Spearman correlation coefficient, 0.84; P < .001) and between the PAQ portion of the LES and the MEPS (Spearman correlation coefficient, 0.76; P < .001). These findings suggest that the PAQ portion of the LES can be used as a reliable and valid tool for assessing the outcome of total elbow arthroplasty by postal questionnaire.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is intended for assessing the outcome of total elbow arthroplasty.\n2. The LES comprises a patient-answered questionnaire (PAQ) and a clinical assessment.\n3. The study aimed to determine if the PAQ of the LES could be used independently as a postal questionnaire.\n4. The response rate to the postal questionnaire of the LES was 98%.\n5. There was a good correlation between the LES and the Mayo Elbow Performance Score (MEPS), with a Spearman correlation coefficient of 0.84 (P < .001).",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is intended for assessing the outcome of total elbow arthroplasty.",
      "The LES comprises a patient-answered questionnaire (PAQ) and a clinical assessment.",
      "The study aimed to determine if the PAQ of the LES could be used independently as a postal questionnaire.",
      "The response rate to the postal questionnaire of the LES was 98%.",
      "There was a good correlation between the LES and the Mayo Elbow Performance Score (MEPS), with a Spearman correlation coefficient of 0.84 (P < .001)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or specifics from the study being referenced regarding the Liverpool Elbow Score (LES), patient-answered questionnaire (PAQ), the response rate to the postal questionnaire, and the correlation with the Mayo Elbow Performance Score (MEPS), it's impossible to verify the truth of statements 3, 4, and 5. These details would need to be confirmed by reviewing the actual study data and results.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the 100,000 Genomes Project has made efforts to study the gene cluster composed of genes coding for calcium-binding proteins of the S100 family. The project has identified a tightly linked gene cluster of six S100 genes on chromosome 1q21, which is the most closely packed mammalian gene cluster discovered to date. The cluster includes four genes that encode cysteine-rich proteins and two genes with a long hydrophobic N-terminal tail. The project has also found that the expression of some S100 genes in the cluster is deregulated during tumor progression, suggesting that chromosomal abnormalities may influence the expression of these genes in late stages of cancer, particularly in association with the formation of metastases.\nIn terms of specific efforts, the project has used pulsed-field gel electrophoresis to establish the linkage of the six S100 genes in the cluster and has characterized a contiguous DNA sequence of 15 kilobases containing the full coding region of four different S100 genes. The project has also used genome sequencing and analysis techniques to identify the location of the gene cluster on chromosome 1q21 and to study the expression of the S100 genes in different tissues and during tumor progression.\nOverall, the 100,000 Genomes Project has made significant efforts to study the gene cluster composed of S100 genes and its role in cancer progression. The project's findings have provided new insights into the molecular mechanisms underlying cancer development and progression and have identified potential targets for cancer therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project has identified a gene cluster of six S100 genes on chromosome 1q21.\n2. The identified gene cluster includes four genes that encode cysteine-rich proteins and two genes with a long hydrophobic N-terminal tail.\n3. The project found that the expression of some S100 genes in the cluster is deregulated during tumor progression.\n4. Pulsed-field gel electrophoresis was used to establish the linkage of the six S100 genes in the cluster.\n5. The project characterized a contiguous DNA sequence of 15 kilobases containing the full coding region of four different S100 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project has identified a gene cluster of six S100 genes on chromosome 1q21.",
      "The identified gene cluster includes four genes that encode cysteine-rich proteins and two genes with a long hydrophobic N-terminal tail.",
      "The project found that the expression of some S100 genes in the cluster is deregulated during tumor progression.",
      "Pulsed-field gel electrophoresis was used to establish the linkage of the six S100 genes in the cluster.",
      "The project characterized a contiguous DNA sequence of 15 kilobases containing the full coding region of four different S100 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There's no clear indication whether the specific detail about the 100,000 Genomes Project identifying a gene cluster of six S100 genes on chromosome 1q21 is correct or not, as the project covers a wide range of genetic research. The S100 gene family is indeed located on chromosome 1q21, but without specific passage reference, the involvement of the 100,000 Genomes Project cannot be confirmed.\n\n2. UNKNOWN: While the S100 protein family is known to include proteins with different structures, including some that are cysteine-rich, the specific details provided about the gene cluster including four genes that encode cysteine-rich proteins and two genes with a long hydrophobic N-terminal tail cannot be verified without additional context.\n\n3. UNKNOWN: It is commonly understood that the expression of S100 genes can be deregulated during tumor progression; however, without the specific passage, it's not possible to verify if the 100,000 Genomes Project found that the expression of some S100 genes in the cluster is deregulated during tumor progression.\n\n4. UNKNOWN: Pulsed-field gel electrophoresis (PFGE) is a technique that can be used to analyze the size of DNA fragments and establish linkage between genes; however, without the specific passage, it's not possible to verify if PFGE was used by the 100,000 Genomes Project to establish the linkage of the six S100 genes in the cluster.\n\n5. UNKNOWN: Characterizing a contiguous DNA sequence of a certain size containing the coding regions of different genes is within the scope of genomic projects, but the specific detail provided about the 100,000 Genomes Project characterizing a 15 kilobase DNA sequence containing the full coding region for four different S100 genes cannot be confirmed without the precise context or reference.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, protein ALEX1 does contain armadillo repeats. The document mentions that the Armadillo repeat family is well-characterized in several plant species, including tomato, and that the SlARM18 protein in tomato contains armadillo repeats. Additionally, the document states that virus-induced gene silencing of SlARM18 in a tolerant tomato cultivar conferred susceptibility, suggesting that SlARM18 plays a role in resistance to virus infection. Therefore, based on the information provided, it can be concluded that protein ALEX1 does contain armadillo repeats and is likely involved in the defense response against virus infection in tomato plants.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. The Armadillo repeat family is characterized in several plant species, including tomato.\n3. SlARM18 protein in tomato contains armadillo repeats.\n4. Virus-induced gene silencing of SlARM18 in a tolerant tomato cultivar conferred susceptibility to virus infection.\n5. SlARM18 is suggested to play a role in resistance to virus infection in tomato plants.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "The Armadillo repeat family is characterized in several plant species, including tomato.",
      "SlARM18 protein in tomato contains armadillo repeats.",
      "Virus-induced gene silencing of SlARM18 in a tolerant tomato cultivar conferred susceptibility to virus infection.",
      "SlARM18 is suggested to play a role in resistance to virus infection in tomato plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific scientific context or literature references provided, the statements regarding the protein ALEX1, the Armadillo repeat family in plants, and the specific functions of the SlARM18 protein in tomato are difficult to verify as true or false. However, it is known that the Armadillo repeat family is characterized in several plant species, so statement 2 can be considered true. The other statements require specific subject knowledge or references to determine their validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following enzymes are known to remove histone modifications:\n1. Histone acetyltransferases (HATs): These enzymes are responsible for adding acetyl groups to histone proteins, including H3-K115Ac and H3-K122Ac.\n2. Histone deacetylases (HDACs): These enzymes are responsible for removing acetyl groups from histone proteins, including H3-K115Ac and H3-K122Ac.\n3. Lysine-specific demethylases (LSD1 and LSD2): These enzymes are responsible for removing methyl groups from lysine residues on histone proteins, which can result in the activation of HATs and the deacetylation of histone proteins.\n4. Histone-modifying enzymes: These enzymes are responsible for modifying other histone residues, such as histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 trimethylation (H3K27me3), which can also affect the interaction between histones and DNA.\nIt is important to note that the removal of histone modifications is a complex process that involves multiple enzymes and can have different effects on chromatin structure and function, depending on the specific modification being removed and the context in which it is removed.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n2. Lysine-specific demethylases (LSD1 and LSD2) remove methyl groups from lysine residues on histone proteins.\n3. The removal of histone modifications can affect chromatin structure and function.\n4. Histone acetyltransferases (HATs) are responsible for adding acetyl groups to histone proteins (although this is not a removal process, it is included here for completeness as it is stated in the provided text).\n\nNote: The fourth point is included to clarify the role of HATs, even though it is related to the addition of modifications rather than the removal as the user's query specifies. If strictly looking for enzymes that remove modifications, only the first three points are relevant.",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Lysine-specific demethylases (LSD1 and LSD2) remove methyl groups from lysine residues on histone proteins.",
      "The removal of histone modifications can affect chromatin structure and function.",
      "Histone acetyltransferases (HATs) are responsible for adding acetyl groups to histone proteins (although this is not a removal process, it is included here for completeness as it is stated in the provided text).",
      "te: The fourth point is included to clarify the role of HATs, even though it is related to the addition of modifications rather than the removal as the user's query specifies. If strictly looking for enzymes that remove modifications, only the first three points are relevant."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the study, there is some evidence to suggest that exposure to head CT scans may increase the risk of brain tumors in children and adolescents. The study found that prenatal and postnatal exposure to medical diagnostic radiation, including X-rays, was not associated with an increased risk of childhood and adolescent brain tumors (CABTs). However, the study did observe a nonsignificant increased risk of CABTs for exposure to head CT scans.\nIt is important to note that the study had some limitations, including a small number of exposed children and a lack of statistical power to detect a significant association. Therefore, further research is needed to confirm these findings and to better understand the potential risks associated with head CT scans.\nIn summary, while the study suggests that exposure to head CT scans may be associated with an increased risk of CABTs, the evidence is not yet conclusive, and more research is needed to fully understand the potential risks. As with any medical imaging procedure, it is important to weigh the potential benefits and risks of head CT scans, particularly in children and adolescents, and to discuss any concerns with a qualified healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. The study indicates that exposure to head CT scans may increase the risk of brain tumors in children and adolescents.\n2. Prenatal and postnatal exposure to medical diagnostic radiation, including X-rays, was not found to be associated with an increased risk of childhood and adolescent brain tumors (CABTs) in the study.\n3. The study observed a nonsignificant increased risk of CABTs for exposure to head CT scans.\n4. The study had limitations, including a small number of exposed children and a lack of statistical power to detect a significant association.\n5. Further research is needed to confirm the findings of the study regarding the potential risks associated with head CT scans.",
    "llama-2-7b-chat-hf_fact": [
      "The study indicates that exposure to head CT scans may increase the risk of brain tumors in children and adolescents.",
      "Prenatal and postnatal exposure to medical diagnostic radiation, including X-rays, was not found to be associated with an increased risk of childhood and adolescent brain tumors (CABTs) in the study.",
      "The study observed a nonsignificant increased risk of CABTs for exposure to head CT scans.",
      "The study had limitations, including a small number of exposed children and a lack of statistical power to detect a significant association.",
      "Further research is needed to confirm the findings of the study regarding the potential risks associated with head CT scans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe statements provided refer to specific findings from a study. Without the actual study details or access to the full text, it's impossible to fact-check these findings (statements 1, 2, and 4) except to note that they are typical concerns and considerations in medical research. Statements 3 and 5, however, reflect common language used in scientific studies to describe their outcomes and the need for additional research, respectively, so those can be assessed as true based on usual scientific reporting.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Otx2 is associated with the pluripotency of the ventrolateral ectoderm. The study shows that regionally restricted factors regulate Otx2 activity, and that otx2-GR is able to activate the cement gland markers XCG and XAG only in the ventrolateral ectoderm, and never in the neural plate. Additionally, the study finds that otx2-GR can activate expression of the cement gland differentiation marker XCG in the absence of protein synthesis, identifying a direct target of otx2. These findings suggest that Otx2 directly controls cement gland differentiation, and that spatial and temporal modulation of Otx2 activity limits cement gland formation to the front of the embryo. Therefore, Otx2 is associated with the pluripotency of the ventrolateral ectoderm during embryonic development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with the pluripotency of the ventrolateral ectoderm.\n2. Otx2-GR can activate the cement gland markers XCG and XAG specifically in the ventrolateral ectoderm.\n3. Otx2-GR never activates the cement gland markers XCG and XAG in the neural plate.\n4. Otx2-GR can activate expression of the cement gland differentiation marker XCG without the need for protein synthesis.\n5. The spatial and temporal modulation of Otx2 activity is implicated in limiting cement gland formation to the front of the embryo.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with the pluripotency of the ventrolateral ectoderm.",
      "Otx2-GR can activate the cement gland markers XCG and XAG specifically in the ventrolateral ectoderm.",
      "Otx2-GR never activates the cement gland markers XCG and XAG in the neural plate.",
      "Otx2-GR can activate expression of the cement gland differentiation marker XCG without the need for protein synthesis.",
      "The spatial and temporal modulation of Otx2 activity is implicated in limiting cement gland formation to the front of the embryo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with the pluripotency of the ectoderm generally, not just the ventrolateral ectoderm. It's involved in the early stages of brain and eye development.\n2. TRUE: Otx2-GR, a modified version of Otx2 fused to a glucocorticoid receptor, can activate cement gland markers such as XCG and XAG in specific regions like the ventrolateral ectoderm when activated by a glucocorticoid.\n3. FALSE [correction]: Otx2-GR can activate cement gland markers XCG and XAG in the neural plate when exposed to a glucocorticoid. The specificity of Otx2-GR activity may depend on the presence of co-factors or inhibitors present in different tissue types.\n4. TRUE: Otx2-GR can activate expression of the cement gland marker XCG without a requirement for protein synthesis, as steroid hormone receptor fusion proteins like Otx2-GR can activate gene transcription directly when translocated to the nucleus.\n5. TRUE: The spatial and temporal modulation of Otx2 activity is important to ensure that cement gland differentiation occurs at the correct location and time during embryonic development, which is typically at the anterior (front) end of the embryo.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 5 DNaseI hypersensitive sites (HS-4 to HS-40) marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 5 DNaseI hypersensitive sites marking the murine beta globin locus region.\n2. These hypersensitive sites are identified as HS-4 to HS-40.",
    "llama-2-7b-chat-hf_fact": [
      "There are 5 DNaseI hypersensitive sites marking the murine beta globin locus region.",
      "These hypersensitive sites are identified as HS-4 to HS-40."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: These hypersensitive sites are typically identified as HS-1 to HS-5, not HS-4 to HS-40.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are some European influenza vaccines:\n1. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is approved for use in individuals aged 6 months and older.\n2. Flulaval (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is approved for use in individuals aged 6 months and older.\n3. Aggripulse (Sanofi Pasteur): This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is approved for use in individuals aged 6 months and older.\n4. Fluzone (Sanofi Pasteur): This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is approved for use in individuals aged 6 months and older.\n5. FluMist (AstraZeneca): This is a quadrivalent nasal spray vaccine that protects against four strains of influenza: two A strains and two B strains. It is approved for use in individuals aged 2-49 years.\n6. Vaxigrip (Sanofi Pasteur): This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is approved for use in individuals aged 6 months and older.\n7. Influvac (Bio-Medical Angle): This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is approved for use in individuals aged 6 months and older.\n8. Fluvirin (Novartis): This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is approved for use in individuals aged 6 months and older.\nIt's important to note that this list may not be exhaustive,",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine by GlaxoSmithKline approved for individuals aged 6 months and older.\n2. Flulaval is a trivalent influenza vaccine by GlaxoSmithKline approved for individuals aged 6 months and older.\n3. Aggripulse is a quadrivalent influenza vaccine by Sanofi Pasteur approved for individuals aged 6 months and older.\n4. FluMist is a quadrivalent nasal spray influenza vaccine by AstraZeneca approved for individuals aged 2-49 years.\n5. Influvac is a quadrivalent influenza vaccine by Bio-Medical Angle approved for individuals aged 6 months and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine by GlaxoSmithKline approved for individuals aged 6 months and older.",
      "Flulaval is a trivalent influenza vaccine by GlaxoSmithKline approved for individuals aged 6 months and older.",
      "Aggripulse is a quadrivalent influenza vaccine by Sanofi Pasteur approved for individuals aged 6 months and older.",
      "FluMist is a quadrivalent nasal spray influenza vaccine by AstraZeneca approved for individuals aged 2-49 years.",
      "Influvac is a quadrivalent influenza vaccine by Bio-Medical Angle approved for individuals aged 6 months and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Flulaval is a quadrivalent influenza vaccine by GlaxoSmithKline approved for individuals aged 6 months and older.\n3. FALSE [correction]: The correct name of the vaccine is Fluzone Quadrivalent, and it is by Sanofi Pasteur approved for individuals aged 6 months and older.\n4. TRUE\n5. FALSE [correction]: Influvac is a quadrivalent influenza vaccine by Mylan (previously Abbott), approved for individuals aged 3 years and older. Bio-Medical Angle is not the correct manufacturer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, the Paramyxovirus geneome is segmented, negative-sense RNA.\nThe document states that the genome of Lymphocytic choriomeningitis virus (LCMV) consists of two negative-sense single-stranded RNA segments, designated L and S. These segments are ambisense, meaning that they contain both sense and antisense coding strategies, with the genes being separated by an intergenic region (IGR). The document also mentions that the LCMV minigenome, which is a negative-sense copy of the chloramphenicol acetyltransferase (CAT) reporter gene, was constructed and found to be capable of producing CAT expression in LCMV-infected cells. This further supports the conclusion that the Paramyxovirus geneome is segmented, negative-sense RNA.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Roflumilast Cream is effective for treating Chronic Obstructive Pulmonary Disease (COPD). The study found that Roflumilast was marketed as an add-on treatment to inhaled bronchodilators and corticosteroids in COPD patients with frequent exacerbations, and that the drug was used by 1573 individuals in Denmark during the study period (2010-2016). Of these users, 705 (45%) redeemed only one prescription, and 67% discontinued treatment within the first year. The study also found that the rate of treatment initiation decreased by 73% from 2011 to 2016, concurrent with a stable prevalence of COPD patients throughout the study period. The median duration of Roflumilast use was 76 days. The study suggests that the decreasing incidence and high level of early discontinuation of Roflumilast could be due to a lack of benefit, low awareness of the drug's indication among physicians, a challenging prescribing procedure, or adverse effects. Therefore, based on the information provided, it can be concluded that Roflumilast Cream is effective in treating COPD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast Cream is used for treating Chronic Obstructive Pulmonary Disease (COPD).\n2. Roflumilast is marketed as an add-on treatment to inhaled bronchodilators and corticosteroids for COPD patients.\n3. During the study period of 2010 to 2016, Roflumilast was used by 1573 individuals in Denmark.\n4. 67% of Roflumilast users discontinued treatment within the first year.\n5. The median duration of Roflumilast use was 76 days.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast Cream is used for treating Chronic Obstructive Pulmonary Disease (COPD).",
      "Roflumilast is marketed as an add-on treatment to inhaled bronchodilators and corticosteroids for COPD patients.",
      "During the study period of 2010 to 2016, Roflumilast was used by 1573 individuals in Denmark.",
      "67% of Roflumilast users discontinued treatment within the first year.",
      "The median duration of Roflumilast use was 76 days."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is an oral medication, not a cream, used for treating Chronic Obstructive Pulmonary Disease (COPD), specifically severe COPD associated with chronic bronchitis and a history of exacerbations.\n2. TRUE\n3. UNKNOWN: Without access to the specific data from the study, it is not possible to verify the exact number of individuals in Denmark who used Roflumilast during that period.\n4. UNKNOWN: The specific discontinuation rate for Roflumilast use within the first year would require access to empirical study data or official reports; without such information, the accuracy of the statement cannot be determined.\n5. UNKNOWN: Similar to the discontinuation rate, the median duration of use can only be verified through specific study data. Without this data, the truthfulness of the statement cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, several tools have been developed for identifying and visualizing ncRNA promoters. Here are some of the tools mentioned in the document:\n1. Direct RNA sequencing: This approach involves sequencing the RNA molecules directly without any prior processing or amplification. This method can provide a comprehensive view of the transcriptome, including ncRNAs, and can be used to identify novel ncRNA promoters.\n2. Sequencing coupled with transcription: This approach involves transcribing the RNA molecules into cDNA before sequencing. This method can provide more accurate information about the transcriptome, including the identification of ncRNA promoters.\n3. Isolation of protein complexes associated with lncRNAs followed by high-throughput sequencing: This approach involves isolating protein complexes associated with lncRNAs and then sequencing the isolated complexes. This method can provide information about the proteins that are associated with ncRNA promoters and can help identify the functional elements in these regions.\n4. Chromatin-associated RNA sequencing: This approach involves isolating the chromatin structure associated with a specific region of interest, such as a ncRNA promoter, and then sequencing the isolated chromatin. This method can provide information about the epigenetic marks and transcription factors associated with ncRNA promoters.\n5. Nascent transcript Global run-on sequencing: This approach involves using a transcriptional run-on assay to measure the transcriptional activity of a specific region of interest, such as a ncRNA promoter. This method can provide information about the transcriptional activity of ncRNA promoters and can help identify the factors that regulate their expression.\n6. Photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation: This approach involves using a photoactivatable probe to cross-link RNA molecules to their associated proteins, followed by immunoprecipitation of the cross-linked complexes. This method can provide information about the proteins that are associated with ncRNA promoters and can help identify the functional elements in these regions.\nThese are some of the tools that have been developed",
    "llama-2-7b-chat-hf_fact_raw": "1. Direct RNA sequencing is used to sequence RNA molecules directly to identify novel ncRNA promoters.\n2. Sequencing coupled with transcription involves transcribing RNA into cDNA before sequencing to identify ncRNA promoters.\n3. Isolation of protein complexes associated with lncRNAs followed by high-throughput sequencing provides information about proteins linked to ncRNA promoters.\n4. Chromatin-associated RNA sequencing is used to isolate and sequence chromatin associated with ncRNA promoters to understand epigenetic marks and transcription factors.\n5. Nascent transcript Global run-on sequencing involves a transcriptional run-on assay to measure the transcriptional activity of ncRNA promoters.",
    "llama-2-7b-chat-hf_fact": [
      "Direct RNA sequencing is used to sequence RNA molecules directly to identify novel ncRNA promoters.",
      "Sequencing coupled with transcription involves transcribing RNA into cDNA before sequencing to identify ncRNA promoters.",
      "Isolation of protein complexes associated with lncRNAs followed by high-throughput sequencing provides information about proteins linked to ncRNA promoters.",
      "Chromatin-associated RNA sequencing is used to isolate and sequence chromatin associated with ncRNA promoters to understand epigenetic marks and transcription factors.",
      "Nascent transcript Global run-on sequencing involves a transcriptional run-on assay to measure the transcriptional activity of ncRNA promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Isolation of protein complexes associated with lncRNAs followed by high-throughput sequencing provides information about proteins linked to lncRNAs, not necessarily their promoters.\n4. FALSE [correction]: Chromatin-associated RNA sequencing is used to isolate and sequence chromatin-associated RNA to understand epigenetic marks and transcription factors, not specifically associated with ncRNA promoters.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some example genes that SWIM tool has identified as being down-regulated in glioblastoma:\n1. N-myc downstream-regulated gene 2 (NDRG2) - As mentioned in the document, NDRG2 has been reported to be downregulated in glioblastoma, and its overexpression has been shown to repress glioblastoma cell proliferation in vitro.\n2. Tumor suppressor gene 1 (TSG1) - The document does not provide specific information on TSG1, but it is mentioned as a gene that is downregulated in glioblastoma in other studies.\n3. Matrix metalloproteinase 9 (MMP9) - MMP9 has been identified as a downregulated gene in glioblastoma by SWIM tool, and its downregulation has been associated with poor prognosis in glioblastoma patients.\n4. Growth differentiation factor 10 (GDF10) - GDF10 has been identified as a downregulated gene in glioblastoma by SWIM tool, and its downregulation has been associated with poor prognosis in glioblastoma patients.\n5. Microtubule-associated protein 2 (MAP2) - MAP2 has been identified as a downregulated gene in glioblastoma by SWIM tool, and its downregulation has been associated with poor prognosis in glioblastoma patients.\nIt is important to note that the list of downregulated genes in glioblastoma may vary depending on the specific dataset used and the criteria for identifying downregulated genes. However, these genes are among the most commonly identified as downregulated in glioblastoma using SWIM tool and other methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. N-myc downstream-regulated gene 2 (NDRG2) is reported to be downregulated in glioblastoma.\n2. NDRG2 overexpression is said to repress glioblastoma cell proliferation in vitro.\n3. Matrix metalloproteinase 9 (MMP9) has been identified by SWIM tool as downregulated in glioblastoma.\n4. Downregulation of MMP9 has been associated with poor prognosis in glioblastoma patients.\n5. Growth differentiation factor 10 (GDF10) and Microtubule-associated protein 2 (MAP2) have been identified as downregulated genes in glioblastoma by SWIM tool and their downregulation has been associated with poor prognosis in glioblastoma patients.",
    "llama-2-7b-chat-hf_fact": [
      "N-myc downstream-regulated gene 2 (NDRG2) is reported to be downregulated in glioblastoma.",
      "NDRG2 overexpression is said to repress glioblastoma cell proliferation in vitro.",
      "Matrix metalloproteinase 9 (MMP9) has been identified by SWIM tool as downregulated in glioblastoma.",
      "Downregulation of MMP9 has been associated with poor prognosis in glioblastoma patients.",
      "Growth differentiation factor 10 (GDF10) and Microtubule-associated protein 2 (MAP2) have been identified as downregulated genes in glioblastoma by SWIM tool and their downregulation has been associated with poor prognosis in glioblastoma patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Matrix metalloproteinase 9 (MMP9) is typically associated with being upregulated in various cancers, including glioblastoma, and is known to aid in tumor progression and invasion.\n4. FALSE [correction]: Upregulation of MMP9 has been associated with poor prognosis in glioblastoma patients due to its role in promoting invasion and angiogenesis.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the passage, the following R packages have been developed for studying TADs:\n1. Critical point drying: This is a method for preserving and visualizing the internal structures of animals, including cartilage and muscle tissue.\n2. Micro-computed tomography (micro-CT): This is a technique for creating three-dimensional reconstructions of internal structures using X-ray micro-computed tomography.\n3. Osmium tetroxide: This is a staining agent that can be used to visualize cartilage and muscle tissue in animals. However, it is toxic and can cause problems with contrast and staining results.\n4. Phosphotungstic acid (PTA): This is another staining agent that can be used to visualize cartilage and muscle tissue in animals.\n5. Iodine: This is a staining agent that can be used to visualize cartilage and muscle tissue in animals. However, it can cause problems with contrast and staining results.\nThese packages can be used in combination with R to analyze and visualize the internal structures of animals, including TADs.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is the whole-cell fluorescent biosensory device. This device is capable of simultaneously detecting the presence of multiple heavy metals, including mercury, lead, cadmium, and gold ions, in aqueous samples with high sensitivity. The device is based on the use of bacterial biosensors, which are simple, cost-effective, and efficient analytical tools for detecting bioavailable heavy metals in the environment. By using whole-cell biosensors, the device can provide a more comprehensive understanding of the regulatory networks involved in heavy metal sensing and response in bacteria, which can inform the development of new biosensors and bioremediation strategies for heavy metal pollution.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bioconductor tool developed for accessing bacterial regulatory networks is the whole-cell fluorescent biosensory device.\n2. The device can detect the presence of multiple heavy metals, including mercury, lead, cadmium, and gold ions.\n3. The tool uses bacterial biosensors for detection purposes.\n4. Bacterial biosensors are described as simple, cost-effective, and efficient analytical tools.\n5. The device aims to provide a comprehensive understanding of the regulatory networks in bacteria related to heavy metal sensing and response.",
    "llama-2-7b-chat-hf_fact": [
      "The bioconductor tool developed for accessing bacterial regulatory networks is the whole-cell fluorescent biosensory device.",
      "The device can detect the presence of multiple heavy metals, including mercury, lead, cadmium, and gold ions.",
      "The tool uses bacterial biosensors for detection purposes.",
      "Bacterial biosensors are described as simple, cost-effective, and efficient analytical tools.",
      "The device aims to provide a comprehensive understanding of the regulatory networks in bacteria related to heavy metal sensing and response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Bioconductor is not a tool but a project that provides tools for the analysis and understanding of high-throughput genomic data. A whole-cell fluorescent biosensory device is not a Bioconductor tool but a type of biosensor device.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The purpose stated for the device is more aligned with what a biosensor would do (detecting heavy metals). Bioconductor tools generally aim to provide a comprehensive understanding of regulatory networks in bacteria but through computational analysis of genomic data, not necessarily related specifically to heavy metal sensing and response.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the end products of the shikimate pathway in the rat are:\n1. Hippurate\n2. Hexahydrohippurate\n3. 3,4,5,6-tetrahydrohippurate\n4. T-3,t-4-dihydroxycyclohexane-r-1-carboxylate\n5. C-3,t-4-dihydroxycyclophexane-r-1-carboxylate\n6. Conjugates of catechol and CO2\nIt is important to note that the shikimate pathway is entirely dependent on microbial transformations in the gut, and the metabolism of shikimate is suppressed in animals pretreated with antibiotics. Additionally, shikimate is not metabolized by mammalian tissues, and the products of microbial metabolism are excreted either unchanged or after further biotransformation in the animal tissues.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hippurate is an end product of the shikimate pathway in the rat.\n2. Hexahydrohippurate is an end product of the shikimate pathway in the rat.\n3. 3,4,5,6-tetrahydrohippurate is an end product of the shikimate pathway in the rat.\n4. The metabolism of shikimate in animals is suppressed when treated with antibiotics.\n5. Shikimate is not metabolized by mammalian tissues; it is metabolized by microbial transformations in the gut.",
    "llama-2-7b-chat-hf_fact": [
      "Hippurate is an end product of the shikimate pathway in the rat.",
      "Hexahydrohippurate is an end product of the shikimate pathway in the rat.",
      "3,4,5,6-tetrahydrohippurate is an end product of the shikimate pathway in the rat.",
      "The metabolism of shikimate in animals is suppressed when treated with antibiotics.",
      "Shikimate is not metabolized by mammalian tissues; it is metabolized by microbial transformations in the gut."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hippurate is not an end product of the shikimate pathway in the rat. Hippurate, also known as benzoic acid, is more related to the metabolism of aromatic compounds in animals.\n\n2. UNKNOWN: The specific end products of the shikimate pathway in rats are not commonly discussed, and hexahydrohippurate seems to be an obscure or incorrect compound in this context. In general, the shikimate pathway is known for its role in plants and microorganisms for the biosynthesis of aromatic amino acids, not typically associated with rats in this way.\n\n3. UNKNOWN: Similar to the previous statement, 3,4,5,6-tetrahydrohippurate is not a commonly discussed compound in relation to the shikimate pathway in the rat, and its reference is obscure or potentially incorrect.\n\n4. UNKNOWN: This statement is difficult to assess without specific research references. While antibiotics can affect microbial populations in the gut which might impact shikimate pathway-related transformations, the statement is too generic to determine its truthfulness, and it is unclear how antibiotics would directly suppress the metabolism of shikimate in animals.\n\n5. TRUE: Shikimate itself is not directly metabolized by mammalian tissues; it is typically associated with the biosynthesis of aromatic amino acids in bacteria, plants, and fungi. Microbial transformations in the gut can metabolize it, which can then potentially have downstream effects on the host organism.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated. In a case series of nine patients with severe Cushing's syndrome of ectopic or occult origin, cabergoline was used in combination with steroidogenesis inhibitors and showed rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism in three of the cases. While the literature review found only 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, 10 of these cases responded. Therefore, based on the available evidence, it is possible that cabergoline may be effective in the treatment of Nelson's syndrome, a rare and severe form of Cushing's syndrome. However, further research is needed to confirm this conclusion.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease.\n2. A case series of nine patients with severe Cushing's syndrome of ectopic or occult origin used cabergoline in combination with steroidogenesis inhibitors.\n3. In the case series, three cases showed rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism after treatment with cabergoline.\n4. A literature review found 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, and 10 of those cases responded to treatment.\n5. Cabergoline may be effective in the treatment of Nelson's syndrome, which is a rare and severe form of Cushing's syndrome, but further research is necessary to confirm this.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease.",
      "A case series of nine patients with severe Cushing's syndrome of ectopic or occult origin used cabergoline in combination with steroidogenesis inhibitors.",
      "In the case series, three cases showed rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism after treatment with cabergoline.",
      "A literature review found 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, and 10 of those cases responded to treatment.",
      "Cabergoline may be effective in the treatment of Nelson's syndrome, which is a rare and severe form of Cushing's syndrome, but further research is necessary to confirm this."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Cabergoline is a dopamine agonist that has been reported to have some effectiveness in the treatment of Cushing's disease, which is often characterized by excessive production of cortisol. It is more commonly used in the treatment of moderate or mild cases.\n2. TRUE - A case series can include a small number of patients, and it is plausible that cabergoline was used in a combination treatment for severe Cushing's syndrome. However, without a specific source, this cannot be independently verified.\n3. UNKNOWN - Without access to the specific case series or its results, it is not possible to confirm the exact outcomes regarding rapid withdrawal and long-term control after cabergoline treatment.\n4. UNKNOWN - As with statement 3, without the specific literature review or access to the individual cases, we cannot confirm the exact response rate to dopamine receptor agonists in the treatment of ectopic or occult Cushing's syndrome.\n5. TRUE - Nelson's syndrome is indeed a rare and severe form of Cushing's syndrome that occurs after bilateral adrenalectomy. There is limited evidence suggesting that cabergoline might be effective in some cases, but the statement rightly asserts that further research is necessary.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the main manifestation of Liebenberg syndrome (also known as Juberg-Marsidi syndrome) is severe mental retardation.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS\n\n(Note: Liebenberg syndrome and Juberg-Marsidi syndrome are not the same condition; this seems to be a factual error in the provided answer, which impacts the ability to extract verifiable factual statements.)",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are orally bioavailable MPS1 kinase inhibitors:\n1. Axitinib: As mentioned in the document, axitinib potently inhibited CYP1A2-dependent 7-ethoxyresorufin O-deethylation activity at lower concentrations, with a Ki of 0.11 ± 0.01 μM and a Km for 7-ethoxyresorufin oxidation of 0.83 ± 0.06 μM. Computational modeling identified two potential binding modes for axitinib in the active site of CYP1A2, which may contribute to both drug metabolism and inhibition.\n2. Irinotecan: Irinotecan is a topoisomerase I inhibitor that has been approved for the treatment of colon cancer. It has been shown to inhibit CYP3A4 and CYP1A2 in vitro, although the extent of inhibition may vary depending on the specific formulation and dosing regimen.\n3. Lapatinib: Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2. It has been shown to inhibit CYP3A4 and CYP2D6 in vitro, although the extent of inhibition may vary depending on the specific formulation and dosing regimen.\n4. Nilotinib: Nilotinib is a tyrosine kinase inhibitor that targets BCR-ABL1 in chronic myeloid leukemia. It has been shown to inhibit CYP3A4 and CYP2C9 in vitro, although the extent of inhibition may vary depending on the specific formulation and dosing regimen.\n5. Pazopanib: Pazopanib is a tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit. It has been shown to inhibit CYP3A4 and CYP2C9 in vitro, although the extent of inhibition may vary depending on the specific formulation and dosing regimen.\nIt is important to note that the in",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib inhibited CYP1A2-dependent 7-ethoxyresorufin O-deethylation activity with a Ki of 0.11 ± 0.01 μM.\n2. Irinotecan has been approved for the treatment of colon cancer.\n3. Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2.\n4. Nilotinib is a tyrosine kinase inhibitor that targets BCR-ABL1 in chronic myeloid leukemia.\n5. Pazopanib is a tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib inhibited CYP1A2-dependent 7-ethoxyresorufin O-deethylation activity with a Ki of 0.11 ± 0.01 μM.",
      "Irinotecan has been approved for the treatment of colon cancer.",
      "Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2.",
      "Nilotinib is a tyrosine kinase inhibitor that targets BCR-ABL1 in chronic myeloid leukemia.",
      "Pazopanib is a tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nExplanation:\n1. The statement provides a specific pharmacological detail about Axitinib which would require access to scientific literature or data to verify.\n2. Irinotecan has been approved for the treatment of colon cancer, so this statement is true.\n3. Lapatinib is indeed a dual tyrosine kinase inhibitor that targets EGFR and HER2, which is true.\n4. Nilotinib is a tyrosine kinase inhibitor used to target BCR-ABL1 in the treatment of chronic myeloid leukemia (CML), so this statement is true.\n5. Pazopanib is a tyrosine kinase inhibitor and it does target VEGFR, PDGFR, and c-Kit among others. Thus, the statement is true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no direct evidence to suggest that golimumab was tested for diabetes. The study described in the document focused on the pharmacokinetics of golimumab in patients with active psoriatic arthritis (PsA), and did not investigate its effects on diabetes.\nHowever, the study did identify some covariates that may affect the pharmacokinetics of golimumab, including body weight, antibody-to-golimumab status, baseline C-reactive protein level, and smoking status. These findings may have implications for the dosing and monitoring of golimumab in patients with diabetes, as well as in other populations.\nIt is important to note that the study did not specifically investigate the effects of golimumab on diabetes, and further research is needed to determine the drug's effects on this condition. If you have diabetes and are taking golimumab, it is important to work closely with your healthcare provider to monitor your blood sugar levels and adjust your dosage as needed to minimize the risk of hypoglycemia or hyperglycemia.",
    "llama-2-7b-chat-hf_fact_raw": "1. The study focused on the pharmacokinetics of golimumab in patients with active psoriatic arthritis.\n2. The study did not investigate the effects of golimumab on diabetes.\n3. Covariates such as body weight, antibody-to-golimumab status, baseline C-reactive protein level, and smoking status may affect the pharmacokinetics of golimumab.\n4. The implications of the study's findings may be relevant for dosing and monitoring of golimumab in patients with diabetes.\n5. It is recommended for patients with diabetes taking golimumab to closely monitor their blood sugar levels.",
    "llama-2-7b-chat-hf_fact": [
      "The study focused on the pharmacokinetics of golimumab in patients with active psoriatic arthritis.",
      "The study did not investigate the effects of golimumab on diabetes.",
      "Covariates such as body weight, antibody-to-golimumab status, baseline C-reactive protein level, and smoking status may affect the pharmacokinetics of golimumab.",
      "The implications of the study's findings may be relevant for dosing and monitoring of golimumab in patients with diabetes.",
      "It is recommended for patients with diabetes taking golimumab to closely monitor their blood sugar levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (The statement mentions a study but provides no specific information that can be verified without additional context.)\n2. UNKNOWN (Without specifics about the study, it is impossible to verify whether the study investigated the effects of golimumab on diabetes.)\n3. TRUE (Covariates such as body weight, antibody-to-golimumab status, baseline C-reactive protein level, and smoking status are known to potentially affect the pharmacokinetics of many drugs, including biologics like golimumab.)\n4. UNKNOWN (The statement assumes findings from the study without providing any specific information, and without access to the study it is not possible to determine the relevance of the implications.)\n5. UNKNOWN (This recommendation is plausible as patients on immunomodulatory drugs like golimumab may need to closely monitor blood sugar levels if they have comorbid diabetes, however, without specific guidelines or study findings, this cannot be confirmed as a recommended practice.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that progeria is caused by an autosomal recessive gene. The document mentions that mutations in the lamin A/C (LMNA) gene lead to the expression of a protein called progerin, which has 50 amino acids deleted from the tail of prelamin A. This mutation is known to cause Hutchinson-Gilford progeria syndrome (HGPS), which is a rare genetic disorder characterized by accelerated aging in children.\nThe document also mentions that both the amount and distribution of heterochromatin are altered in cells from patients with HGPS, which suggests that the mutation in the LMNA gene may affect the way in which chromatin is organized and accessed. This could potentially lead to changes in the expression of genes involved in various cellular processes, including cell growth and division, which could contribute to the development of the symptoms associated with progeria.\nOverall, while the document does not directly answer the question of whether progeria is caused by an autosomal recessive gene, it does provide evidence to suggest that mutations in the LMNA gene may play a role in the development of this disorder.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the common variants at 12q14 and 12q24 associated with colorectal cancer (CRC) are:\n1. SNP on 9p24 (rs719725): The document reports an association between this SNP and risk of CRC in the population-based series, with odds ratios of 1.46 and 1.50 for the AA and AC genotypes compared to the CC genotype, respectively.\n2. SNPs on 8q24 (rs10505477 and rs6983267): The document also reports associations between these SNPs and risk of CRC in the population-based series, with odds ratios of 1.05 and 1.02 for the minor alleles compared to the major allele, respectively.\nIt is important to note that these associations were observed in the population-based series and may not be generalizable to all individuals or populations. Additionally, the document does not provide information on the specific variants at 12q14 and 12q24 that may be associated with CRC.",
    "llama-2-7b-chat-hf_fact_raw": "1. SNP on 9p24 (rs719725) is associated with an increased risk of colorectal cancer (CRC).\n2. The odds ratios for the AA and AC genotypes of SNP rs719725 compared to the CC genotype are 1.46 and 1.50, respectively.\n3. SNPs on 8q24 (rs10505477 and rs6983267) are associated with an increased risk of CRC.\n4. The odds ratios for the minor alleles of SNPs rs10505477 and rs6983267 compared to the major allele are 1.05 and 1.02, respectively.\n5. The associations mentioned are observed in a population-based series and may not be applicable to all individuals or populations.",
    "llama-2-7b-chat-hf_fact": [
      "SNP on 9p24 (rs719725) is associated with an increased risk of colorectal cancer (CRC).",
      "The odds ratios for the AA and AC genotypes of SNP rs719725 compared to the CC genotype are 1.46 and 1.50, respectively.",
      "SNPs on 8q24 (rs10505477 and rs6983267) are associated with an increased risk of CRC.",
      "The odds ratios for the minor alleles of SNPs rs10505477 and rs6983267 compared to the major allele are 1.05 and 1.02, respectively.",
      "The associations mentioned are observed in a population-based series and may not be applicable to all individuals or populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - SNP on 9p24 (rs719725) has been identified in genetic association studies as being associated with an increased risk of colorectal cancer (CRC).\n2. UNKNOWN - Without the specific study or source with the odds ratios, this statement is difficult to verify because odds ratios can vary between studies and populations.\n3. TRUE - SNPs on 8q24, including rs10505477 and rs6983267, have been reported in various studies to be associated with an increased risk of colorectal cancer (CRC).\n4. UNKNOWN - Similar to statement 2, without the specific study or data, it is difficult to verify the exact odds ratios, as they can differ between studies and populations.\n5. TRUE - Associations found in population-based series indeed may not be universally applicable, as genetic risk factors can differ by individual genetic backgrounds and other environmental factors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the ligands of the Roundabout (Robo) receptors are:\n1. Magic Roundabout (ROBO4): The document identifies a novel, endothelial-specific gene encoding a protein with homology to the axon guidance protein roundabout (ROBO1). The new gene has been called magic roundabout and is smaller than other members of the roundabout gene family. Expression of magic roundabout in vitro was detected in only endothelial cells and was greater in cells exposed to hypoxia. In situ hybridization and immunohistochemistry validated the bioinformatic prediction that magic roundabout expression would be endothelial specific in vivo.\n2. Other Roundabout Genes: The document mentions that the roundabout gene family extends beyond neuronal tissue, suggesting that other members of the family may also have ligand functions in angiogenesis.\nTherefore, based on the information provided in the document, the ligands of the Roundabout (Robo) receptors are magic roundabout (ROBO4) and other members of the roundabout gene family.",
    "llama-2-7b-chat-hf_fact_raw": "1. Magic Roundabout (ROBO4) is a ligand of the Roundabout (Robo) receptors.\n2. Magic Roundabout is an endothelial-specific gene.\n3. Magic Roundabout shows greater expression in vitro in endothelial cells that are exposed to hypoxia.\n4. In situ hybridization and immunohistochemistry confirmed that the expression of Magic Roundabout is endothelial specific in vivo.\n5. The roundabout gene family includes members beyond ROBO4 that may function as ligands in angiogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "Magic Roundabout (ROBO4) is a ligand of the Roundabout (Robo) receptors.",
      "Magic Roundabout is an endothelial-specific gene.",
      "Magic Roundabout shows greater expression in vitro in endothelial cells that are exposed to hypoxia.",
      "In situ hybridization and immunohistochemistry confirmed that the expression of Magic Roundabout is endothelial specific in vivo.",
      "The roundabout gene family includes members beyond ROBO4 that may function as ligands in angiogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Magic Roundabout (ROBO4) is not a ligand but rather a member of the Roundabout (Robo) receptor family.\n2. TRUE\n3. TRUE: It is generally correct that genes involved in angiogenesis, like Magic Roundabout (ROBO4), can show greater expression in response to hypoxic conditions, which are a potent driver of angiogenic processes.\n4. TRUE: If studies have used in situ hybridization and immunohistochemistry to confirm expression and this statement is derived from those studies, then it would be true.\n5. FALSE [correction]: The Roundabout gene family generally includes receptors, not ligands. However, the family may interact with various ligands to mediate angiogenesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is evidence to suggest that TFII-I (TFIID) plays a role in megakaryopoiesis. The document mentions that TAFII80, one of the TAFs involved in TFIID, interacts with other general factors such as TFIIE alpha and TFIIF alpha (RAP74), which are also involved in activator-dependent transcription. These interactions could be important for recruiting GTFs during megakaryocyte differentiation. Additionally, the document notes that TAFs 80, 31, and 20 show sequence similarities to histones H4, H3, and H2B, respectively, and that this subset of TAFs may form a related core structure within TFIID. While the document does not specifically mention megakaryopoiesis, these findings suggest that TFII-I may play a role in the regulation of gene expression during this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is suggested to play a role in megakaryopoiesis.\n2. TAFII80, a component of TFIID, interacts with TFIIE alpha and TFIIF alpha (RAP74) in activator-dependent transcription.\n3. The interactions of TAFII80 with TFIIE alpha and TFIIF alpha could be significant for recruiting General Transcription Factors (GTFs) during megakaryocyte differentiation.\n4. TAFs 80, 31, and 20 show sequence similarities to histones H4, H3, and H2B, respectively.\n5. The subset of TAFs that show sequence similarities to histones may form a core structure within TFIID.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is suggested to play a role in megakaryopoiesis.",
      "TAFII80, a component of TFIID, interacts with TFIIE alpha and TFIIF alpha (RAP74) in activator-dependent transcription.",
      "The interactions of TAFII80 with TFIIE alpha and TFIIF alpha could be significant for recruiting General Transcription Factors (GTFs) during megakaryocyte differentiation.",
      "TAFs 80, 31, and 20 show sequence similarities to histones H4, H3, and H2B, respectively.",
      "The subset of TAFs that show sequence similarities to histones may form a core structure within TFIID."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: TAFs 80, 31, and 20 show sequence similarities to histones H4, H3, and H2A, respectively.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, atenolol is not metabolized by CYP2D6. The document states that \"relevant amounts of active metabolites do not become apparent for either of the three drugs investigated,\" including atenolol. Additionally, the document notes that \"monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso)\" are observed for the three drugs, indicating that they are eliminated from the body through a single phase. This suggests that atenolol is not metabolized by CYP2D6, as this enzyme is involved in the metabolism of many drugs through multiple phases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is not metabolized by CYP2D6.\n2. The document mentions that \"relevant amounts of active metabolites do not become apparent\" for atenolol.\n3. Atenolol exhibits monophasic elimination characteristics.\n4. The half-life (t1/2) of atenolol is approximately 6.87 +/- 0.46 hours.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is not metabolized by CYP2D6.",
      "The document mentions that \"relevant amounts of active metabolites do not become apparent\" for atenolol.",
      "Atenolol exhibits monophasic elimination characteristics.",
      "The half-life (t1/2) of atenolol is approximately 6.87 +/- 0.46 hours."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nWithout additional context or reference values, I cannot verify statements 3 and 4 about atenolol's elimination characteristics and the precise value of its half-life. Statements about pharmacokinetics can vary based on the population studied, methods of measurement, concurrent conditions, and individual patient variables.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the versions of ExpansionHunter:\n1. Newest version of MUMmer\n2. Open-source software\nThe document mentions that the newest version of MUMmer is the one that easily handles comparisons of large eukaryotic genomes at varying evolutionary distances, and that it is the first version of MUMmer to be released as open-source software. This means that there is a new version of MUMmer that is available for use and development by other developers.",
    "llama-2-7b-chat-hf_fact_raw": "1. The newest version of MUMmer can handle comparisons of large eukaryotic genomes at varying evolutionary distances.\n2. The latest version of MUMmer is the first to be released as open-source software.",
    "llama-2-7b-chat-hf_fact": [
      "The newest version of MUMmer can handle comparisons of large eukaryotic genomes at varying evolutionary distances.",
      "The latest version of MUMmer is the first to be released as open-source software."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Previous versions of MUMmer were already released as open-source software before the newest version.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Adamts18 plays a role in hormone receptor signaling by being involved in TGF- mediated epithelial to mesenchymal transition (EMT) in cancer progression. The document states that ADAM12 expression is induced by TGF- and promotes TGF--dependent signaling through interaction with the type II receptor of TGF-. Additionally, the document shows that ADAM12 expression is correlated with EMT markers in human breast cancer cell lines and biopsies, and that overexpression of ADAM12L in a non-malignant breast epithelial cell line (MCF10A) is sufficient to induce loss of cell-cell contact, reorganization of actin cytoskeleton, up-regulation of EMT markers and chemoresistance. These effects are independent of the proteolytic activity but require the cytoplasmic tail and are specific of ADAM12L since overexpression of ADAM12S failed to induce similar changes. The document also demonstrates that ADAM12L-dependent EMT is associated with increased phosphorylation of Smad3, Akt and ERK proteins. Finally, the document shows that inhibition of TGF- receptors or ERK activities reverses ADAM12L-induced mesenchymal phenotype. Therefore, based on the information provided in the document, Adamts18 plays a role in hormone receptor signaling by being involved in TGF- mediated EMT in cancer progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in TGF-β mediated epithelial to mesenchymal transition (EMT) in cancer progression.\n2. ADAM12 expression is induced by TGF-β and promotes TGF-β-dependent signaling through interaction with the type II receptor of TGF-β.\n3. ADAM12 expression correlates with EMT markers in human breast cancer cell lines and biopsies.\n4. Overexpression of ADAM12L in the non-malignant breast epithelial cell line MCF10A induces loss of cell-cell contact, reorganization of actin cytoskeleton, up-regulation of EMT markers, and chemoresistance.\n5. Inhibition of TGF-β receptors or ERK activities reverses ADAM12L-induced mesenchymal phenotype.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in TGF-β mediated epithelial to mesenchymal transition (EMT) in cancer progression.",
      "ADAM12 expression is induced by TGF-β and promotes TGF-β-dependent signaling through interaction with the type II receptor of TGF-β.",
      "ADAM12 expression correlates with EMT markers in human breast cancer cell lines and biopsies.",
      "Overexpression of ADAM12L in the non-malignant breast epithelial cell line MCF10A induces loss of cell-cell contact, reorganization of actin cytoskeleton, up-regulation of EMT markers, and chemoresistance.",
      "Inhibition of TGF-β receptors or ERK activities reverses ADAM12L-induced mesenchymal phenotype."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The role of Adamts18 in EMT and cancer progression would require specific scientific references to confirm its involvement in this context.\n2. UNKNOWN: The expression and function of ADAM12 in TGF-β signaling would also need to be verified with specific scientific studies.\n3. UNKNOWN: Correlation of ADAM12 expression with EMT markers in human breast cancer would require reviewing relevant scientific literature for validation.\n4. UNKNOWN: The effects of overexpressing ADAM12L in a specific cell line like MCF10A and its relationship to various cellular behaviors is subject to verification through scientific research.\n5. UNKNOWN: The impact of inhibiting TGF-β receptors or ERK activities on the mesenchymal phenotype induced by ADAM12L requires supporting evidence from research studies.\n\nAll the statements provided are specific to biochemical and cellular research findings and would need references to specific scientific studies to confirm their accuracy. Without access to the relevant data or publications, one cannot definitively determine the truth of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mode of action of Thiazovivin is likely similar to that of Bronopol, which is the oxidation of essential protein thiol causing inhibition of enzyme activity and subsequent inhibition of microbial growth.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin's mode of action involves the oxidation of essential protein thiol.\n2. The mode of action of Thiazovivin leads to inhibition of enzyme activity.\n3. Thiazovivin’s mode of action results in the inhibition of microbial growth.\n4. Thiazovivin's mode of action is likely similar to that of Bronopol.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin's mode of action involves the oxidation of essential protein thiol.",
      "The mode of action of Thiazovivin leads to inhibition of enzyme activity.",
      "Thiazovivin’s mode of action results in the inhibition of microbial growth.",
      "Thiazovivin's mode of action is likely similar to that of Bronopol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin does not involve the oxidation of essential protein thiol; its main action is to inhibit Rho-associated kinase (ROCK), which enhances the survival and cloning efficiency of human embryonic stem cells during cell reprogramming, passaging, and derivation.\n2. TRUE: Since Thiazovivin inhibits ROCK, it leads to inhibition of the enzyme's activity.\n3. FALSE [correction]: Thiazovivin is used in stem cell research and does not target microbial growth; its mode of action is related to stem cell survival and efficiency rather than antimicrobial activity.\n4. FALSE [correction]: Thiazovivin's mode of action is not related to Bronopol. Bronopol is an antimicrobial that acts by releasing reactive bromine species, while Thiazovivin is a selective inhibitor of ROCK involved in stem cell research.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false"
    ]
  }
]